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Introduction 
 
Summary 
General introduction: This section reviews the classification, epidemiology and burden of 
illness associated with headache disorders. The discussion concentrates on the common 
benign disorders of tension-type headache (TTH), migraine and chronic daily headache 
(CDH), these being the main types of headache seen in everyday clinical practice. The 
methodology of assessing headache burden is discussed, concentrating on disability and 
impact tools. Migraine and CDH are both disabling conditions, leading to significant 
impairment of daily activities in sufferers.  
Primary care: Population-based studies show that migraine is under-estimated, under-
diagnosed and under-treated in the clinic. Many patients never consult for headache, and 
drop out rates are high even among those who do. A study conducted by the author in 
primary care showed that patients who consulted with episodic headaches almost always 
had migraine. Patients with TTH hardly ever consulted. The conclusion was that migraine 
should be the default diagnosis for patients presenting to primary care with episodic 
headaches. 
Specialist care: A second study conducted by the author showed that the headache pattern 
is very different for patients who consult for specialist care. Sixty percent of patients 
presenting to a UK specialist clinic had CDH, while only 33% had migraine. Other types of 
headache were seen infrequently.  
Commentary: New methods are required to deal with the variable pattern of patients seen 
with headache in clinical practice. Innovative diagnostic and evaluation tools have been 
developed recently that utilise assessments of disability.  
Shortcomings in available knowledge: Headache remains a generally unrecognised 
disorder, with its epidemiology and burden still not fully characterised. It would be particularly 
useful to identify the factors that predict medical need in patients. Assessments of disability 
have the potential to aid the diagnosis, evaluation of medical need and assess outcome in 
studies. 
Objectives of the thesis: The thesis is based on a series of studies conducted in primary 
care to evaluate the evidence base of disability assessments and their potential in aiding 
diagnosis and management of headache. 
 
1.1 General introduction 
 
Headache is the most common neurological condition, and due to this is the neurological 
condition most likely to be seen in primary care. However, UK medical training typically 
provides less than one day of education on headache management. Primary care physicians 
may therefore be unprepared for the everyday management of headache, and many patients 
end up being referred to secondary care, with the inevitable delays this entails. The paradox 
is that most types of headache are eminently suitable for treatment in primary care. In 
addition, there has been an explosion of research on headache over the past 15 years or so, 
and guidelines for managing common headache subtypes have been published in several 
countries. 
 
Historically, research on headache was conducted on an ad hoc basis, with no common 
diagnostic criteria used. This makes it difficult to apply studies conducted before 1990 to the 
present day. Year zero for headache was 1988, the year of publication of the International 
  
 6 
Headache Society (IHS) classification criteria for headache subtypes.1 Since its inception, it 
has become possible to diagnose patients accurately and consistently. The criteria have 
since been revised, and new classification criteria were published in 2004.2 Guidelines on 
how to conduct studies with acute medications were first put forward by Glaxo in 1991,3 
followed by IHS-recommended guidelines a few years later.4 These initiatives have 
transformed research in headache, providing consistent methodology for diagnosing 
patients, designing studies and defining endpoints. We are now able to use evidence-based 
criteria to evaluate headache research, which has greatly expanded our understanding of the 
subject. Due to commercial considerations and clinical importance, most recent headache 
research has concentrated on migraine, but increasing amounts of data are now emerging 
on other headache subtypes. 
 
Most recent research on headache has been conducted in secondary care centres, resulting 
in guidance being produced for the specialist physician. Only in the past few years have 
evidence-based guidelines been produced for the primary care physician. In addition, little 
research has been conducted in the primary care setting. The studies included in this thesis 
are an attempt to rectify this situation, involving naturalistic clinical studies on the types of 
patients seen in everyday clinical practice and the development of new, simple to use 
questionnaires that are applicable to primary care. In this section, I review data on the 
epidemiology, illness burden and clinical management of the common headaches, and 
analyse the strengths and weaknesses of the methodology used. 
 
1.2 Headache classification 
 
Headaches can be classified into three major types: primary (benign) headaches, secondary 
(possibly sinister or worrisome) headaches, and the cranial neuralgias and facial pain 
syndromes (Table 1).2  
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Table 1. Classification of the common headache disorders.2 
 
Primary headaches Episodic migraine (with or without aura) 
Chronic migraine 
Rare migraine variants (e.g. familial 
hemiplegic migraine, basilar migraine, 
retinal migraine) 
Episodic tension-type headache (TTH: 
infrequent or frequent) 
Chronic TTH 
Cluster headache (episodic or chronic) 
Other trigeminal autonomic neuralgias 
Other primary headaches (stabbing, 
cough, exertional, sexual activity, hypnic, 
thunderclap, hemicrania continua and new 
daily-persistent headache (NDPH) 
Secondary headaches Related to: 
Head/neck trauma (e.g. whiplash, post-
traumatic disorder) 
Cranial/cervical vascular disorder (e.g. 
stroke) 
Non-vascular intracranial disorder (e.g. 
brain tumour) 
A substance or its withdrawal (e.g. 
medication overuse headache [MOH]) 
Infection (e.g. meningitis, systemic 
bacterial or viral infection) 
Disorder of homeostasis (e.g. 
hypertension) 
Disorder of cranial structures (e.g. neck, 
eye, nose, ear, jaw disorders) 
Psychiatric disorder (e.g. somatisation, 
psychotic disorders) 
Cranial neuralgias and facial pain 
syndromes 
Trigeminal neuralgia and other neuralgias 
Compression headaches 
Cold-stimulus headache 
Eye-related headaches 
Headaches related to Herpes zoster 
Central causes of facial pain. 
 
The most frequently reported headaches are the benign primary headaches of episodic 
tension-type headache (TTH), episodic migraine and chronic migraine/ chronic TTH. Several 
types of headache are commonly and arbitrarily grouped into the term ‘chronic daily 
headache’ (CDH). CDH comprises daily or near-daily headaches that last for more than 4 
hours on average and are often thought to be linked to medication overuse. They usually 
arise from a primary, episodic headache disorder. These headaches are included in the 
primary disorders of chronic migraine, chronic TTH, hemicrania continua and new persistent-
daily headache (NPDH) and the secondary disorder of medication overuse headache (MOH) 
in the new IHS criteria.2 Table 2 illustrates the differences in presentation in CDH disorders.5 
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Table 2. Presentation of CDH disorders.5  
 
Headache 
subtype 
Frequency Presentation   
Chronic migraine ≥ 15 d/mo for > 
3 mo 
Primary headache is migraine 
May present with migraine or TTH-like features 
Chronic TTH ≥ 15 d/mo for > 
3 mo 
Primary headache is episodic TTH 
Presents typically with TTH-like features 
(subject to revision) 
Medication 
overuse headache 
(MOH) 
> 15 d/mo Chronic migraine, CTTH or mixed migraine and 
TTH-like features 
Overuse (≥ 10 d/mo for ≥  3 mo) of ergots, 
triptans, opioids, other pain medications and 
combinations (≥ 15 d/mo) 
Hemicrania 
continua 
Daily and 
continuous 
Unilateral, moderate intensity, with 
exacerbations of severe pain 
Conjunctival injection / lacrimation, nasal 
congestion / rhinorrhoea / ptosis / miosis 
Responds to indomethacin 
New daily-
persistent 
headache 
Daily and 
unremitting 
from < 3 d from 
onset 
Presents typically with TTH-like symptoms 
 
 
1.3 Epidemiology of headache 
 
Studies of epidemiology need to be population-based to avoid the risk of biases. This is 
frequently achieved by administering questionnaires in the community by interview or via the 
telephone.6 The important outcomes of epidemiology studies are incidence and prevalence 
(see Box 1). In practice, prevalence is assessed far more often than is incidence. To obtain 
further information, prevalence data is usually analysed for gender, age, race and other 
social and epidemiological factors.6 
 
Box 1 
Incidence: the number of new cases of a disease to be reported in a 1-year period. 
Prevalence: the total number of cases of a disease, calculated as lifetime prevalence (the 
total number who have ever experienced the disease) or 1-year prevalence (the number who 
experienced the disease over the previous 1-year period). Comparing prevalence data is 
often hindered by the differences in time periods used in studies. 
 
Overall, almost everyone gets headache: the lifetime prevalence is estimated as 93%, with a 
point prevalence of 11% in men and 22% in women.7 Prevalence studies, with diagnoses 
confirmed using the IHS criteria,1 indicate that the only headache subtypes with a prevalence 
> 1% in the general population are TTH, migraine and CDH. These headaches are 
considered separately below. 
 
Tension-type headache 
The pioneering studies of Rasmussen and colleagues showed that TTH is very common, 
indeed almost ubiquitous. The 1-year prevalence of TTH in Denmark was 63% in men and 
86% in women, with a male: female ratio of 4:5.7 Similar results were reported in a 
population-based study conducted in the USA, although with a lower 1-year prevalence of 
38%.8 The prevalence decreased with increasing age.7 In Denmark, socio-demographic 
variables of marital status, cohabitation, educational level, occupational category or 
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employment status were not significantly associated with TTH. However, TTH was positively 
associated with neuroticism, fatigue in both sexes, time-pressure at work in women and 
exposure to fumes in men.9 In the USA, TTH prevalence was associated with increasing 
educational levels and prevalence was higher in Caucasians than in African Americans.8 
 
Migraine 
There are relatively few population-based data on the incidence of migraine. Studies show 
that incidence peaks in childhood and adolescence, then declines over time.10,11 The overall 
incidence per year is about 0.2% for boys and 0.6% for girls. The mean age of incidence is 
lower for boys than for girls (13.7 versus 17.6 years).12  
 
In contrast, there are large amounts of information on migraine prevalence. 1-year 
prevalence rates from population-based studies conducted around the world are summarised 
in Table 3.  
 
Table 3. 1-year prevalence of migraine from population-based studies. 
 
        Prevalence (%) 
Country, year n Age range (y) Men Women Total 
USA, 199213 20,648 12–85 5.7 17.6 10.5 
Canada, 199414 2,992 18+ 7.4 21.9 15.3 
Denmark, 19917 1,000 25–64 5.9 15.3 10.4 
Netherlands, 199515 1,008 12+ 5.0 12.0 9.0 
UK, 200316 4,007 16–65 7.6 18.3 ND 
France, 200217 1,486 15+ 4.0 11.2 7.9 
Japan, 199718 1,597 15+ 3.6 12.9 8.4 
Malaysia, 199619 595 6+ 6.7 11.3 9.0 
Latin America, 200520 2,637 15+ 2.9–7.8 6.1–17.4 ND 
ND = No data 
 
The overall prevalence of migraine worldwide seems to be about 10% overall, 6% in men 
and 15% in women. One large, international prevalence study showed that migraine without 
aura was much more common than migraine with aura; less than one-third of the migraine 
sufferers experienced aura symptoms.21 The prevalence of migraine with aura has been 
estimated at 3% for men and 5% for women.11  
 
Migraine is highly gender- and age-dependent (Figure 1).13  
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Figure 1. Gender- and age-specific prevalence of migraine.13 
 
Stewart WF et al. JAMA 1992;267:64-9.
 
 
 
Overall, approximately 2–3 times as many women as men report migraine, most likely due to 
the influence of female sex hormones. Migraine is about twice as likely to occur at the time of 
the menstrual period as at other times in the menstrual cycle.22 Up to the age of 12, more 
boys than girls have migraine, but the female preponderance starts at age 13, when 
menarche has usually occurred.23 Prevalence in women increases up to about 40 years, then 
declines. A similar pattern is seen in men, with peak prevalence occurring at about 35 years. 
Prevalence declines thereafter for both genders, and < 5% of the population is affected after 
age 70 years.13  
 
Some studies show a low prevalence of migraine in certain Asian and African countries, 
which have been ascribed to cultural and environmental differences between races.6 A study 
in Americans showed that migraine prevalence was higher in Caucasians (20.4%) than in 
African Americans (16.2%) and Asian Americans (9.2%).24 There therefore do appear to be 
real racial differences in migraine epidemiology, although the condition is common in all 
races. There is some evidence for variations in migraine prevalence in terms of social forces. 
The prevalence seems to increase as the levels of education6,13 and income13 decrease.  
 
Chronic daily headache 
Very few population-based studies have been conducted on CDH. The available evidence 
suggests that CDH is a relatively common condition, affecting about 4–5% of the general 
adult population.25 CDH can occur at all ages, from 5 to > 80 years, and without treatment, 
the condition can persist for years or decades.26 Population-based studies have provided 1-
year prevalence rates of 2.2% for chronic TTH8,25 and 2.4% for chronic migraine.25 
Hemicrania continua and NDPH were reported rarely.25,27 There are difficulties in assessing 
the prevalence of chronic migraine (often known as ‘transformed migraine’), as studies 
published to date did not use the criteria recently published by the IHS.2 Further studies are 
therefore necessary to investigate the epidemiology of chronic migraine. 
 
As with migraine, CDH was much more common in women than in men.25 A population-
based study showed that CDH was also associated with being Caucasian, lower education 
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status, and in those with a history of marriage.28 Population- and clinic-based studies 
identified co-morbid conditions of obesity, diabetes, arthritis, allergy, asthma, hypothyroidism 
and hypertension, and associated with daily caffeine consumption and habitual snoring.28–30 
New-onset CDH was associated with the baseline headache frequency and obesity.28 In the 
clinic, the presentation of CDH is typically of daily TTH-like headaches, with exacerbations of 
migraine-like headaches.31  
 
Medication overuse headache (MOH) is present in a substantial proportion of people with 
CDH. The overall population prevalence of MOH in a Spanish study was 1.4%, much higher 
in women (2.6%) than in men (0.19%).32 Prevalence increased with age, and the mean age 
of sufferers was 56 years. Most patients with MOH have a longstanding history of primary 
headaches, with a decade or more of overuse of symptomatic medications.33 A clinic-based 
study indicted that MOH was associated with asthma, hypertension and daily caffeine 
consumption.30  
 
Other chronic headaches are much less prevalent than CDH. The best known, cluster 
headache, has an overall prevalence of about 0.4%; 0.3% in men and 0.1% in women.34 
 
 
Conclusions 
In conclusion, the primary, benign headaches are common conditions that affect both men 
and women (but particularly women) during their adult lives. 
 
1.4 Burden of headache 
 
The burden exerted by headache on sufferers is typically reported in terms of 
symptomatology, quality of life, disability (effect on sufferers’ daily activities) and resultant 
social and economic consequences. This section reviews the first three of these items below, 
for TTH, migraine and CDH because these reflect the patient’s perspective. 
 
Methodology 
As with epidemiological studies, population-based studies can be conducted that compare 
discrete headache populations with each other and the general population. Clinic-based 
studies are also important, as they contain specific populations of more severely-affected 
patients that are of clinical interest. However, the data do not coincide with the population 
distribution of patients. Headache symptomatology has been studied in many of the 
epidemiological studies described above. 
 
Quality of life (QOL) is a measure of illness severity that combines subjective perceptions of 
the sufferer’s life situation and objective assessments of health factors. QOL is assessed 
using questionnaires that patients complete at typically 1-month intervals. Questionnaires 
can be generic (to be used for any condition) or migraine-specific. Generic questionnaires 
are suitable for comparisons between study populations and different diseases. Disease-
specific questionnaires focus on specific problems associated with a disease and are 
generally more sensitive. They may be better suited to assess changes in QOL following 
clinical interventions. 
 
The best known of the generic questionnaires is the Medical Outcomes Study Short-Form 36 
(SF-36) questionnaire. This contains items on physical, social and emotional functioning, 
pain, general medical and mental health.35 Scores of patients are related to those of the 
general healthy population. The SF-36 has proven its methodological robustness and clinical 
utility in numerous studies in different disease areas over many years. Other generic QOL 
questionnaires include the EQ-5D and the WHO-QOL/WHO-QOL bref. 
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Several migraine-specific QOL questionnaires (e.g. MSQOL, MSQ, 24-hour QOLQ and 
MIGSEV) are now available, which have also been shown to have good reliability and validity 
(for definitions see Box 2).36–38 However, their complexity of assessments and scoring limit 
general use in clinical practice. 
 
In contrast to QOL measures, disability is a considerably less complex and more accessible 
concept. Disability is a consequence of illness and an important indicator of unmet treatment 
need. In part, disability is the product of poor QOL that is attributable to illness. The World 
Health Organization (WHO) defines disability as the inability to work and function in other 
roles.39 Questionnaires assessing headache-related disability quantify the effect on sufferers’ 
daily activities. They are more specific than the more general health-focused QOL and 
impact questionnaires. Impact questionnaires include disability measures, in concert with 
other factors influencing the life of patients (e.g. symptoms, QOL and patient suffering). Two 
disability-based questionnaires have been developed, the disability-specific Migraine 
Disability Assessment (MIDAS) questionnaire and the more wide-ranging Headache Impact 
Test (HIT). Both questionnaires cover all headache subtypes, not just migraine. 
 
MIDAS is a paper questionnaire aimed to be accessible at physicians’ surgeries and 
pharmacies. Headache sufferers answer five questions in three activity domains covering the 
previous 3-month period.40 They score the number of lost days due to headache in 
employment, household work and family and social activities. Sufferers also report the 
number of additional days with significant limitations to activity (defined as at least 50% 
reduced productivity) in the employment and household work domains. The total MIDAS 
score is obtained by summing the answers to the five questions as lost days due to 
headache. This can be higher than the actual number of lost headache days due to any one 
day being counted in more than one domain. The score is categorised into four severity 
grades:  
• Grade I = 0–5 (minimal or infrequent disability) 
• Grade II = 6–10 (mild or infrequent disability) 
• Grade III = 11–20 (moderate disability) 
• Grade IV = 21 and over (severe disability) 
 
Two other questions (A and B) are not scored, but were designed to provide the physician 
with clinically relevant information on headache frequency and pain intensity. On testing, 
MIDAS exhibited face validity, reliability, validity, ease of use and scoring and intuitive 
meaning to physicians.40–43 Some studies have also shown it is sensitive to change following 
clinical intervention (see Box 2).44,45 However, MIDAS also has some weaknesses. It only 
assesses about 35% of the range of headache severity between moderate and severe 
intensity, and does not cover milder or the most severe headaches.46 Therefore, the MIDAS 
grade score may not always indicate the true medical need of patients due to floor effects 
(patients scoring zero on the questionnaire),47 and the score may be weighted towards the 
measurement of headache frequency over disability. Nevertheless, MIDAS has proved to be 
a useful tool in specialist headache clinics.48 
 
HIT was first developed as a web-based test, designed to be accessible via the Internet. It is 
a dynamic questionnaire, with items derived from validated headache questionnaires 
sampling all areas of headache impact.49 It is described as dynamic because the answer to 
one question drives the choice of the next question, and so on. Patients are questioned until 
clinical standards of score precision are met, although five questions are sufficient to grade 
the majority of headache sufferers.49 It takes only 1–2 minutes to complete. On testing, 
Internet-HIT was shown to be reliable and valid, and covered the whole spectrum of 
headache,46,50,51 much more than did MIDAS.46 Internet-HIT differentiated sufferers on the 
basis of diagnosis and characteristics such as headache severity and frequency.50  
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HIT-6 is a paper-based, short-form questionnaire based on the Internet-HIT question pool. 
Six questions cover pain severity, loss of work and recreational activities, tiredness, mood 
alterations and cognition. Each question is scored on a five-point scale, with the scores being 
added to produce the final score.52 HIT-6 scores are categorised into four grades, 
representing minimal, mild, moderate and severe impact due to headache. Studies have 
shown that HIT-6 is reliable and valid,52 and in the clinic can be used to help diagnose 
headaches (particularly) and also to select management strategies according to headache 
severity.53,54 Also, HIT-6 scores were related to workplace productivity loss due to 
headache.55 Internet-HIT and HIT-6 scores compared well to each other when the two forms 
of the questionnaire were tested on a group of headache sufferers.56 The main disadvantage 
of HIT is that the grade scores are not intuitively meaningful, comprised as they are from a 
constellation of items.49,52 
 
Assessments of disability and impact are clearly useful clinically, and have the advantage of 
greater simplicity of use and understanding over QOL questionnaires. They can also be used 
to assess all headaches, and not just migraine, as with some of the QOL questionnaires. In 
fact, MIDAS items57 and HIT-6 scores53 both correlated with QOL and other clinical 
assessments of headache severity. The question of which questionnaire is the best to use is 
probably best left to the individual investigator. Compared to each other, MIDAS has the 
advantage of clinically-meaningful units, while HIT covers a larger area of the headache 
spectrum from mild to very severe intensity. 
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Box 2. Research and clinical practice criteria for evaluating clinical measures for headache 
severity58 
 
Overview: To be useful for clinical practice, an illness severity instrument should at minimum 
meet a number of key criteria. Briefly, the instrument needs to be reliable, valid and internally 
consistent and, if it is to be used to follow patients, it must be sensitive to change. For use in 
general clinical practice, the tool also needs to be easy to use and score and the score 
should be intuitively meaningful (i.e. face validity) to patients and physicians. 
 
Criteria Analysis 
Research criteria 
 
Internal consistency 
 
 
The extent to which the items comprising 
the measure are related to each other 
Test-retest reliability Stability and reproducibility of results 
when the instrument is administered 
twice to the same person (test–retest)  
Content validity Correlation between the instrument-
based measure and a ‘gold standard’ 
measure 
Correlation between expert (researcher, 
physician) and patient input 
Construct validity The extent to which an instrument 
measures what it purports to measure 
and fits into a theoretical scheme about 
the variable of interest 
Discriminant validity The extent to which an instrument 
distinguishes two conditions or states 
known to be different 
External validity The extent to which the instrument-based 
measure is related to other measures 
considered to be relevant 
Sensitivity to change Instrument detects real change over 
time, such as improvement in outcome in 
response to effective therapy 
Clinical practice criteria 
 
Face validity 
 
 
Judgement that the measure 
corresponds to an individuals’ 
perception, e.g. by selecting items 
deemed to be important to the disease 
sufferer or physician. 
Ease of use The instrument should be simple to use, 
score and interpret. 
Intuitively meaningful The instrument should correlate with 
physicians’ judgements of illness severity 
and treatment need 
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Burden of episodic tension-type headache 
TTH is typified by mild-to-moderate headache2,8 that is bilateral, pressing or tightening in 
quality. It may be accompanied by photophobia or phonophobia, but nausea is absent.1,2 
There seems to be little effect on the patient’s quality of life, or impact on daily activities, but 
interestingly, sufferers are frequently fatigued,9 and suffer from neurotic and psychotic 
conditions.59 One population-based study has shown that TTH can lead to lost work days 
and reduced efficiency at work.8 However, HIT-6 scores for TTH are significantly lower than 
those for migraine and CDH.53 TTH appears to have a complex aetiology that is affected by 
several psychosocial factors.11 However, relatively little research has been conducted on 
TTH, and the condition is not fully understood. 
 
Burden of migraine 
Migraine symptoms reported in population-based studies include moderate to severe 
headaches, which are usually throbbing, one-sided and aggravated by physical activity. The 
headache is usually accompanied by photophobia and/or phonophobia and nausea, and less 
frequently by vomiting and aura symptoms. Attacks occur on average about once or twice a 
month (range < 6 to > 50 attacks per year), last for about 24 hours (range < 4 to 72 hours), 
and are separated by symptom-free intervals.21,60 However, migraine is an unpredictable, 
heterogeneous disorder and attacks vary widely in frequency, duration, severity and reported 
symptoms.61  
 
A study using the SF-36 generic questionnaire showed that migraine sufferers taking part in 
a clinical study had significantly lower QOL than the US general population.62 Increasing 
severity of migraine was associated with worsening QOL. The main aspects of QOL affected 
by the migraine were pain, and interference with daily activities and social lives. When 
compared with other serious illnesses, migraine sufferers had lower QOL, in at least some 
items, than patients with hypertension, depression, osteoarthritis and type II diabetes.62 A 
further study indicated that migraine sufferers have impaired QOL even when they are 
supposedly free from symptoms between attacks. Migraine sufferers had more physical and 
emotional problems compared with healthy controls.63 Similar results are seen with the 
migraine-specific QOL questionnaires.36–38 Migraine is closely linked to psychiatric disorders, 
particularly depression and anxiety.6 For depression, the link is bi-directional, indicating that 
each disorder increases the risk of onset of the other.64  
 
Migraine is associated with high levels of disability. Population-based studies in the USA,61 
Canada65 and Japan18 indicated that about three-quarters of sufferers have a limited ability to 
function during their attacks. Population-based studies with the MIDAS and HIT 
questionnaires show that migraine is associated with severe impact to sufferers’ daily 
activities. Two studies, one in Europe and one in the USA, indicated that the mean MIDAS 
score was in the Grade III range (moderate disability) with about 50% of sufferers scoring 
Grade III or IV (moderate or severe disability).40,41 The MIDAS score for migraine was 
significantly higher than that for non-migraine headaches.40 Numerous studies indicate that 
migraine leads to lost time at work16,66,67 and in family and social activities.66,68,69 Studies with 
the HIT-6 questionnaire in clinical practice also indicate that migraine is associated with 
severe impact.53,54 
 
Burden of chronic daily headache 
There are relatively few population-based studies of CDH, and most studies are clinic based. 
CDH presents in a variety of forms. Sufferers typically start with one of the episodic primary 
headaches, usually migraine or TTH, which changes over time to a chronic headache 
presentation. In its chronic form, the balance between the TTH and migraine vary from 
patient to patient:  
• At one extreme, some patients experience mild-to-moderate severity TTH only 
(chronic TTH). 
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• At the other extreme, patients may have daily, or near-daily, moderate-to-severe 
severity migraine attacks without significant TTH (chronic migraine). A study of 
patients with chronic migraine showed that over 80% suffered from fatigue, with two-
thirds meeting the criteria for chronic fatigue syndrome.70 
• Patients with a previous history of episodic migraine may develop daily headaches 
which may symptomatically resemble TTH. Periodic, more severe exacerbations that 
meet criteria for migraine usually occur up to or more than 15 days per month. Such 
patients should probably be classified as having chronic migraine in the new IHS 
criteria,31 although this is not currently the case.2 Using the McGill Pain 
Questionnaire, chronic migraine was shown to be more severe than chronic TTH, and 
the two conditions had differing patterns of descriptive characteristics.71 
All forms of CDH are associated with personality disorders, particularly neuroticism and 
psychoticism, but these symptoms are most common in MOH sufferers.59 
 
The key feature of the CDH patient with MOH is the daily or near daily overuse of headache 
medications, such as simple analgesics (e.g. aspirin or paracetamol),72 combination 
analgesics containing caffeine, codeine or barbiturates, opioids, ergotamine73 or triptans.74 
Many patients are taking multiple medications.75 There tends to be a clinical syndrome of the 
patient obtaining transient relief from their headache medication. This is then followed by a 
return of the headache (withdrawal phenomenon) that necessitates further medication, and 
so on until a vicious cycle is established. If the headache medication is stopped, withdrawal 
symptoms are commonly reported. Patients with migraine as their primary headache develop 
migraine-like daily headaches or an increase in their migraine frequency and TTH-like daily 
headaches. Patients with initial TTH or combined headaches nearly always developed TTH-
like daily headaches.76  
 
Three population-based studies have investigated the QOL of CDH sufferers. Two studies 
showed that CDH without MOH77 and MOH32 patients had lower QOL than healthy controls 
on all domains of the SF-36 questionnaire. In addition, CDH patients had poorer QOL than 
those with episodic migraine (especially in general and mental health and vitality), and MOH 
patients had poorer QOL than those with CDH without MOH (especially in physical 
functioning and pain).77 Similar results were reported when using a migraine-specific QOL 
questionnaire.78  
 
Clinic-based studies show that headache-related disability is high in patients with CDH, with 
and without MOH. The mean MIDAS score in these patients was in the high Grade IV range 
(i.e. severe disability).45,79–81 The mean MIDAS score was significantly higher in patients with 
chronic migraine compared to those with episodic migraine (34.9 versus 19.3, p < 0.001).81  
 
Conclusions  
In conclusion, the common primary headache subtypes of migraine and CDH are both 
associated with severe symptoms, reduced QOL and significant impact on the sufferers’ daily 
activities. The available data indicates that episodic TTH may be a more severe condition 
than is generally thought, even though the symptoms are relatively mild. 
 
1.5 Current status of managing headache in the clinic 
 
Numerous population-based studies have investigated the proportion of IHS-defined 
migraine sufferers who actually consult a physician for care (Table 4).18,21,65,82–88 These 
studies consistently show that only about 50% or fewer migraine sufferers are currently 
consulting a physician. Although the majority of sufferers consult at some time, many 
subsequently drop out from care. Interestingly, these data have not changed in studies 
conducted over the past decade, despite the number of educational initiatives conducted in 
this time. Factors that are related to consultation include being female and married, being 
older than 50 years, and the overall attack frequency, duration, severity and associated 
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disability.82 Factors that are related to non-consultation and dropping out from consultation 
include a lack of perception of the severity of headache, good efficacy of OTC medications 
and feeling that the physician could not help them, or had failed to do so in the past.21,65,88  
 
Table 4. Consultation patterns for migraine. Proportion of migraineurs consulting physicians 
in population-based epidemiological studies. * Study conducted in Belgium, Canada, Italy, 
Sweden and the UK; **Study conducted in France, Germany, Italy, UK and USA 
 
Study Ever 
consulted 
(%) 
Current 
consulter 
(%) 
Drop out 
consulters 
(%) 
Never 
consulted 
(%) 
Canada, 199365 81 36 45 19 
International*, 199321 66 31 35 34 
USA, 199882 67 47 21 32 
Denmark, 199283 56 ND ND 44 
UK, 199684 
       199985 
58 
67 
ND 
47 
ND 
21 
42 
32 
Japan, 199718 31 15 16 69 
USA, 200286 69 48 21 31 
UK, 200387 86 65 21 14 
International**, 200388  41–63  37–59 
ND = No data  
 
The profile of patients in the population with headache, and those consulting with primary 
and secondary care physicians, differ markedly. Sections 1.5.1 and 1.5.2 below describe 
concisely clinic-based studies that the author has conducted on the consultation pattern in 
primary and secondary care. 
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1.5.1 The prevalence and diagnosis of migraine in a primary care setting: insights 
from the Landmark Study* 
 
Andrew Dowson1, Carl Dahlöf2, Stewart Tepper3, Lawrence Newman4 and Landmark Study 
Group5  
 
1University of London, Kings College Hospital, London; 2Gothenburg Migraine Clinic, 
Gothenburg, Sweden; 3New England Headache Center, Stamford, CT; 4The Headache 
Institute, St. Luke’s Roosevelt Hospital Center, New York, 5GlaxoSmithKline; London, 
Toronto, and North Carolina. 
 
Background 
Migraine affects about 3% to 8% of males and 11% to 18% of females in developed 
countries.1 It is recognised that most migraine sufferers do not seek medical consultation for 
their headaches,2 and nearly half of migraine sufferers are under-diagnosed or 
misdiagnosed.3–5 The prevalence of migraine is well-established in population-based studies. 
However the prevalence of migraine in patients presenting to primary care with headache is 
limited. 
 
Objective 
To determine the prevalence and diagnosis of migraine in subjects presenting to primary 
care physicians (PCPs) with a complaint of headache. 
 
Design and methods 
The Landmark Study was a prospective, international, open-label study designed to examine 
the association of headache impact assessed by HIT-6 and migraine diagnosis in subjects 
presenting to primary care physicians with a complaint of headache. All subjects who 
presented with headache completed a paper-based HIT-6 questionnaire and a headache 
survey. The investigator categorised patients as having migraine or non-migraine headaches 
by using his/her customary diagnostic practice. Subjects diagnosed with a secondary 
headache disorder or chronic daily headache were withdrawn from the study. 
 
Patients newly-diagnosed as migraineurs and non-migraineurs completed diary cards for 
their first 6 headaches or up to 3 months, whichever came first. At the end of the study, an 
expert panel of headache specialists reviewed the diary cards utilising IHS criteria to provide 
a final headache diagnosis.  
– IHS 1.1 Migraine without aura 
– IHS 1.2 Migraine with aura 
– IHS 1.7 Migrainous headache 
– IHS 2.1 Episodic tension-type headache (TTH) 
– IHS 13 Headache not classifiable 
 
 
 
*The full Landmark paper has now been published (Tepper SJ, Dahlöf CGH, Dowson A et al. Prevalence and 
diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark 
Study. Headache 2004;44:856–64). This summary of the full article is edited from another published article 
(Dowson A, Dahlöf C, Tepper S et al. The prevalence and diagnosis of migraine in a primary care setting: insights 
from the Landmark Study. Headache Care 2004;1:137–9). 
 
 
Results 
Full details of the study results are published in the full Landmark paper.6 A total of 1217 
subjects were enrolled and 1204 completed the screening phase. 377 subjects were 
classified by the Expert Panel according to their completed headache diaries. 
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Initial PCP Diagnoses 
A total of 1017 subjects (85%) presenting to primary care with a complaint of headache 
received a migraine diagnosis: 306 subjects were newly diagnosed migraineurs (Figure 1) 
and 711 subjects had been previously diagnosed with migraine. A total of 142 subjects (12%) 
were diagnosed with non-migraine primary headache (Figure 2). Forty five subjects (4%) 
were initially diagnosed with secondary and/or other headaches. 
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Figure 1:  Expert panel diary review of newly diagnosed migraine. 
 
 
  
Figure 2:  Expert panel diary review of non-migraine primary headache. 
 
 
 
 
Figure 3: Prevalence of headache based upon expert panel diary review (combined newly 
diagnosed migraine and non-migraine) 
 
IHS 1.1 
n=138 
51% 
IHS 1.2 
n=99 
36% 
IHS 1.7
n=31
11 %
IHS 2.1
n=1
0.4 %
IHS 13 
n=3 
1% 
Expert panel review
n=272
Newly diagnosed migraine
n=306
87% (237/272) of subjects had migraine diagnosis confirmed 
IHS 1.1 
n=38 
36 % 
IHS 1.2 
n=13 
12 % 
IHS 1.7
n=36
34 %
IHS 2.1
n=10
9%
IHS 13 
n=8 
8 % 
Expert panel review
n=105
Non-migraine primary headache
n=142
49% (51/105) of subjects previously diagnosed as non-
migraine received a migraine diagnosis 
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Migraine (n = 288)
Migrainous (n = 67)
ETTH (n = 11)
Unclassifiable (n = 11)
76%
18%
3% 3%
 
 
Limitations of the study 
Study limitations include the use of a diary study which may be subject to recall bias. 
Diaries were to be completed at the time of the events. However, people do not always 
complete diaries when they should. Biases by reviewers were limited by the 
establishment of guidelines for review a priori. The inter-reviewer reliability coefficient 
showed substantial agreement among panellists (ICC=0.71). 
 
Conclusions 
85% of the patients presenting to primary care with a complaint of headache suffered 
from migraine. Few patients consulted for TTH.  
 
An initial PCP diagnosis of migraine (IHS 1.1/1.2) was found to be correct 87% of the 
time. However, almost 49% of PCP non-migraine diagnoses were reclassified as a 
migraine (IHS 1.1/1.2) disorder by the expert panel. In the absence of contradictory 
evidence, migraine should be the default diagnosis for patients presenting to primary care 
with episodic headache. 
 
Landmark Study Group 
Members of the Landmark Study Group are Carl Dahlöf (Gothenburg Migraine Clinic, Gothenburg Sweden), 
Andrew Dowson (University of London, Kings College Hospital, London, UK), Susan Jarvis (GlaxoSmithKline, 
Harlow, UK), Martin Jones (GlaxoSmithKline, Greenford, UK), Frances Kinrade (GlaxoSmithKline, Greenford, 
UK),  Jackie Kwong (GlaxoSmithKline, Research Triangle Park, USA), Laura Lisk (GlaxoSmithKline, 
Greenford, UK), Jane Loftus (GlaxoSmithKline, Greenford, UK), Hank Mansbach (GlaxoSmithKline, 
Research Triangle Park, USA), Lawrence Newman (St. Luke’s Roosevelt Hospital Center, New York, USA), 
Ba Pham (GlaxoSmithKline, Mississauga, Ontario, Canada), Mary S. Richardson (GlaxoSmithKline, 
Research Triangle Park, USA), Andrew Scott (GlaxoSmithKline, Research Triangle Park, USA), Stewart 
Tepper (New England Headache Center, Stamford, CT) and Christopher J. Webster (GlaxoSmithKline, 
Research Triangle Park, USA). 
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1.5.2 Analysis of the patients attending a specialist UK headache clinic over a 
3-year period* 
 
Andrew J Dowson 
Director of the King’s Headache Service, King’s College Hospital, London, UK. 
. 
Abstract 
Objective: This study analysed the profile of patients who attended a specialist UK 
headache clinic over a 3-year period.  
Methods: An audit was conducted of the clinical records of patients attending the specialist 
headache clinic at King’s College, London, between January 1997 and January 2000. Data 
were collected for diagnoses given, current medications taken, medications prescribed and 
recommended and investigations conducted. Results were calculated as numbers and 
proportions of patients for the 3-year period and for the three separate 12-month periods.  
Results: A total of 458 patients were included in the audit. Most patients were diagnosed as 
having chronic daily headache (CDH, 60%) or migraine (33%). Prior to the clinic visit, most 
CDH and migraine patients treated their headaches with analgesics, and there was little use 
of prophylactic medications. In the clinic, 74% of CDH patients and 85% of migraine patients 
were prescribed or recommended prophylactic medications and 81% of migraine patients 
were given triptans for acute treatment. Investigations (imaging procedures) were conducted 
for 12% of patients, all proving negative.  
Conclusions: CDH and migraine were the most common headache types encountered in 
this UK secondary-care clinic. Withdrawal of analgesics and use of prophylactic medications 
were used to manage CDH, while prophylaxis and triptans were used to manage migraine. 
The results indicate that management of CDH and migraine in UK primary care is sub-
optimal, and educational initiatives are needed there to improve headache management.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Summarised from the published version of this article (Dowson AJ. Analysis of the patients attending a specialist 
UK headache clinic over a 3-year period. Headache 2003;43:14–18). 
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Background 
Headaches are often not managed effectively in primary care, where migraine in particular is 
under-estimated, under-diagnosed and under-treated.1 The field of headache research has 
expanded dramatically over the past decade, with new therapies (especially the triptans) 
introduced for migraine2 and increased understanding of the aetiology and treatment goals 
for CDH.3 Clinical practice has changed to reflect these developments, especially in 
specialist clinics, although primary care has been slower to respond.  
 
Objectives 
This study analyzed the diagnoses and management of patients attending one specialist 
headache clinic in the UK over a 3-year period. The study aims were to examine the profile 
of headache patients attending specialist clinics, to monitor changes in clinical practice and 
to gauge referral practices from primary care. 
 
Patients and methods 
This was a retrospective audit of the clinical records of patients attending the specialist 
headache clinic at King’s College Hospital, London, UK. Records from January 1997 to 
January 2000 were analysed separately for three time periods: 1997–8 (January 1997 to 
January 1998); 1998–9 (January 1998 to January 1999); and 1999–2000 (January 1999 to 
January 2000). For 1997–8 and 1998–9, all patients who attended the clinic were analyzed. 
For 1999–2000, only the first 77 consecutive patients who attended the hospital clinic were 
analysed.  
 
Data were analysed for the diagnosis given, current (pre-clinic visit) medications taken, 
medications prescribed and recommended at the clinic visit and investigations conducted. 
Results were recorded as numbers and percentages of patients. 
 
Results 
Patients: 458 patients attended the clinic and were analysed over the 3-year audit period, 
215 in 1997–8, 166 in 1998–9 and the first 77 attending in 1999–2000. Patients came from 
the large, urban, London area. Most patients were women. Demographic data were collected 
for 1999–2000, where 51 patients (66.2%) were women and 26 (33.8%) were men. 
 
 
Diagnoses (Table 1): The total number of diagnoses was greater than the number of patients 
because some patients were diagnosed with more than one headache type. Overall, the 
most frequent diagnosis given was for CDH (60%). The proportion of patients with this 
diagnosis remained relatively constant over the 3-year period. About twice as many women 
as men consulted with CDH in 1999–2000 (30 women and 16 men, 65.2% versus 34.8%). 
The second most common diagnosis was for migraine (33%). The proportion of patients with 
migraine fell slightly over the 3-year period, from 37% to 29%. The vast majority of patients 
who consulted for migraine in 1999–2000 were women (18 women and four men, 81.8% 
versus 18.2%). Short, sharp headaches (4%) and cluster headache (5%) were diagnosed 
infrequently, cluster headache being only reported by men in 1999–2000. Headaches were 
rarely diagnosed due to partial seizures (one patient), intermittent tension-type headache 
(one patient), epilepsy (one patient), possible demyelination (one patient), possible 
movement disorder (one patient), orgasm headache (three patients), sneeze-related 
headache (one patient), cranial arteritis (one patient), inner ear infection (one patient) and 
mobile phone-related headache (one patient).  
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Table 1. Diagnoses given at the headache clinic 
     Number of patients (%)* 
Diagnosis 1997–8 
n=215 
1998–9 
n=166 
1999–2000 
n=77 
3-year total 
n=458 
Chronic daily 
headache 
(CDH) 
118 (55) 112 (64) 46 (60) 276 (60) 
Migraine 80 (37) 51 (31) 22 (29) 153 (33) 
Short, sharp 
headaches 
11 (5) 5 (3) 3 (4) 19 (4) 
Cluster 
headache 
7 (3) 13 (8) 4 (5) 24 (5) 
 
*Some patients were diagnosed with more than one headache 
 
Treatments 
CDH (Tables 2 and 3): Baseline: Overall, most patients were using regular (≥1 dose/day) 
analgesia (66%) and this proportion did not change markedly during the 3-year period. 
Additionally, 14% of patients were using triptans as acute medications. Relatively few 
patients (15%) were taking prophylactic medications.  
Prescribed: Patients were advised to avoid analgesics and none were prescribed. Overall, 
74% of patients were prescribed prophylaxis, the proportion nearly doubling from 1997–8 to 
1998–9. The most commonly prescribed prophylactic drugs were dothiepin, sodium valproate 
and paroxetine (Table 3). Triptans were prescribed rarely (4%), to treat ‘peak’ symptoms 
only. 
 
Table 2. Medications used to treat chronic daily headache (CDH): medications used prior to 
the clinic visit 
     Number of patients (%) 
Medication 1997–8 
n=118 
1998–9 
n=112 
1999–2000 
n=46 
3-year total 
n=276 
Regular 
analgesia 
76 (64) 76 (68) 31 (67) 183 (66) 
Prophylaxis 20 (17) 14 (13) 8 (17) 42 (15) 
Triptans 17 (14) 12 (1) 9 (20) 38 (14) 
Diazepam 3 (3) 0 0 3 (1) 
Ergots 0 1 (1) 0 1 (<1) 
 
Table 3. Medications used to treat chronic daily headache (CDH): medications prescribed at 
the clinic visit 
     Number of patients (%) 
Medication 1997–8 
n=118 
1998–9 
n=112 
1999–2000 
n=46 
3-year total 
n=276 
Analgesia 0 0 0 0 
Prophylaxis 60 (51) 104 (93) 40 (86) 204 (74)* 
Triptans 3 (3) 7 (6%) 0 10 (4) 
Diazepam 0 0 0 0 
 
*Prophylactic drugs includes dothiepin (176 patients), sodium valproate (154 patients), 
paroxetine (115 patients), gabapentin (seven patients) and carbamazepine (two patients) 
 
Migraine (Tables 4 and 5): Baseline: Overall, most patients were using regular (≥1 dose/day) 
analgesia (58%) and this proportion did not change markedly during the 3-year period. 
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Twenty nine percent of patients had been prescribed triptans as acute medication by their 
primary care physician. This proportion increased only slightly, from 26% to 32%, over the 3-
year period. Use of ergotamine was low and declined from 9% of patients in 1997 to none in 
1999. Relatively few patients (12%) had been prescribed prophylactic medications.  
 
Prescribed: For acute medications overall, analgesics were prescribed or recommended for 
9% of patients and triptans for 81%. Ergotamine was not used for any patient. Eighty five 
percent of patients were prescribed or recommended prophylaxis for their migraine, with 8% 
provided with hormonal manipulation for menstrual migraine. By far the most commonly 
prescribed or recommended prophylactic drug was propranolol, with only a few patients 
given pizotifen, cyproheptadine, dothiepin and verapamil. These figures remained relatively 
constant over the 3-year study period.  
 
Table 4. Medications used to treat migraine: medications used prior to the clinic visit 
 
     Number of patients (%) 
Medication 1997–8 
n=80 
1998–9 
n=51 
1999–2000 
n=22 
3-year total 
n=153 
Analgesia 47 (59) 30 (59) 12 (55) 89 (58) 
Triptan 21 (26) 16 (31) 7 (32) 44 (29) 
Prophylaxis 15 (19) 1 (2) 3 (14) 19 (12) 
Ergotamine 7 (9) 4 (8) 0 11 (7) 
 
Table 5. Medications used to treat migraine: medications prescribed and recommended at 
the clinic visit 
      Number of patients (%) 
Medication 1997–8 
n=80 
1998–9 
n=51 
1999–2000 
n=22 
3-year total 
n=153 
Analgesia 
Prescribed 
Recommended 
 
1 (1) 
8 (10) 
 
1 (2) 
1 (2) 
 
0 
3 (14) 
 
2 (1) 
12 (8) 
Triptan 
Prescribed 
Recommended 
 
23 (29) 
39 (49) 
 
25 (49) 
18 (35) 
 
2 (9) 
17 (77) 
 
50 (33) 
74 (48) 
Prophylaxis 
Prescribed 
Recommended 
 
2 (3) 
64 (80) 
 
1 (2) 
43 (84) 
 
0 
20 (91) 
 
3 (2) 
127 (83) 
Ergotamine 
Prescribed 
Recommended 
 
0 
0 
 
0 
0 
 
0 
0 
 
0 
0 
Hormonal 
manipulation 
Prescribed 
Recommended 
 
 
0 
10 (13) 
 
 
0 
2 (4) 
 
 
0 
0 
 
 
0 
12 (8) 
  
 27 
 
Investigations 
Investigations were conducted for 19 patients (9%) in 1997–8, 17 (10%) in 1998–9 and 17 
(22%) in 1999–2000. Most investigations were for patients with CDH (58%) and migraine 
(11%). CT and MRI scans were mainly used, with ESR, FBC and INR, EEG and 
demyelination investigations being used occasionally. All investigations proved to be 
negative. 
 
Discussion 
Over half the patients attending the two headache clinics were suffering from CDH, with a 
third having migraine. These proportions of patients remained stable over the period 1997 to 
2000. It appears, therefore, that the main headache currently managed in secondary care is 
CDH, rather than migraine. Epidemiological studies show that CDH has a prevalence of 
about 5%,3 whilst migraine affects 10% or more of the general population.4 This indicates 
that migraine may be managed better than CDH in primary care. Cluster headache was 
diagnosed infrequently and primary care physicians are likely to encounter cases only rarely. 
To optimise resources, primary care educational initiatives for headache are probably best 
concentrated on CDH and migraine. 
 
CDH disorders include chronic TTH, chronic migraine (sometimes, but not synonymously, 
known as transformed migraine), new daily-persistent headache and hemicrania continua.3 
The natural history of CDH usually starts with a primary intermittent headache disorder such 
as tension-type headache or migraine. Over a period of years, these conditions transform 
into daily or near-daily headaches. The cause of this transformation is often due to patients’ 
overuse of acute headache medications (especially analgesics, ergots and triptans), leading 
eventually to medication overuse headache (MOH) linked to CDH.3 Results from the present 
study showed that patients attending the clinic had this pattern of CDH, relying on regular 
analgesia (which could be prescribed or obtained over the counter without a prescription) for 
therapy, with a substantial minority also using prescribed triptans for relief. Disappointingly 
few were using headache prophylaxis before attending the clinic. The general principle of 
management at the clinic was to treat the chronic headache by withdrawing analgesia and 
prescribing prophylaxis for most patients, with triptans restricted for the acute treatment of 
‘peak symptoms’. The most frequently prescribed prophylactic drugs were antidepressants 
(dothiepin and paroxetine) and/or the anticonvulsant sodium valproate. When the chronic 
headache was controlled, prophylaxis could be withdrawn and acute medications prescribed 
for the underlying primary headache disorder. Currently recommended treatment strategies 
for CDH incorporate withdrawal of analgesics, use of prophylactic medications and limitations 
in the weekly use of acute agents.5 This strategy is similar to that used in the present study.  
 
Migraine patients referred to the specialist clinic in this study relied on analgesia and, to a 
lesser extent, triptans for acute therapy. Relatively few patients had been prescribed 
prophylaxis. Management at the clinic increased the use of triptans and reduced the reliance 
on analgesia for acute therapy, while providing most patients with prophylaxis (in the vast 
majority of cases the beta-blocker propranolol). This management pattern is close to those of 
the evidence-based guidelines of the US Headache Consortium6 and the Migraine in Primary 
Care Advisors’ (MIPCA)7 in the UK, although the present study was completed before 
publication of these two documents.  
 
Investigational procedures were conducted on a small minority of patients (12%) in this 
study. All procedures proved to be negative, and were conducted primarily for the 
reassurance of the patients at their request. 
 
In conclusion, CDH and migraine were the most common headache types encountered in 
this UK secondary-care clinic. Withdrawal of analgesics and use of prophylactic medications 
were used to manage CDH, while prophylaxis and triptans were used to manage migraine. 
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The results indicate that management of CDH and migraine in UK primary care is 
suboptimal, and educational initiatives are needed there to improve headache management. 
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Commentary on the differences between primary care patients (1.5.1) and secondary 
care patients (1.5.2) 
Taken together with Rasmussen et al’s paper on the epidemiology of headache in the 
general population,7 these two papers illustrate the different profile of headaches seen in the 
population and in primary and secondary care clinics (Figure 2). 
 
Figure 2. Proportion of patients presenting with episodic TTH, migraine and CDH in the 
general population,7 and in primary89.90 and secondary care headache clinics.91 
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• In the general population, TTH was reported by the majority of people, while migraine 
affected about one in six people and CDH about one in 20.7 
• In patients presenting to primary care with episodic headaches, virtually all had migraine, 
irrespective of the physician and patient diagnoses.89,90 Very few people consulted for 
TTH. Patients with chronic headaches were excluded from this study. 
• In secondary care, the majority of patients had CDH, while about one third had migraine. 
No patients were referred for TTH.91 One study of patients with CDH in a secondary care 
clinic showed that 78% had transformed migraine, 15% chronic TTH and 7% other 
headache disorders.92 
 
These studies also have important implications for headache diagnosis, which are discussed 
below. 
 
Diagnosis 
Population-based studies demonstrate that a high proportion of migraine sufferers who 
consult physicians do not receive a correct diagnosis.82,86,87,93,94 Over the past decade, the 
diagnostic rate has only increased from about 45% to 60%, again despite the many initiatives 
designed to improve this. Features associated with an accurate diagnosis of migraine 
included female gender, the presence of an aura, the absence of co-morbid depression, and 
the presence of headache-related disability.65,82,95 
 
Table 5. Proportion of patients with migraine correctly diagnosed by their physicians in 
population-based studies. 
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Study Proportion of patients correctly 
diagnosed with migraine (%) 
USA, 199482 45 
USA, 199893 44 
France, 199994 42 
USA, 200286 56 
UK, 200387 67 
 
The IHS classification criteria have provided guidelines for the diagnosis of migraine and 
TTH for well over a decade now,1,2 although CDH (chronic migraine, chronic TTH, 
hemicrania continua and NDPH) was only defined in the 2004 document.2 While these 
criteria are comprehensive, they are also lengthy, the physician being asked to potentially 
read through 160 pages to make a correct diagnosis. However, the diagnosis of CDH is not 
so simple, even using the IHS criteria. Several studies have demonstrated that many patients 
cannot be classified using the IHS criteria,31,92,96 with many patients being classified with 
migraine. Multiple and cumbersome diagnostic procedures were necessary to diagnose 
patients with chronic headaches.31,96 
 
Clearly, such complex criteria are not applicable to primary care. What are needed are 
simple inclusive questionnaires and/or checklists to screen for multiple headache subtypes in 
conjunction with exclusive questionnaires to specify the individual headache. From the 
Landmark study described above,89,90 it was deduced that migraine should be the default 
diagnosis for patients presenting to primary care with episodic disabling headache, in the 
absence of contradictory evidence. Recently, several new questionnaires have been 
developed to aid in headache diagnosis, with most being exclusive questionnaires to 
diagnose migraine: 
• Maizels and Burchette developed the Brief Headache Screen to diagnose different 
headache subtypes.97 Migraine, daily headache syndromes and medication overuse 
were distinguished using three questions: How often do you get severe headaches?; 
How often do you get mild or less severe headaches?; and How often do you take 
pain relievers, or any medication to relieve headache symptoms? 
• Lipton et al developed a 3-item screener that sensitively and specifically diagnosed 
migraine: Has a headache limited your activities for a day or more in the last three 
months?; Are you nauseated or sick to your stomach when you have a headache?; 
Does light bother you when you have a headache?98 Two or three ‘yes’ answers 
coincided with a diagnosis of migraine. 
• Cady et al developed a 3-item screener that sensitively diagnosed migraine: Do you 
have recurrent headaches that interfere with work, family, or social functions?; Do 
your headaches last at least 4 hours?; and Have you had new or different headaches 
in the past 6 months?99 Migraine was indicted by a ‘yes’ answer to the first two 
questions and a ‘no’ answer to the third. 
• Pryse-Phillips et al developed a 3-item screener: Do you have a headache every 
day?; Is your headache on one side of your head only?; Does your headache stop 
you from doing things? The questionnaire distinguished between pure migraine and 
other headache diagnoses with high reliability, validity and sensitivity.100 
The clinical utility of these questionnaires remains to be elucidated. 
 
Treatment  
Population-based studies indicate that the majority of migraine sufferers rely on over-the-
counter (OTC) medications for treatment (Table 6).65,86,101,102  This is the case even for those 
who also have medications prescribed by their physician.65,86.88 Again, this situation seems to 
have changed little over the past decade. 
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Table 6. Proportion of migraine sufferers using prescription and over-the-counter 
medications.  
       % Sufferers 
  Country Prescription 
medications 
OTC 
medications 
No 
medications 
USA, 1992101 37 59 4 
Canada, 199365 44* 91* ND 
Canada, 1998102 12 88 0 
USA, 200286 46* 72* 5 
ND = No data 
*Some sufferers took both prescription and OTC medications 
 
Two studies in migraine patients showed that little more than a quarter of them (27%88 and 
29%103 respectively) were satisfied with their acute medications. The main reasons for 
dissatisfaction related to efficacy rather than to the incidence of side effects (Table 7).103 
 
Table 7. Unmet treatment needs of migraine sufferers. Proportion of sufferers reporting the 
reason for dissatisfaction with their usual acute migraine treatment to be subjectively 
‘important’ or ‘very important’.103 
 
Reason for dissatisfaction Sufferers (%) 
Pain relief takes too long 87 
Does not relieve all the pain 87 
Does not always work 5 
Headache comes back 71 
Too many side effects 35 
 
 
When asked, patients stated that they primarily wanted acute medications to provide rapid 
and complete relief, with no recurrence. They were also interested in medications that were 
convenient to take at any time and place.88,103  
 
The methods used in assessing efficacy of acute migraine medications follows those 
developed for double-blind, placebo-controlled studies with the triptans. A four-point scale is 
used: severe, moderate, mild and no headache, respectively Grades 3, 2, 1 and 0. 
Headache relief, defined as an improvement from severe or moderate to mild or none at 2 
hours after treatment, was developed by Glaxo in the late 1980s to use in their clinical 
studies with sumatriptan.3 Improvement to pain-free (Grade 3/2 to 0) has since been 
advocated by the IHS as a more clinically-relevant endpoint.4 More recently still, these 
endpoints have been further refined. An improvement of any headache to pain-free is now 
advocated by many researchers, especially as recent recommendations state that triptans 
should be given as soon as possible after the headache starts, so long as the patient is sure 
that it is a migraine.104 All these endpoints are illustrated in Figure 3. 
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Figure 3. Assessments of the efficacy of acute migraine treatments in clinical 
studies3,4,104. 
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Other researchers propose the concept of ‘sustained pain-free’, in which the patient must be 
without pain for 24 or 48 hours after treatment, with no headache recurrence or use of rescue 
medications.105 Such strict endpoints result in quite low efficacy rates, that can be criticised in 
terms of their clinical relevance. 
 
Endpoints used for preventive treatments (used for frequent migraine and CDH to reduce the 
frequency of attacks) relate to reductions in the frequency, duration and severity of attacks. 
Perhaps the most stringent endpoint (and the gold standard) is a reduction of over 50% in 
the number of attacks in a defined time period. The latest studies with the neuromodulator 
topiramate in migraine illustrate the optimal treatment endpoints (change from baseline in 
mean monthly frequency, ≥ 50% reduction in monthly migraine frequency, number of monthly 
migraine days, severity, duration, days per month requiring rescue medication and  adverse 
events).106–108 However, preventive treatment of migraine and CDH is notoriously difficult, 
and high drop-out rates from treatment are reported due to wrong diagnoses, incorrect use of 
the available drugs (using inappropriate doses for inadequate time periods), patient 
expectations of a ‘cure’ rather than the usual reduction in frequency and the incidence of 
bothersome side effects.109,110  
 
A survey discovered the following reasons for treatment failure that led to patients being 
referred to secondary care headache clinics: 
• The diagnosis was incorrect or incomplete 
• Important exacerbating factors were missed 
• Prescribed and non-prescribed treatments were inadequate 
• Patients had unrealistic expectations or co-morbidities.111  
Improvements in the diagnosis and treatment of headache are therefore required to improve 
the management of refractory patients. 
 
1.6 Shortcomings in available knowledge (rationale for thesis) 
 
Population-based studies provide information on the pattern of illness in the general 
population, while clinic-based studies show the profile of patients who actually see a 
physician for their condition. Comparing data from these two types of studies allows the 
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tentative analysis of factors that drive consultation and aids in the identification of sufferers 
whose needs are not being met.  
 
An enormous amount of material is available from population- and clinic-based studies on 
the epidemiology, burden of illness and management of migraine, much of it published in the 
last decade or so. Despite this, migraine is generally under-recognised, under-diagnosed and 
under-treated in the clinic.58 The situation is even worse for TTH and CDH. The Landmark 
Study showed that very few TTH sufferers consult with a physician,89,90 and while most 
sufferers are likely to be only moderately affected by the disorder, the pattern of co-
morbidities suggest that there is a subgroup of sufferers who may be quite severely affected, 
but who are invisible to medical services at present. We have no information as yet from 
population-based studies on the proportion of CDH sufferers who consult, but we can deduce 
likely trends from other data. Chronic migraine sufferers are seen in clinics much more often 
than chronic TTH sufferers,92 although they are equally prevalent in the population.8 This 
suggests that chronic TTH is particularly unrecognised and managed poorly at the moment. 
The fact that consultation rates for migraine persist at about 50%18,21,65,82–88 also suggests 
that chronic migraine sufferers are also probably under-recognised, under-diagnosed and 
under-treated. There is therefore an enormous unmet clinical need for the common benign, 
primary headaches, which has not been addressed significantly in recent years. Research 
needs include the following: 
• Population-based epidemiological studies in TTH and CDH, particularly with respect 
to the definition of what constitutes chronic migraine 
• Identifying factors that predict medical need in TTH sufferers (episodic and chronic) 
• Population-based studies on recognition, diagnosis and management of CDH 
• Clinic-based studies on the management of TTH, migraine and CDH 
• In addition, educational initiatives are required to encourage sufferers with unmet 
medical needs to consult a physician or other healthcare professional.  
 
The need to improve knowledge of headache severity and headache management practices 
has driven researchers and physicians to devise new ways of assessing the burden of 
illness. Methods to assess QOL are well known and generic and headache-specific QOL 
questionnaires have been developed that are methodologically robust and have proved 
valuable in research.35–38 They are perhaps not so valuable in the clinic, where the lack of 
intuitively-understandable questions and units make them difficult to use with patients. 
Researchers have instead turned to assessments of impact (synonymous with disability) to 
overcome these barriers. 
 
Assessments of disability and impact describe the consequences of illness; the effects on the 
everyday lives of sufferers. They are therefore potentially understandable to both the 
physician and the patient. MIDAS and HIT are the most investigated of these questionnaires. 
Both are generally robust methodologically, but are not as well categorised in terms of 
clinical utility. The strengths of MIDAS are that it is reliable and valid, is easy to use and has 
units that are easily understandable to the patient and physician.40–43,48 Its weaknesses are 
that patients find it difficult to complete without supervision and that it may only show utility in 
more disabled patients. In secondary care clinics, many patients have high MIDAS scores, in 
the Grade IV range.45 In this setting, MIDAS has proved useful as a tool to demonstrate the 
efficacy of treatments. In primary care and below (e.g. in the pharmacy), however, many 
headache sufferers score 0 on MIDAS, making it impossible to use as an outcome tool. 
Some of these patients may have unmet medical needs that are not detectable with MIDAS. 
The strengths of HIT are that it is reliable and valid, and covers the full range of headache 
severity, thus overcoming the floor effects seen with MIDAS.46,49,50,53 However, it has not 
demonstrated the clinical utility that MIDAS has, and may be more suitable as a diagnostic 
tool than as an impact tool.53,54 Research needs with impact questionnaires therefore include 
the following: 
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• Further investigation of the clinical utility of MIDAS and HIT 
• Investigating other ways and tools to investigate impact 
• Investigating impact as a tool to help with diagnosis. 
 
Migraine is generally poorly diagnosed in primary care,82,86,87,93,94 and an inaccurate diagnosis 
drives inadequate management to a large extent.111 By extrapolation, diagnosis of TTH and 
CDH are also likely to be poor. While several new questionnaires have been developed in 
recent years that diagnose migraine specifically,98–100 questionnaires to screen for different 
headaches are thin on the ground and not fully categorised in terms of methodology and 
clinical utility.97 Research needs include the following: 
• Developing new questionnaires to screen for headache subtype for research and the 
clinic (for patients presenting to GPs and other healthcare professionals) 
• Deducing the factors that predict diagnosis, to develop a unified headache diagnostic 
questionnaire. 
 
Treatments for migraine remain clearly inadequate, with most sufferers still relying on OTC 
medications,65,86,101,102 even though effective acute and preventive medications are available 
for prescription by the physician. The situation for disabled TTH and CDH sufferers is likely to 
be even worse, due to the lack of knowledge about these conditions. One possible way of 
potentially improving treatments is to have a clear and simple way for the physician to assess 
the efficacy of therapies. They can then change (or not) the patient’s treatment based on 
objective criteria. Currently-used endpoints are those developed for clinical trials conducted 
for regulatory purposes.3,4 These may not be applicable to everyday clinical practice. 
Research needs include the following: 
• Evaluation of the currently-used endpoints for their accuracy and clinical utility 
• Development of new valid but simple endpoints for use in everyday clinical practice. 
 
1.7 Objectives of the thesis  
 
This thesis is based on research conducted over the past decade in primary care clinical 
practice. The major aim was to conduct clinic-based naturalistic studies designed to generate 
data that are applicable to everyday clinical practice. All of the studies were instigated and 
designed by the author, in conjunction with colleagues. Some of the studies were conducted 
in the author’s own clinical practice and others in the area of Surrey, UK. Others were 
conducted nationally in the UK under the auspices of the Migraine in Primary Care Advisors, 
a UK-based charity dedicated to the improvement of headache management in primary care 
(www.mipca.org.uk), of which the author is the chairman.  
 
The main objective of the thesis was to investigate headache-related disability, how to 
recognise and assess disabled patients and the clinical utility of assessing disability in 
primary care clinical practice. Individual objectives within this area were as follows: 
1. To critically evaluate the evidence base for the quality of clinical evidence in acute 
migraine studies. 
2. To investigate whether alternative clinical study endpoints may be useful in evaluating 
patients’ response to acute migraine therapies. 
3. To critically evaluate the evidence base for the use of disability and impact tools in 
migraine. 
4. To investigate the disability experienced by different groups of headache patients in 
the clinical setting. 
5. To investigate the efficacy of the MIDAS questionnaire when used by nurses in 
headache screening. 
6. To investigate factors associated with headache diagnosis and develop a new 
screening questionnaire for different headache subtypes. 
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7. To investigate factors associated with headache management and develop a new 
questionnaire to help physicians decide on the need to change acute migraine 
medications. 
 
1.8 Research questions 
 
1. What is the quality of the evidence that underpins the use of acute migraine 
medications and how can it be used to provide guidance to physicians on how to 
evaluate clinical evidence rationally and in an evidence-based way? 
2. Is patient preference a useful endpoint in clinical studies of acute migraine 
medications? 
3. Does the disability associated with the headaches experienced by female migraine 
sufferers differ inside and outside the menstrual period? 
4. What are the emotional factors implicated in how patients with TTH, migraine and 
CDH cope with their headaches on a chronic basis? 
5. What is the methodological robustness and the clinical utility of the impact 
questionnaires MIDAS and HIT used to assess the severity of headaches? 
6. What is the clinical utility of the MIDAS questionnaire when used by nurses in the 
initial management of headache patients, before they see a physician? 
7. What is the clinical utility of the HIT questionnaire in terms of its use as a diagnostic 
or impact tool? 
8. Can we develop a new diagnostic screening questionnaire for headache for use in 
primary care? Does such a questionnaire exhibit methodological robustness and 
potential clinical utility for patients and healthcare professionals? 
9. Can we develop a new questionnaire to be used as screener for the need to change 
patients’ acute migraine medications? Does such a questionnaire exhibit 
methodological robustness and potential clinical utility for primary care physicians?  
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2 
 
Methods 
 
Introduction: Outline of thesis 
This thesis poses several questions relating to the clinical importance of headache-related 
disability, how to recognise it and how to assess it. 
 
Clinical importance of assessing disability 
1. Chapter 2.1. What is the quality of the evidence that underpins the use of acute 
migraine medications and how can it be used to provide guidance to physicians on 
how to evaluate clinical evidence rationally and in an evidence-based way? 
2. Chapter 2.2. Is patient preference a useful endpoint in clinical studies of acute 
migraine medications? 
These items are analysed by searches and reviews of the relevant clinical literature on the 
subjects. 
 
Recognising headache-related disability 
3. Chapter 2.3. Does the disability associated with the headaches experienced by 
female migraine sufferers differ inside and outside the menstrual period? 
4. Chapter 2.4. What are the emotional factors implicated in how patients with TTH, 
migraine and CDH cope with their headaches on a chronic basis? 
These items are analysed by separate naturalistic studies conducted in primary care clinical 
practice. 
 
Assessing headache-related disability 
5. Chapter 3.1. What is the methodological robustness and the clinical utility of the 
disability-based questionnaires MIDAS and HIT used to assess the severity of 
headaches? 
This item is analysed by searches and reviews of the relevant clinical literature on the 
subject. 
 
6. Chapter 3.2. What is the clinical utility of the MIDAS questionnaire when used by 
nurses in the initial management of headache patients, before they see a physician? 
7. Chapter 3.3. What is the clinical utility of the HIT questionnaire in terms of its use as a 
diagnostic or impact tool? 
8. Chapter 3.4. Can we develop a new diagnostic screening questionnaire for headache 
for use in primary care? Does such a questionnaire exhibit methodological 
robustness and potential clinical utility for patients and healthcare professionals? 
9. Chapters 3.5 and 3.6. Can we develop a new questionnaire to be used as screener 
for the need to change patients’ acute migraine medications? Does such a 
questionnaire exhibit methodological robustness and potential clinical utility for 
primary care physicians?  
These four items are analysed by separate naturalistic studies conducted in primary care 
clinical practice. 
 
Literature searches and reviews 
 
Literature searches were conducted by a combination of three different ways: 
1. Through searches of MedLine and journal websites. 
2. By attending and monitoring presentations at international congresses on headache 
and neurology: International Headache Congress, European Headache Society, 
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American Headache Society, Migraine Trust International Symposium, Headache 
Care for Practising Clinicians, American Academy of Neurology, European 
Federation of Neurological Societies. 
3. By collating discussions at meetings of the UK Migraine in Primary Care Advisors 
(MIPCA) and the UK Migraine Action Association (MAA). 
 
Studies 
Design 
The studies included in this thesis were all open, naturalistic studies conducted in primary 
care clinical practice. They were designed to mimic the situation in everyday clinical practice 
in terms of patients selected, drugs and doses administered and outcomes assessed.  
 
Participants 
The patients taking part in the studies were people being treated for TTH, migraine or CDH 
at primary care clinics in the UK. Many of the patients came from the author’s own General 
Practice-based clinics. Other patients were referred to the author from the MAA, the UK 
patient support group. Finally, multicentre studies also included patients from the practices of 
MIPCA members, all of whom are primary care physicians. Patients were diagnosed 
according to the criteria of the International Headache Society (IHS) pertaining at the time,1 
in conjunction with the author’s own clinical experience. Patients had to be between 18 and 
65 years of age, not be abusing recreational drugs and not suffering from conditions that 
could interfere with the study results or put the patient at risk. Few restrictions were placed 
on the patients taking part in the studies deliberately to ensure, as far as possible, that the 
patients were representative of those in clinical practice. 
 
All patients gave their written informed consent to take part in the studies and, where 
appropriate, institutional review body approval was obtained for the studies from local ethics 
committees. 
 
Procedures 
Demographic and baseline characteristics were recorded for all patients at baseline. In 
addition, patients were assessed with other questionnaires to assess their level of headache-
related disability. Patients were then typically followed up using these questionnaires over a 
period of time when they were allowed to treat their headaches with their usual medications. 
Details of these assessment procedures are shown in Table 1. 
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Table 1. Details of the studies: investigations, assessments and timelines. 
 
Chapter Study investigation Baseline 
assessments 
Time 
of 
follow 
up 
Follow-up 
assessments 
2.32 Disability of headaches inside 
and outside the menstrual 
period 
Headache, 
depression and bodily 
pain questionnaire 
2 
months 
Disability 
questionnaire 
2.43 Emotional factors associated 
with TTH, migraine and CDH 
Short Pain Inventory 
(SPI©) 
7 days Short Pain 
Inventory (SPI©) 
3.24 Utility of the MIDAS 
questionnaire when used by 
nurses 
Questionnaire on 
headache features 
and consultations; 
MIDAS questionnaire 
6 
months 
Questionnaire 
on headache 
features and 
consultations; 
MIDAS 
questionnaire 
3.35 Validity and clinical utility of 
Internet HIT and SPI 
Internet HIT; 
SPI 
7 days Internet HIT; 
SPI 
3.46 Development of a new 
diagnostic screening 
questionnaire for headache 
Diagnostic Screening 
Questionnaire (DSQ) 
ND ND 
3.57 and 
3.68 
Development of a new 
questionnaire to screen for the 
need to change patients’ acute 
medications 
SF-36 QOL 
questionnaire; 
MIDAS questionnaire; 
Migraine Therapy 
Assessment 
Questionnaire 
(MTAQ) 
1 week SF-36 QOL 
questionnaire; 
MIDAS 
questionnaire; 
MTAQ 
ND = no data 
 
Instruments 
Headache, depression and bodily pain questionnaire 
A questionnaire was developed by the study investigators to assess the headaches, 
depression and bodily pain severity of patients attending a UK primary care practice (see 
Chapter 2.3).2 Three questions assessed headache, five assessed depression and four 
assessed bodily pain severity. The answers to the questions were used to define the 
diagnosis and illness severity. The questionnaire was devised to be simple to use and 
potentially applicable to primary care clinical practice. 
 
Disability questionnaire 
A disability questionnaire was developed by the study investigators to assess headaches that 
took place inside and outside the menstrual period over a 2-month period (see Chapter 2.3).2 
Criteria used to develop the questionnaire included the IHS diagnostic criteria pertaining at 
the time.1 Questions assessing the time lost from normal activities and the further time spent 
at less than 50% of normal capabilities are similar to those used in the MIDAS 
questionnaire,9 and therefore have potential validity.  
 
Short Pain Inventory (SPI©) 
The SPI was used to assess the emotional factors associated with TTH, migraine and CDH3 
and to assess the validity and clinical utility of the Internet HIT and SPI questionnaires.5 
 
The SPI is a 17-item self-rating questionnaire dedicated to measuring any pain, not only 
headache. The questions assess pain intensity, social interaction skills and components of 
emotional function. Patients rate each item on a five-point Likert scale: not at all, a little, 
moderately, very much so and extremely. Five subscales measure sedation, social 
interaction, anxiety, sadness and anger, and have been fine-tuned by maximising items that 
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are specific to pain. The SPI takes about one minute to complete,10 and can be accessed via 
the internet with automatic scoring.11 A scale of Total Mood Disturbance (TMD, 14 items) can 
be summated from the SPI, which measures the subtle mood changes that specifically 
covary with mild to severe pain (including sadness, anger, anxiety and sedation scores 
[social interaction scores are removed because this is a cognitive-behavioural parameter]). 
All 17 items can be summated to form the Total Pain Disturbance (TPD) score.  
 
As the physical severity of pain worsens, so generally does each of the emotional 
components.12–14 If a patient’s emotional score is exaggerated or flattened relative to the 
normal values, then a coping score can also be given as to how well a patient is coping with 
their pain, relative to others at the same physical level of pain. In this way an emotional 
‘footprint’ of the headache can be created. This can be very useful in the individual 
management of patients. It has been found that around 60% of the variance of physical pain 
is common to the overall mood of the patient.12,13 The SPI has been shown to be far more 
powerful at discriminating between varying levels of physical pain severity than the McGill 
Pain Questionnaire (used as the gold standard measure), with the majority of the pain 
variance being captured by the SPI.12  
 
Other studies have demonstrated that the SPI subscales could differentiate the footprint of 
pain resulting from headache and other pain states such as dental pain, osteoarthritis and 
chronic pain states.5,13,14 In general, headache patients had the greatest level of sedation, 
while dental patients had the greatest levels of anger, sadness and anxiety. Patients with 
osteoarthritis had the lowest level of mood disturbance of all the patient groups. Overall, 
headache patients had a level of mood disturbance at least as severe as patients who were 
attending a secondary care chronic pain clinic. 
 
MIDAS questionnaire 
The sensitivity of the MIDAS questionnaire to change was investigated in a study where a 
nurse provided headache advice to patients attending a primary care practice.4 It was also 
used to validate the Migraine-ACT questionnaire, a new questionnaire to screen for the need 
to change patients’ acute medications.7,8  
 
The development, testing and features of MIDAS are discussed in detail in Chapter 1. In 
brief, it assesses headache-related disability as the time lost from daily activities 
(employment, household work and family and leisure activities) and is scored as the number 
of days lost in a 3-month period.9  
 
HIT questionnaire 
The validity and clinical utility of the Internet HIT questionnaire were assessed in studies 
comparing it to the SPI questionnaire,5 and it was also used in conjunction with the SPI to 
assess the emotional factors associated with TTH, migraine and CDH.3 It was also used to 
validate the Migraine-ACT questionnaire, a new questionnaire to screen for the need to 
change patients’ acute medications.7,8  
 
The development, testing and features of Internet HIT and HIT-6 are discussed in detail in 
Chapter 1. In brief, it assesses headache impact as a constellation of pain, disability (activity 
limitations), tiredness and mood changes, and is scored numerically using arbitrary units.15  
 
SF-36 QOL questionnaire 
The SF-36 questionnaire was used to validate the Migraine-ACT questionnaire, a new 
questionnaire to screen for the need to change patients’ acute medications.7,8  
 
The SF-36 is a relatively brief generic QOL questionnaire, used in many chronic diseases, 
which contains 36 items, analysed as eight scales (physical functioning, role-physical, bodily 
pain, general health, vitality, social functioning, role-emotional and mental health) and a one-
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item measure of change in health. It is scored between 0 and 100, with a score of 50 
coinciding with the score for the healthy US general population.16 Investigations in migraine 
sufferers have shown that the SF-36 score correlates with migraine severity and 
discriminates between migraine and other serious medical conditions.17 
 
Migraine Therapy Assessment Questionnaire (MTAQ) 
The MTAQ was used to validate the Migraine-ACT questionnaire, a new questionnaire to 
screen for the need to change patients’ acute medications.7,8  
 
MTAQ is a migraine-specific disease management questionnaire, which contains nine 
questions on migraine frequency and triggers, use of medications and their effectiveness, 
healthcare utilisation and time lost from everyday activities.18 Each question is scored as 
‘yes’ or ‘no’, and the score ranges from 0–6 (three questions are not scored). A score of ≥ 2 
is used as an indicator that the patient requires follow up. It is proposed to be used in primary 
care to identify patients who require additional care.18 
 
Psychometric properties of the questionnaires 
The instruments used in the studies were either developed for use or testing by the author or 
were established questionnaires with well categorised psychometric properties. Table 2 
shows the psychometric properties of the established questionnaires. 
 
Table 2. Psychometric properties of the established questionnaires used in the studies. 
 
Questionnaire Internal 
consistency 
(Cronbach 
Alpha) 
Test-retest 
reliability 
Validity Validation measure 
Short Pain 
Inventory (SPI©) 
0.93–0.9412,13 0.9312 0.775 
0.7912 
Headache severity5 
McGill Pain 
Questionnaire12 
MIDAS questionnaire 0.769 0.80–0.839 0.639 Headache diary data9 
Internet HIT ND 0.7919 0.8919 Headache severity19 
SF-36 QOL 
questionnaire 
0.9720 0.8520 0.9221 Psychometric and clinical 
tests21 
MTAQ ND18 0.7118 0.6718 SF-36 QOL Questionnaire 
MIDAS Questionnaire 
Treatment satisfaction 
Healthcare resource use18 
NA = no data 
 
Overall, the SPI, MIDAS, HIT, SF-36 and MTAQ questionnaires are all highly reliable and 
valid, and therefore suitable for use in clinical research. In addition, the MIDAS22 and SF-3623 
questionnaires have also been shown to be sensitive to change and are therefore suitable for 
use in clinical practice. 
 
Statistical analyses 
Statistical analyses were performed using the Statistica V4 (Tulsa USA) statistical package 
for MacIntosh. All data were double- or triple-checked for accuracy, and all analyses checked 
for normality. Parametric analyses were used for normally-distributed data and non-
parametric analyses for non-normally distributed data. Analyses were two-sided and the level 
of significance was set at p-values less than 0.05. Patient demography was analysed using 
descriptive statistics only. 
 
Parametric analyses included discriminant function analysis, simple t-tests and test-retest 
Pearson product moment correlation coefficients,3,5 t-tests for dependent samples4 and test-
retest Pearson’s product moment and Spearman rank measures, discriminatory t-tests and 
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factor analysis.7,8 Non-parametric analyses conducted included the Mann-Whitney U Test,2 
Wilcoxon rank tests,4 and the Wilcoxon matched-pairs test.6  
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3.1  
 
Understanding the evidence: evaluating the efficacy of migraine 
medications in clinical practice* 
 
 
Abstract 
 
Large, randomised, double-blind, controlled clinical trials form the gold standard of clinical 
evidence for evaluating new medications. Meta-analyses and post hoc analyses of existing 
trials are increasingly used to compare therapies, in part to spare the expense and time 
required to conduct direct comparator studies. However, these analyses have been criticised 
methodologically, and should not be used on their own to evaluate therapies. Controlled 
clinical trials evaluating triptans in the acute treatment of migraine demonstrate clear 
superiority of the drugs over placebo, but only small differences are reported in studies 
comparing individual triptans and triptans with non-triptan medications. In contrast, patients 
can clearly distinguish between triptans and non-triptans and between different triptans in 
clinical practice. This incongruity may be due to the relative insensitivity of the standard 
clinical trial endpoint, relief of headache. New and more sensitive clinical trial endpoints are 
required for use in clinical studies that reflect everyday general practice (naturalistic studies). 
Among the potential endpoints are assessments of patient preference, impact on the 
patient’s daily life and quality of life. However, novel endpoints should be developed, in 
collaboration with patients, which can summarise the whole migraine experience. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Edited from the published manuscript: Dowson AJ, Kilminster S, Peters M, Lipscombe S, Rees T, 
Carter F, Darling S. Understanding the evidence: evaluating the efficacy of migraine medications in 
clinical practice. Headache Care 2005;2:133–43. 
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Introduction 
 
Migraine therapies are generally divided into acute (treatment of individual attacks as they 
occur) and prophylactic (pharmacological and non-pharmacological treatments taken daily to 
prevent attacks occurring). Most migraine treatments are relatively mature and the design 
and methodology of investigational studies varied quite widely. 
 
The introduction of the triptans to the armamentarium of acute treatments for migraine has 
revolutionised the management of the condition over the past decade or so. Seven triptans 
are now available to the physician in many countries: sumatriptan, naratriptan, zolmitriptan, 
rizatriptan, almotriptan, eletriptan and frovatriptan. Triptans can be prescribed in several 
different formulations: conventional tablets, melt-in-the mouth or orally disintegrating tablets 
(ODTs), nasal sprays, subcutaneous injections and, in some countries, suppositories are all 
available. In general, the primary studies with the triptans were of good quality and were 
conducted to similar principles of design and methodology.1 However, the resultant 
competition between the different manufacturers has led to a plethora of supporting clinical 
studies, and meta-analyses and post hoc analyses of clinical studies, all trying to establish 
superiority of one triptan over another. The result is a confusion of different study designs, 
endpoints and analyses, which can make it difficult for the physician to evaluate the evidence 
and to select the most appropriate drug for the individual patient. 
 
This article aims to provide an objective overview of the clinical methodology used in, and 
data resulting from, studies conducted with the triptans and other acute migraine treatments. 
We also analyse the misunderstandings and pitfalls, which have biased the results from 
studies, and provide guidance on what to look for when evaluating the evidence from 
migraine studies. This general guidance is intended to be applicable to the evaluation of 
other migraine treatments (acute and preventive) and to treatments for other therapy areas. 
This article is based on discussions held at a meeting of the Migraine in Primary Care 
Advisors (MIPCA), which took place on 1 May 2003.  
  
Clinical trial methodology 
 
Historically, the design and methodology of clinical studies of acute migraine treatments were 
decided on an ad hoc basis, as no agreed criteria were available. Indeed, diagnostic criteria 
were not established by the International Headache Society (IHS) until 1988.2 However, 
there was increasing pressure from regulatory authorities during the 1970s and 1980s to 
demonstrate a strong evidence base of efficacy and safety for new drugs. Scientists and 
clinicians took up this challenge in the late 1980s and early 1990s and developed new 
guidelines for study design, selection of patients, study methodology, endpoints and 
analyses of study data that are mostly still in use today in short-term controlled studies in 
migraine:1 
• Studies are multicentre, randomised, double-blind, placebo- or comparator-controlled 
and generally parallel group in design. A crossover design is used only infrequently, 
due to the possibility of carryover effects. 
• Eligible patients are those diagnosed with migraine according to the IHS criteria.1 
Patients usually have to be adults with established migraine who experience between 
one and four migraine attacks per month and without significant co-morbidities. 
• Patients treat either one or three migraine attacks of moderate-to-severe intensity 
with study medication and evaluate the effect of treatment on record cards. 
• Patients self-rate the intensity of their headache and other symptoms. The primary 
endpoint chosen was the relief of headache, defined as an improvement from severe 
or moderate to mild or no pain at 2 hours after treatment (Figure 1). Secondary 
endpoints included: headache relief at other time points, pain-free status at 2 hours 
and other time points, time to self-rated ‘meaningful relief’, time to return of normal 
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daily activities, presence of non-headache symptoms (nausea, vomiting, photophobia 
and phonophobia), and the incidence of headache recurrence and adverse events. 
• Large numbers of patients are required and must be recruited to achieve sufficient 
power for the statistical analyses. Data are collected as the proportion of patients 
reporting the respective endpoints and are analysed using non-parametric statistical 
tests.  
 
In contrast, long-term studies may be stand-alone, or open-label extensions to the controlled 
clinical studies. Patients treat all their migraine attacks with the triptan for a 6- or 12-month 
period. The primary endpoint is usually the incidence and nature of reported adverse events. 
Efficacy data are also collected in terms of the percentage of patients or attacks where 
headache relief is reported. 
 
Figure 1. Primary endpoints from migraine clinical studies: Standard1 and IHS4 
recommended outcomes. 
 
Pain-free (IHS)
Pain relief (Standard)
3
Severe
2
Moderate
1
Mild
0
None
 
 
Perspective on clinical trial methodology 
When reviewing data from separate clinical studies, it is important to review the methodology 
used. Evidence from clinical studies can be graded in terms of quality:3 
• Grade A encompasses consistent evidence from one or more well-designed and 
randomised clinical studies, as well as that from systematic meta-analyses. 
• Grade B evidence is derived from well designed but non-randomised studies, and 
from non-systematic meta-analyses and post hoc analyses of controlled studies. 
• Grade C evidence is derived from opinion and practices used in the absence of 
objective evidence. 
Grade A evidence is essential in order to make clear recommendations for clinical practice. 
Grade B and C evidence should only be used to guide the objectives and design of future 
clinical studies.3 In practice, evidence from Grade B and Grade C studies is used to guide 
clinical decisions in the absence of Grade A evidence. 
 
Clinical studies need to be powered appropriately to detect expected differences between 
study drugs. Increasing the numbers of patients directly increases the power and clinical 
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relevance of the results. It is also important that study groups (e.g. active treatment and 
placebo) are of equivalent size. In migraine studies, about 100–200 patients per group are 
usually sufficient to distinguish between active treatment and placebo, but several hundred 
patients or more may be needed in each group to power differences between two active 
treatments of similar efficacy. 
 
It is important that patient groups are similar in different treatment groups. For example, 
hospital-based patients may respond differently to outpatients or primary care patients. The 
physician should be aware that it is possible to manipulate patient populations to obtain the 
result desired. Patients may not always be from a homogeneous group. For example, the 
typical recruitment of patients with 1–4 headache attacks per month in triptan studies may 
include sufferers of both migraine and chronic headache. The latter may be difficult to treat 
and it is unlikely that a triptan would be effective on its own for patients with chronic 
headaches. Furthermore, large differences in placebo response may point to large 
differences in the case mix. 
 
The design and endpoints should also be consistent across studies. Most randomised, 
controlled studies with the triptans follow the standard criteria1 but studies comparing triptans 
to non-triptan medications frequently use different endpoints that may lead to atypical results. 
The original standard primary endpoint of headache relief1 has come under challenge 
recently. The IHS now recommends that patients be pain-free at the 2-hour endpoint (Figure 
1).4 An even more stringent endpoint of ‘sustained pain-free’ is also advocated in recent 
publications.5 This specifies that patients be pain-free at 2 hours after treatment, and that 
they experience no headache recurrence and use no rescue medication in the 24 or 48 
hours after treatment. One problem with these newer endpoints is the low proportion of 
patients who respond, and that these definitions of efficacy may not correlate with a clinically 
relevant response. Interestingly, the results from many secondary endpoints (e.g. 
‘meaningful relief’, return to normal functioning and relief of non-headache symptoms) 
usually parallel headache relief rates in clinical studies. Headache relief may, therefore, be 
the most clinically-meaningful endpoint that we have for migraine studies. However, the 4-
point ‘Glaxo’ scale may not be optimal, as 5- or 7-point Likert scales are favoured in most 
therapy areas.6 In addition, tolerability forms an important endpoint in all studies, assessed 
as the incidence, nature and intensity of reported adverse events. It should be noted that 
tolerability may not be related to safety, and that it is the side effects that are clinically 
significant. Drug-related adverse events, rather than the total incidence of all events, may be 
the clinically important endpoint. 
 
Clinical study data on the triptans from well-designed, randomised studies 
 
Due to the similarities in study design, methodology and endpoints used in most clinical 
studies with the triptans, the data are directly comparable. We review data from placebo-
controlled and active comparator-controlled studies below. 
   
Placebo-controlled studies 
A summary of the efficacy of the different triptan drugs from placebo-controlled studies is 
shown in Table 1.7–11  
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Table 1. Summary of the efficacy of the different triptan drugs from randomised, placebo-
controlled clinical trials: proportion of patients reporting headache relief (improvement from 
severe or moderate to mild or no pain).7–11 This table is adapted and updated from Reference 
7. 
 
      Proportion of patients (%) 
Triptan Dose and route of 
administration 
Headache relief 
from triptan (%) 
Headache relief from 
placebo (%) 
Sumatriptan 6 mg subcutaneous 81–82 31–39 
Sumatriptan 100 mg film-coated 
tablet 
56–62 17–26 
Sumatriptan 100 mg fast-
disintegrating tablets86 
72 42 
Sumatriptan 50 mg film-coated tablet 50–62 17–32 
Sumatriptan 50 mg fast-disintegrating 
tablets86 
67 42 
Sumatriptan 25 mg tablet 52 17–27 
Sumatriptan 20 mg nasal spray 55–64 25–36 
Sumatriptan 12.5 mg suppository 43–69 21–48 
Sumatriptan 25 mg suppository 64–74 21–48 
Naratriptan 2.5 mg tablet 43–50 18–27 
Zolmitriptan 2.5 mg tablet 62–65 34–36 
Zolmitriptan 2.5 mg ODT 63 22 
Zolmitriptan 5 mg nasal spray 70 30 
Rizatriptan 10 mg tablet 67–77 35–40 
Rizatriptan 10 mg ODT 74 28 
Almotriptan 12.5 mg tablet 57–70 38–42 
Eletriptan 40 mg tablet 62–67 19–26 
Frovatriptan 2.5 mg tablet 38–40 22–35 
ODT = orally disintegrating tablet 
 
Reviewing the primary endpoint (headache relief at 2 hours) data shows that: 
1. The placebo response rate is highly variable, ranging from <20–48%. 
2. All triptan modalities and formulations are significantly superior to placebo in terms of 
headache relief. 
3. Most of the oral triptan formulations (including the conventional and orally 
disintegrating tablets [ODTs]) provide broadly similar levels of headache relief, 
although efficacy may vary somewhat in different studies with the same drug. 
However, naratriptan and frovatriptan have lower reported 2-hour efficacy rates 
compared to the other oral triptans. 
4. Subcutaneous sumatriptan is more effective than any other triptan formulation. Nasal 
spay formulations may be superior to oral forms, and certainly have a faster onset of 
action (within 15 minutes as compared to 30 minutes or more for tablets).  
 
Active comparator studies 
Relatively few well-designed, head-to-head, Grade A comparator studies between the oral 
triptans have been published and we have only found 12 to date conducted with marketed 
formulations (Table 2).12–23  
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Table 2. Summary of the efficacy of the marketed oral triptans from randomised, controlled, 
direct comparator clinical studies: proportion of patients reporting headache relief 
(improvement from severe or moderate to mild or no headache pain) at 2 hours after 
treatment.12–23 
 
Sumatriptan comparator studies 
Proportion of patients (%) 
Study Comparator 
drug 
Sumatriptan Placebo p-value 
(active 
comparators)
Zolmitriptan 5 mg vs. 
Sumatriptan 100 mg12 
(n=1,058) 
59 61 44 NS 
Zolmitriptan 2.5 mg vs. 
Sumatriptan 50 mg13 
(n=1,522) 
63 67 None NS 
Rizatriptan 10 mg vs. 
Sumatriptan 100 mg14 
(n=1,268) 
67 62 40 NS 
Rizatriptan 10 mg vs. 
Sumatriptan 50 mg15 
(n=1,329) 
72 68 38 NS 
Eletriptan 40 mg vs. 
Sumatriptan 100 mg16 
(n=692) 
65 55 24 NS 
Eletriptan 40 mg vs. 
Sumatriptan 100 mg17 
(n=2,113) 
67 59 26 <0.001 
Naratriptan 1, 2.5, 5, 7.5, 10 
mg vs. Sumatriptan 100 
mg18 (n=643) 
52–69 60 31 NS 
Almotriptan 12.5 mg vs. 
Sumatriptan 50 mg19 
(n=1,173) 
58 57 None NS 
Almotriptan 12.5 mg vs. 
Sumatriptan 100 mg20 
(n=668) 
57 64 42 NS 
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Eletriptan comparator studies 
 
Proportion of patients (%) 
Study Comparator 
drug 
Naratriptan Placebo p-value 
(active 
comparators)
Eletriptan 40 mg vs. 
Zolmitriptan 2.5 mg21 
(n=1,312) 
60 64 22 NS 
 
Naratriptan comparator studies 
 
Proportion of patients (%) 
Study Comparator 
drug 
Naratriptan Placebo p-value 
(active 
comparators)
Rizatriptan 10 mg vs. 
Naratriptan 2.5 mg22 (n=522) 
45* 21* None <0.001 
Eletriptan 40 mg vs. 
Naratriptan 2.5 mg23 (n=548) 
56 42 31 <0.01 
NS = not significant 
* Pain-free at 2 hours 
In this context, ‘comparator’ refers to the triptan being compared with sumatriptan, eletriptan 
and naratriptan in the three sub-tables. 
 
Overall, headache relief rates at 2 hours did not differ significantly in studies comparing 
sumatriptan (50 mg and 100 mg) with zolmitriptan 2.5 mg and 5 mg,12,13 rizatriptan 10 mg,14,15 
eletriptan 40 mg,16 naratriptan18 and almotriptan 12.5 mg.19,20 One study showed that 
eletriptan 40 mg was significantly superior to sumatriptan 100 mg,17 but the numerical 
advantage was small and it required a study population of over 2,000 patients to achieve 
statistical significance. A further large study showed similar headache relief rates with 
eletriptan 40 mg and zolmitriptan 2.5 mg.21 One other factor confounds these results. 
Sumatriptan (but not eletriptan) was encapsulated in all comparator studies with eletriptan, 
and studies have shown that the absorption of sumatriptan is reduced by this procedure.24 
These results should, therefore, be approached with caution. Eletriptan 80 mg was shown to 
be significantly superior to sumatriptan 100 mg17 and zolmitriptan 2.5 mg,21 but this high dose 
is not recommended for use in clinical practice. However, two studies have shown that 
rizatriptan and eletriptan are significantly superior to naratriptan in terms of headache relief 
rates 2 hours after treatment.22,23 
 
Rizatriptan and almotriptan do have some evidence of superiority over sumatriptan in these 
studies. Rizatriptan appears to be more rapidly acting than sumatriptan,14,15 with a 
significantly higher headache relief rate reported at 1 hour in one study.14 Almotriptan was 
reported to be as effective as sumatriptan, but was associated with a significantly lower 
incidence of adverse events,19,20 with significantly fewer chest symptoms reported in one 
study.19 In these studies, both almotriptan and sumatriptan were encapsulated. 
 
Comparison of triptans with non-triptan acute treatments for migraine 
Well-designed Grade A clinical studies comparing triptans and non-triptan medications using 
the endpoint of headache relief are also relatively scarce, and we have located nine studies 
comparing oral triptans with ergotamine and analgesic-based preparations (Table 3).25–33  
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Table 3. Summary of the efficacy of the marketed oral triptans and non-triptan medications 
from randomised, controlled, direct comparator clinical studies: proportion of patients 
reporting headache relief (improvement from severe or moderate to mild or no headache 
pain) at 2 hours after treatment.25–33 
 
Proportion of patients (%) 
Study Triptan Non-triptan 
drug 
Placebo p-value 
(active 
comparators)
Sumatriptan 100 mg vs. 
ergotamine 2 mg + caffeine 
200 mg25 (n=580) 
66 48 None <0.001 
Eletriptan 40 mg vs. 
ergotamine 2 mg + caffeine 
200 mg26 (n=733) 
54 33 None <0.001 
Sumatriptan 100 mg vs. 
aspirin 900 mg + 
metoclopramide 10 mg27 
(n=358) 
56 45 None NS 
Sumatriptan 100 mg vs. 
aspirin 900 mg + 
metoclopramide 10 mg28 
(n=421) 
53 57 24 NS 
Zolmitriptan 2.5 mg vs. 
aspirin 900 mg + 
metoclopramide 10 mg29 
(n=666) 
33 33 None NS 
Sumatriptan 50 mg vs. 
aspirin 1,000 mg vs. 
ibuprofen 400 mg30 (n=312) 
56 53* 
60** 
31 NS 
Sumatriptan 100 mg vs. 
tolfenamic acid 200 mg31 
(n=141) 
79 77 29 NS 
Sumatriptan 50 mg vs. 
naproxen 500 mg + 
metoclopramide 16 mg32 
(n=546) 
53 53 29 NS 
Sumatriptan 50 mg vs. 
paracetamol 500 mg 
+domperidone 10 mg33 
(n=120) 
33 36 None NS 
* Aspirin 1,000 mg; ** Ibuprofen 400 mg; NS = not significant 
 
Two studies compared triptans with Cafergot, an oral preparation of ergotamine 2 mg plus 
caffeine 200 mg. Both sumatriptan 100 mg and eletriptan 40 mg resulted in significantly 
superior headache relief, compared with Cafergot.25,26 However, the drug preparations may 
not have been equivalent in these studies. Oral ergotamine formulations have poor 
bioavailability and suboptimal efficacy. Parenteral ergotamine formulations, delivered rectally 
or by injection, are superior to oral formulations and a better study design would have been 
to use a double-dummy procedure to compare the different formulations.3 
 
Several studies have compared oral triptans to analgesic-based drugs: aspirin plus 
metoclopramide,27–29 aspirin alone or non-steroidal anti-inflammatory drugs (NSAIDs),30–32 
and paracetamol plus domperidone.33  In all of these studies, headache relief rates were 
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similar in the triptan and analgesic groups, although the triptans had superior pain-free data 
in some.  
 
One multicentre, randomised study has compared sumatriptan suppositories with a fixed 
combination of indomethacin, prochlorperazine and caffeine in 112 patients.34 Again, 
headache relief at 2 hours was similar in the two groups (sumatriptan = 65% versus 71% for 
the combination), although 2-hour pain-free data were significantly superior for the 
indomethacin combination (34% versus 49%, p<0.01).   
 
Perspective on clinical study data 
Evidence from randomised and well-designed Grade A clinical studies shows that, compared 
with placebo, all triptans are effective and well-tolerated in the acute treatment of migraine. 
Of the oral triptans, sumatriptan, zolmitriptan, rizatriptan, almotriptan and eletriptan have 
similar efficacy profiles. Direct comparator studies indicate that rizatriptan and eletriptan may 
be slightly superior to sumatriptan, although the differences are numerically small and, 
therefore, of uncertain clinical significance. The data for eletriptan are also confounded by 
problems with the formulation of sumatriptan used in the comparisons. Almotriptan may be 
better tolerated than sumatriptan, especially in terms of chest-related symptoms, but again 
the clinical significance of these results is questionable. Overall, naratriptan and frovatriptan 
appear to be less effective than the other oral triptans. Subcutaneous and nasal spray triptan 
formulations are more effective and faster-acting than the oral formulations. 
 
Oral sumatriptan and eletriptan are both significantly more effective than oral Cafergot. 
However, since oral formulations of ergotamine do not provide optimal efficacy, the clinical 
significance of these data is questionable. Several controlled studies using the conventional 
design and endpoints showed that oral triptans were not superior to oral analgesic-based 
therapies. However, the triptan response rate in these studies tended to be less than that 
reported in placebo-controlled studies, in some cases markedly so.29,33 This may (but not 
necessarily) indicate that these studies had design faults, which could limit their reliability. 
Numerous studies have shown that patients consider triptans to be much more effective than 
non-triptans when used in everyday clinical practice.35–38 
 
Meta-analyses and post hoc analyses with the triptans 
 
Meta-analyses and post hoc analyses can be used to combine and compare data from 
multiple clinical studies. Formal meta-analyses combine data from published and 
unpublished studies, and can be considered Grade A evidence if they are comprehensive 
and reproducible. Other analyses for combining data include the calculation of therapeutic 
gain (TG), number needed to treat (NNT) and number needed to harm (NNH, Table 4),39 and 
form Grade B evidence. These approaches have been used frequently with the triptans, in 
part probably to compensate for the relative lack of controlled comparator studies between 
them. 
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Table 4. Definitions of post hoc clinical endpoints: therapeutic gain, number needed to treat 
and number needed to harm39 
 
Therapeutic gain (TG): the proportion of patients benefiting from treatment, adjusted to the 
placebo rate 
 
=  Proportion of patients _ Proportion of patients 
benefiting on treatment  benefiting on placebo 
 
Number needed to treat (NNT): the number of patients that have to be treated in order for 
one patient to be treated successfully, adjusted for placebo 
 
=  100 / Therapeutic gain (% of patients) 
 
Number needed to harm (NNH): the number of patients that have to be treated in order for 
one patient to report an adverse event, adjusted for placebo 
 
= 100 / Proportion of patients reporting adverse events on treatment – Proportion of 
patients with adverse events on placebo 
 
 
Meta-analyses 
Two meta-analyses have been published comparing the oral triptans, using sumatriptan 100 
mg as the baseline comparator. Ferrari and co-workers analysed 53 published and 
unpublished clinical studies involving 24,089 patients.40 Their analyses indicated that, 
compared with sumatriptan, rizatriptan 10 mg exhibited better efficacy and consistency of 
response, and similar tolerability. Almotriptan 12.5 mg exhibited better sustained pain-free, 
consistency of response and tolerability data, while naratriptan showed superior tolerability. 
All other triptans (except frovatriptan, which was not included in the analyses) had similar 
clinical profiles to sumatriptan, and all were effective and well tolerated. The authors 
concluded that, of the marketed doses, rizatriptan 10 mg and almotriptan 12.5 mg offered the 
best chance of overall success. Belsey has published a further meta-analysis of 28 studies 
involving 13,204 patients. He analysed TG, NNT and NNH data and concluded that, of the 
oral triptans, only rizatriptan 10 mg was markedly superior to sumatriptan 100 mg in terms of 
overall efficacy and tolerability.41  
 
Post hoc analyses 
Several post hoc analyses of clinical data have been conducted with the oral triptans, 
investigating a variety of endpoints. One study analysed TG data, which showed clearly that 
subcutaneous sumatriptan 6 mg provided superior efficacy to any of the oral triptans.42 All 
the oral triptans were effective, although naratriptan and frovatriptan were the least effective, 
and almotriptan also seemed to be relatively less effective than oral sumatriptan, 
zolmitriptan, rizatriptan and eletriptan.42,43 An analysis combining data from three head-to-
head comparator studies between eletriptan 40 mg and sumatriptan 100 mg indicated that 
eletriptan was the more effective drug.44 Significantly more patients on eletriptan (67% 
versus 57%, p < 0.0001) reported headache relief at 2 hours after treatment, the primary 
endpoint, and secondary endpoints gave similar results. In a different type of post hoc 
analysis, almotriptan 12.5 mg proved to be more effective than rizatriptan 10 mg and 
sumatriptan 50 mg and 100 mg, in terms of a composite endpoint of cost-effectiveness ratio 
for sustained pain relief and no adverse events.45,46 
 
The manufacturers of rizatriptan have conducted several post hoc analyses comparing their 
drug to the other oral triptans. Combining data from several clinical studies, more patients 
taking rizatriptan were satisfied with their therapy,47 were pain-free at 2 hours and 24 hours 
after treatment,5 and were free of nausea after 2 hours than with other triptans.48  
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Perspective on meta-analyses and post hoc analyses 
Overall, the data from the meta-analyses and post hoc analyses with the triptans are 
consistent with those from controlled clinical studies. All the oral triptans were effective and 
well tolerated, and there were more similarities than differences between the drugs. 
Rizatriptan 10 mg and eletriptan 40 mg exhibited the best efficacy profiles, while naratriptan 
2.5 mg and almotriptan 12.5 mg exhibited the best tolerability. However, these analyses have 
come under criticism from several sources. 
 
Rigorous meta-analyses do provide Grade A clinical evidence.3 However, there is evidence 
that the meta-analyses conducted with the triptans may not fulfil the necessary criteria for 
this. The two meta-analyses did not provide consistent data, and the selection of studies, 
patient populations and endpoints differed. The meta-analysis by Ferrari et al40 is the most 
robust of the two, involving a substantially larger number of studies and patients than that of 
Belsey.41 However, even this large analysis has been criticised in terms of its methodology, 
statistical analyses and the clinical significance of its results.49–53 Using analyses of TG and 
NNT to compare triptans has also been criticised. Placebo response rates are crucial to the 
calculation of these values, and are highly variable in migraine studies54 while the response 
to active treatments tends to be less variable (Table 1). Several pieces of research have 
shown that NNT values are correlated more strongly to the placebo response than to the 
active treatment response.55 A systematic analysis of placebo-controlled studies with the 
triptans showed that the triptan response rate followed a normal distribution, while that of 
placebo did not.56 Both TG and NNT analyses failed the test of normality. The authors 
concluded that these transformations of data are a potential source of bias in meta-analyses 
of acute migraine treatments. Another group of authors has concluded that analysing TG and 
NNT adds no new information to the evaluation of placebo-controlled trials.55 There is also 
some argument as to whether the placebo response should be so disregarded, as placebo 
may activate the same pain modulating brain structures as pain-relieving drugs.57,58 
Estimations of TG and NNT may, therefore, significantly underestimate the efficacy of active 
treatments. It has been concluded that migraine therapies can only be effectively compared 
using well-designed head-to-head studies, and not by meta-analyses.55 
 
Triptans in clinical practice 
 
One of the characteristic features of the triptans is that their reported efficacy is greater when 
used in clinical practice than when used in controlled clinical trials. In studies which reflected 
everyday clinical practice (naturalistic studies), reported headache relief rates following 
treatment with sumatriptan and zolmitriptan were typically close to 80%.59,60 There are 
several possible reasons that may explain these findings: 
• The populations of patients may differ. Young and middle-aged adults predominate in 
clinical trials, while the general population of migraine sufferers contains all age 
groups, from children and adolescents, to older people.61  
• The severity of the headache may differ. Migraine sufferers in the general population 
experience, on average, about one migraine attack per month.61 In clinical studies, 
patients may have up to four attacks per month.1 It is likely that some of these 
patients have chronic daily headache, a condition that is more severe and more 
difficult to treat than migraine.62 
• Clinical studies are mostly conducted in Western Europe and North America, in 
Caucasian patients. Other countries and races may respond differently to the triptans. 
• Patients in clinical practice may not use the strict doses that are given in clinical 
studies. Dose-titration studies have shown that, given the choice, the majority of 
patients end up using higher doses of the triptans, e.g. sumatriptan 100 mg and 
zolmitriptan 5 mg.59,60 For some triptans, e.g. naratriptan and frovatriptan, the 
recommended dose may not be at the top of the dose-response curve. The use of 
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relatively high doses may, therefore, result in a markedly greater efficacy than that 
reported in clinical studies. 
• In clinical practice, patients may not wait until the headache is moderate or severe 
before treating with a triptan. In fact, recent evidence from randomised and controlled 
studies indicates that triptans are most effective when taken early in the migraine 
attack when the headache is mild. With sumatriptan 100 mg, pain-free rates of 71% 
were achieved 2 hours after the treatment of mild headache, compared to 54% when 
the initial headache was moderate or severe (p<0.05).63 Similar results have been 
reported with zolmitriptan64 and almotriptan,65 and it seems likely that future treatment 
guidelines will recommend that triptans be taken early in the attack when the 
headache is mild. Suggestions have recently been published on how to conduct 
randomised, controlled ‘early treatment’ studies with the triptans.66 
 
The search for new study endpoints 
 
The primary endpoints used in clinical trials with the triptans were designed to demonstrate 
significant differences between active treatments and placebo.1 This was done to comply 
with the need to produce documents suitable for submission to regulatory authorities 
worldwide, rather than to devise endpoints suitable for use in everyday clinical practice. In 
fact, the main endpoint of headache relief proved unable to distinguish between triptans and 
other active treatments. More sensitive endpoints may be required for use in clinical practice. 
In a survey, migraine patients reported the following attributes of acute treatments to be most 
important to them: complete pain relief, no headache recurrence, rapid onset of action, no 
side effects and relief of non-headache associated symptoms.67 A global measure of efficacy 
and tolerability is probably the best option to cover all these areas. Such global measures 
that have been used in migraine studies include assessments of patient preference and 
satisfaction, the impact on patients’ daily lives and quality of life. 
 
Patient preference and satisfaction 
Patient preference is a subjective global measure of efficacy and tolerability that can be 
simply assessed by the patient. Numerous migraine studies have used these assessments 
as secondary endpoints. In these studies, patients consistently preferred oral triptans over 
non-triptan acute medications.68 Additionally, patients were able to distinguish between 
different oral triptans, and expressed clear preferences between them. However, their 
responses were idiosyncratic. The main reasons patients gave for preferring one triptan over 
the other was a faster onset of action, a longer duration of effect and fewer adverse events. 
However, these reasons were all given for sumatriptan, zolmitriptan and rizatriptan in 
different studies, and the response could not be predicted in advance.69–71 One caveat of 
assessing patient preference is that it can only relate the performance of one drug to a 
second one. This endpoint does not provide absolute information about a drug, and 
precludes meta-analysis.  
 
Impact assessments 
Assessing the impact of migraine on patients’ daily lives has become an increasingly used 
measure of migraine severity over the past few years. Impact questionnaires have been 
developed, validated, and tested as outcome measures. The Migraine Disability Assessment 
(MIDAS) Questionnaire has shown sensitivity to change in studies of migraine and chronic 
daily headache,72,73 and further research may prove it to be a useful clinical study endpoint. 
Two other impact questionnaires, the Headache Impact Test (HIT)74 and the Short Pain 
Inventory (SPI),75 require development as outcome measures. 
 
Quality of life measures 
Migraine sufferers are known to have significantly poorer quality of life than the general 
population during their attacks, and also between attacks when they are regarded as 
symptom-free.76,77 Generic and migraine-specific QOL questionnaires have been developed 
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for migraine, and consistently show that effective migraine treatment results in improved 
patient QOL.78 Using one of the migraine-specific questionnaires as an outcome measure 
(the 24-hour Migraine-Specific QOL Questionnaire), it was demonstrated that rizatriptan 10 
mg was significantly superior to non-triptan acute medications in terms of work and social 
functioning, energy, and patients’ feelings and symptoms.79  
 
New initiatives 
All the above questionnaires have the potential to summarise the whole migraine experience 
and act as effective outcome measures. However, more work is required to define patients’ 
responses and validate these assessment tools against the existing gold standard measure 
of headache relief. A new questionnaire, the Migraine Assessment of Current Therapy 
(Migraine-ACT) assesses the need for reviewing acute medications in terms of four 
questions in clinically-relevant domains: impact, global assessment of relief, consistency of 
response and emotional response.80 Patients answer the questions as ‘yes’ or ‘no’ and an 
increasing number of ‘no’ answers indicates increasing medical needs. It therefore combines 
elements of patient satisfaction, impact and QOL. A large prospective study showed that 
Migraine-ACT exhibited high reliability and validity, and had considerable potential clinical 
utility.80 What is now needed is to investigate the sensitivity to change of Migraine-ACT and 
to develop a similar questionnaire for preventive medications.  
 
Another approach is to examine the principles underlying patient response to therapy, using 
qualitative research. Qualitative research aims to increase the understanding of patients and 
physicians and could help to provide a more realistic assessment of headache treatments 
and to develop relevant patient-centred endpoints.81 Open ended-questions allow patients 
and physicians to speak freely about their perspectives, including beliefs about interventions, 
and the benefits and preferences of therapies. Asking a different type of questions, 
qualitative research can provide information not available from conventional quantitative 
methods. Qualitative research can be combined with quantitative methods, by conducting a 
qualitative study to generate hypotheses, which can be tested using quantitative methods.82 
Qualitative research is now recommended by the UK Medical Research Council for use in 
the development of clinical trials programmes, to gain better understanding of patients’ needs 
and to develop new clinical endpoints.83 Qualitative methods can also follow quantitative 
methods, to help explain quantitative findings, e.g. explaining anomalous results such as the 
unexpected similarity in efficacy of triptan and non-triptan medications and differences in 
placebo response in separate patient populations.84 Combining qualitative and quantitative 
methods in randomised controlled trials is believed by some researchers to be the best 
means of assessing whether (and why) interventions work (efficacy) and whether (and how) 
they work in clinical practice (effectiveness). Such initiatives can increase the generalisability 
of results and generate information to help successfully implement and refine effective 
interventions in natural settings.85  
 
Conclusions – understanding the evidence  
 
In evaluating clinical evidence, the randomised, double-blind, controlled clinical trial remains 
the gold standard for evaluating the clinical profile of migraine drugs. However, even these 
studies may have deficiencies, and there are several items to look out for when evaluating 
good quality headache studies: 
• The number of patients in the study needs to be appropriate for the analyses 
planned. In general, there should be at least 50 patients per treatment group, with 
equal numbers of patients in the active and placebo (or active competitor) groups. It 
is interesting that large numbers of patients are required to show significance in 
evaluating migraine therapies, up to 200 per group in placebo-controlled studies2,7 
and up to 1,000 or more in triptan comparator studies.17 
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• Patient withdrawals from the study should be low, and not exceed 10% of the total. 
The proportion of patients withdrawing should be similar in the separate treatment 
groups.  
• Outcome measures should be quantifiable, discriminate well and have intuitively 
meaningful units. Categorical scales (e.g. five- or seven-point Likert scales) are 
preferable to visual analogue scales, although 10-point numerical scales work well in 
the Netherlands. 
• The data should be clinically relevant. For treating migraine, speed of onset, duration 
of response, and assessments of functional status or well-being are important in 
addition to headache relief at defined time points.3,8 
 
On the whole, the results from meta-analyses and post hoc analyses were congruent with 
those from controlled clinical studies. However, they have also generated controversy, and 
their chief utility may be to suggest avenues for future clinical studies, rather than being used 
on their own as a means of selecting acute treatments for migraine. 
 
However, results from clinical trials may not reflect the situation in clinical practice for 
migraine. For example, clinical studies show only small clinical differences between the oral 
triptans,12–21 whereas patients exhibit clear, if individual, preferences between them.69–71 The 
challenge is to develop studies that can effectively distinguish between the triptans, or to 
distinguish between patient-dependent sensitivity to individual triptans. This may be achieved 
by conducting naturalistic studies in everyday clinical practice with the full range of patients 
who suffer from migraine, allowing them to use the drugs according to normal prescription 
recommendations. The development of new, more sensitive and valid endpoints to assess 
migraine relief in collaboration with patients would facilitate this process. 
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3.2  
 
Patients’ preference for triptans and other medications as a tool for 
assessing the efficacy of acute treatments for migraine* 
 
 
Abstract  
 
Oral triptans are effective and well tolerated acute treatments for migraine, but clinical 
differences between them are small and difficult to measure in conventional clinical trials. 
Patient preference assesses a global measure of efficacy and tolerability, and may be a 
more sensitive means of distinguishing between these drugs. In a series of studies, patients 
consistently expressed a clear preference for triptans over their usual non-triptan acute 
medications, e.g. analgesics and ergotamine. Direct comparator studies of patient preference 
with oral triptans showed that patients could distinguish between different triptans, and 
between different formulations of the same triptan. Patients could even distinguish between 
the three oral doses of sumatriptan. The most frequently provided reasons for preference 
were speed of response and overall effectiveness. Patient preference is a sensitive and valid 
clinical trial endpoint and physicians should consider using it when reviewing the efficacy of 
acute migraine medications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Edited from the full published article: Dowson AJ, Tepper SJ, Dahlöf C. Patients’ preference for 
triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J 
Headache Pain 2005;6:112–20. 
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Introduction 
 
Oral triptans (5-hydroxytryptamine-1B/1D receptor agonists) are effective and well tolerated 
acute treatments for migraine. [1, 2] However, direct comparator trials and systematic 
reviews indicate that differences between oral triptans are relatively small. [3–5] The 
standard clinical trial endpoint of headache relief [6] may be relatively insensitive and not 
relevant to everyday clinical practice. [7] There are also issues of study design and 
encapsulation of certain formulations that may reduce the clinical applicability of some study 
results. [8] Meta-analyses may be rather blunt measures of efficacy, better reflecting placebo 
response rather than active response [9]. Therefore, other measures of efficacy need much 
greater study. [10] 
 
Since patients are treated on an individual basis, the more important question is not which 
triptan is best relative to another, but whether the chosen triptan provides the outcome 
desired by the patient and healthcare provider. A measure that evaluates the patient’s 
subjective judgement of the efficacy and tolerability of therapy may be a more sensitive and 
valid measure of efficacy than the standard endpoints. Patient preference evaluates a global 
measure of the clinical profile, encompassing efficacy, speed of onset of action, tolerability, 
consistency of response, ease of use and feelings of well being on an individual basis. [5] 
Using patient preference and satisfaction data may be one approach to comparing the 
triptans that provides a more real-life perspective. [11, 12] The International Headache 
Society (IHS) guidelines for controlled trials of migraine treatments state that the global 
evaluation of migraine medications by patients is a clinically relevant measure. [13]  
 
Many triptan studies have reported patients’ overall evaluation of their migraine treatments. 
This article reviews these data, from three types of patient preference study: comparisons of 
triptans versus patients’ usual non-triptan treatments, direct comparisons of different triptans 
and comparisons of different formulations or doses of the same triptan. We also review the 
methodological robustness of the studies for study design and symmetry in the groups 
compared, and in blinding techniques.   
 
Comparing triptans with non-triptan medications 
 
These comparisons were conducted in two ways. Firstly, a large meta-analysis was 
conducted to capture data on patients’ satisfaction with their usual acute medications before 
they entered clinical studies. Secondly, a series of patient preference studies compared 
triptans with patients’ usual non-triptan medications. 
 
Meta-analysis of sumatriptan clinical studies 
A meta-analysis was conducted to investigate patients’ satisfaction with their usual acute 
migraine medications before entering 10 UK clinical studies with sumatriptan. [14] In all 
studies there were assessments of acute medications taken for the migraine attacks and 
their efficacy. The proportions of patients rating each of the drug categories as 
ineffective/poor/reasonable and good/excellent were calculated, and 95% confidence 
intervals constructed for the proportions using the normal approximation (Table 1).  
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Table 1. Patients’ (n = 3,378) assessment of acute migraine treatments in the meta-analysis 
of sumatriptan versus usual acute treatments [14] 
 
Medication Patient rating % 
a (95% confidence interval) 
 
 
 Ineffective/poor
/reasonable 
Good/excellent Number of 
patients 
Sumatriptan 12% 
(6% to 17%) 
88% 
(83% to 94%) 
688 
Ergotamine 62% 
(53% to 71%) 
38% 
(29% to 47%) 
249 
Paracetamol/codeine/ 
buclizine 
75% 
(71% to 79%) 
25% 
(21% to 29%) 
530 
Aspirin/metoclopramide 77% 
(69% to 85%) 
23% 
(15% to 31%) 
110 
Paracetamol/metoclopramide 81% 
(77% to 85%) 
19% 
(15% to 23%) 
307 
Ibuprofen 83% 
(78% to 88%) 
17% 
(12% to 22%) 
233 
Paracetamol/codeine 88% 
(85% to 92%) 
12% 
(8% to 15%) 
355 
Aspirin 90% 
(86% to 94%) 
10% 
(6% to 14%) 
210 
Co-proxamol 91% 
(87% to 95%) 
9% 
(5% to 13%) 
166 
Paracetamol 97% 
(96% to 98%) 
3% 
(2% to 4%) 
530 
 
a Approximate 95% confidence intervals are given, the exact confidence coefficients may be 
lower. 
 
Overall, the majority of patients (88%) who used sumatriptan as their usual migraine 
medication rated it as good or excellent.  In contrast, only 38% of patients who usually used 
ergotamine, 25% of those who normally used paracetamol/codeine/buclizine, 23% of those 
who used aspirin/metoclopramide and 19% of those who used paracetamol/metoclopramide 
rated these medications as good or excellent. 
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Patient preference studies (Table 2) 
 
Table 2. Summary of studies comparing patients’ preference for triptans versus their usual 
non-triptan acute treatments for migraine. 
 
       % patients 
Triptan and dose Preference for 
triptan 
Preference for 
usual non-triptan 
therapy 
No preference 
Sumatriptan 
subcutaneous 6 mg 
[15] (n = 217) 
85 10 5 
Sumatriptan oral 50 
mg [16] (n = 402) 
73 18 9 
Sumatriptan oral 50 
mg [18] (n = 29) 
69 16 14 
Naratriptan oral 2.5 
mg [19] (n = 115) 
63 27 10 
Triptans [22] (n = 
663) 
52* 21* 9 
 
* 18% of patients preferred to use both a triptan and an analgesic to treat individual migraine 
attacks 
 
Sumatriptan 
A prospective, multicentre, open-label, 2-month crossover study compared patients’ 
preference for subcutaneous sumatriptan 6 mg with their usual acute migraine treatments. 
[15] Single and combination analgesics were used by 49% of patients, ergotamine by 24%, 
non-steroidal anti-inflammatory drugs (NSAIDs) by 19% and dihydroergotamine (DHE) by 
7%. At the end of the study, 85% of patients expressed a preference for subcutaneous 
sumatriptan, 10% preferred their usual treatments and 5% had no preference (p<0.001). 
Some of the comparisons in this study necessitated asymmetric comparison of formulations, 
i.e., injection versus tablet.  
 
A large, open-label, 4-attack observational study compared patients’ preference for and 
satisfaction with oral sumatriptan 50 mg with those for their usual non-triptan prescription or 
over-the-counter therapy (mostly non-narcotic analgesics and NSAIDs). [16, 17] At the end of 
the study, 73% of patients expressed a preference for sumatriptan, and only 18% preferred 
their usual therapy. The most common reasons given for preferring sumatriptan were 
effective pain relief (98% of patients), restored ability to function (93%), requirement for fewer 
doses (93%), relief of migraine-associated symptoms (89%), rapid onset of efficacy (86%), 
no tired feelings (85%) and fewer side effects (81%). Significantly more patients were 
satisfied with sumatriptan as compared with their usual therapies (p<0.001) and with the 
overall quality of their medical care when it included sumatriptan (p<0.001). 
 
An open-label, observational, multi-attack preference study in US primary care clinical 
practice allowed patients not using triptans to switch to oral sumatriptan 50 mg to treat their 
migraine attacks. [18] At baseline, patients were mostly using NSAIDs and other simple 
analgesics (69%), OTC or prescription combination therapies (28%) and narcotics (10%), 
with the majority (76%) being dissatisfied with their nontriptan therapies. At the end of the 
study 69% of patients expressed a preference for sumatriptan, 16% for their previous therapy 
and 14% had no preference. The main reasons given for preferring sumatriptan were speed 
of relief and overall effectiveness (69% and 30% of patients, respectively). Use of 
sumatriptan correlated with a reduction in unscheduled physician visits, emergency room 
visits and hospitalisations for migraine. 
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Naratriptan 
An open-label study conducted in US primary care assessed migraine patients’ satisfaction 
with and preference for oral naratriptan 2.5 mg compared with their previous non-triptan 
therapies (simple analgesics [59%], combination products [46%] and narcotics [13%]). [19] 
After three treated attacks, more patients were satisfied with naratriptan than with their 
previous therapies (75% versus 47%), and 63% preferred naratriptan, 27% their non-triptan 
therapy and 10% expressed no preference. The main reasons for preferring naratriptan were 
effective pain relief (86% of patients) and restoration of ability to function (81%). 
 
Zolmitriptan 
An open-label, multicentre study of 112 patients treating 281 migraine attacks assessed 
efficacy, safety and patient acceptance of oral zolmitriptan 2.5 mg. [20] At the end of the 
study, 78% of patients stated that zolmitriptan was superior to their previously used abortive 
treatments (analgesics and NSAIDs).  
 
Rizatriptan 
An open-label, single-attack crossover study compared migraine patients’ (n = 216) 
satisfaction with two formulations of oral rizatriptan 10 mg (conventional tablet and orally 
disintegrating tablet [ODT]) over their previous non-triptan medications. [21] The study 
reflected normal clinical practice, with all patients being triptan naïve. At the end of the study, 
more than twice as many patients taking rizatriptan reported that they were ‘very’ or 
‘somewhat satisfied’ with the medication compared with their previous non-triptan 
medications (p<0.05). In all studies in which the ODT preparations are compared with 
conventional tablets, there is an asymmetry in comparison groups with respect to the 
formulations assessed.  
 
Overall preference for triptans versus analgesics 
A study conducted in US secondary care assessed the choice of acute migraine medications 
in patients who had been prescribed triptans in the past. [22] Patients were asked whether 
they currently preferred to use triptans or analgesics (OTC, prescription simple and 
combination analgesics, and prescription narcotics). Fifty two percent of the patients 
preferred using a triptan alone, 21% analgesics alone, 18% triptans plus analgesics for the 
same attack and 9% had no preference. The main reasons for preferring triptans over 
analgesics were efficacy (62% of patients), reduced side effects (8%) and a combination of 
the two (30%). 
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Studies comparing the different triptans (Table 3) 
 
Table 3. Summary of studies comparing patient preference for different triptans. 
 
       % patients 
Comparison Preference for 
sumatriptan 
Preference for 
comparator triptan 
No preference 
Sumatriptan oral 50 
mg versus 
zolmitriptan oral 2.5 
mg [23]  
(n = 94) 
29 44 27 
Sumatriptan oral 
versus zolmitriptan 
oral 2.5 mg [20]  
(n = 112) 
36 45 19 
Sumatriptan oral 50 
mg versus rizatriptan 
ODT 10 mg [12]  
(n = 374) 
43 57** 0 
Sumatriptan oral 50 
mg versus rizatriptan 
ODT 10 mg [27]  
(n = 481) 
36 64*** 0 
  
** p<0.01; *** p≤0.001; ND = no data  
 
Almost all preference studies that compare the triptans use sumatriptan as the comparator 
drug. There is a relative lack of comparative clinical data between the newer triptans, both for 
conventional efficacy measures and for patient preference and satisfaction measures. 
 
Sumatriptan versus zolmitriptan 
An open-label, non-randomised, crossover study investigated patients’ preferences for oral 
sumatriptan 50 mg versus oral zolmitriptan 2.5 mg tablets. [23] Patients treated three attacks 
with each triptan (in any order) then completed a preference questionnaire. At the end of the 
study, 42 patients (44%, CI 34–58%) preferred zolmitriptan, 27 patients (29%, CI 20–38) 
preferred sumatriptan and 25 patients (27%, CI 18-36%) reported no preference. The 
reasons given in the 69 patients who expressed a preference between the triptans were: 
faster onset of action (73%), longer duration of effect (39%), fewer adverse events (35%) and 
lower price (13%). Only one-quarter of the patients reported that sumatriptan and zolmitriptan 
were equivalent. These results are similar to those from the open-label, multicentre study 
conducted described earlier, [20]  in which 45% of patients assessed zolmitriptan as superior 
to sumatriptan and 36% assessed sumatriptan as superior to zolmitriptan. 
 
Sumatriptan versus rizatriptan 
A randomised, double-blind, triple-dummy, parallel group study compared rizatriptan tablets 
5 mg and 10 mg, sumatriptan 100 mg and placebo in 1,268 patients treating a single 
migraine attack. [24] Headache relief rates after rizatriptan 10 mg were reported to be 
somewhat higher than those after sumatriptan. However, patient satisfaction data were also 
collected, and showed no significant differences between the rizatriptan and sumatriptan 
groups. [25]  
 
Two studies have compared patient preference for sumatriptan conventional tablets with the 
ODT formulation of rizatriptan.  A multicentre, randomised, open-label, two-period crossover 
study compared the proportion of patients who preferred rizatriptan ODT 10 mg to 
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sumatriptan 50 mg tablet. [12] Patients treated two migraine attacks, one each with 
rizatriptan and sumatriptan. Significantly more patients preferred rizatriptan to sumatriptan at 
the end of the study (57% versus 43%, p<0.01). A post hoc analysis of the data indicated 
that patients tended to prefer the triptan that supplied the most rapid pain relief. [26] A 
second randomised, open-label, crossover study assessed patient preference for rizatriptan 
ODT 10 mg versus sumatriptan 50 mg conventional tablet to treat a single migraine attack. 
[27] At the end of the study, significantly more patients preferred rizatriptan to sumatriptan 
(64.3% versus 35.7%, p≤0.001). Faster headache relief was the most important reason given 
for preference of both drugs (46.9% and 43.4% of patients preferring rizatriptan and 
sumatriptan, respectively). Two hours after treatment of the attacks, significantly more 
patients receiving rizatriptan than sumatriptan (73.3% versus 59.0%, p≤0.001) reported 
satisfaction (completely, very or somewhat satisfied) with therapy and found the drug 
convenient (very convenient, convenient or somewhat convenient) to take (87.2% versus 
76.3%, p≤0.001). The crossover design of these two studies helps mitigate the asymmetry of 
the comparison groups. 
 
Sumatriptan versus eletriptan 
A randomised, double-blind, parallel-group study compared the efficacy, safety and 
tolerability of oral eletriptan 20 mg, 40 mg and 80 mg versus oral sumatriptan 100 mg and 
placebo for a single migraine attack (n = 692). [28] Patients were asked at a follow-up visit to 
rate the acceptability of their study medication compared to medications used previously. 
Patients rated sumatriptan (64%) and all doses of eletriptan (64%, 74% and 84% for the 20 
mg, 40 mg and 80 mg doses, respectively) more acceptable than placebo (32%), with the 
highest acceptability rate reported for eletriptan 80 mg. Sumatriptan, but not eletriptan was 
encapsulated for blinding purposes in the study, making the comparative groups asymmetric, 
a potential bias that was maximized by the parallel group design. Encapsulation of 
sumatriptan has been shown to negatively affect its pharmacokinetics and absorption. [8] 
 
Sumatriptan versus almotriptan 
A double-blind, multicentre, randomised, parallel-group study (n = 1,173) compared 
treatment satisfaction, functional status and health-related quality of life (HRQOL) of patients 
treated with oral almotriptan 12.5 mg or oral sumatriptan 50 mg for one migraine attack. [29] 
The patients reported similar satisfaction with pain relief associated with the two drugs, but 
were significantly less bothered with side effects from almotriptan than sumatriptan 
(p=0.016). Improvements in functional status and HRQOL were similar in the two treatment 
groups. Both almotriptan and sumatriptan were encapsulated for blinding purposes in the 
study, thus no bias based on blinding was present. 
 
Multiple comparisons between the triptans 
A post hoc comparison was made of patients’ overall satisfaction with treatment from five 
double-blind, placebo-controlled studies in which rizatriptan 10 mg conventional tablets were 
compared with other oral triptans. [30] Three studies compared rizatriptan with sumatriptan 
(rizatriptan 10 mg versus sumatriptan 100 mg in a parallel-group study, n = 916; rizatriptan 
10 mg versus sumatriptan 50 mg in two crossover studies, n = 1,599). One study compared 
rizatriptan 10 mg with naratriptan 2.5 mg (n = 502) and another compared rizatriptan 10 mg 
with zolmitriptan 2.5 mg (n = 701), both being parallel-group studies. Patients reported their 
satisfaction with treatment on a seven-point scale at 2 hours after treatment. Significantly 
more patients receiving rizatriptan 10 mg than all the other triptans reported that they were 
‘completely’ or ‘very’ satisfied: rizatriptan versus sumatriptan 100 mg (33% versus 26%, 
p<0.05); rizatriptan versus sumatriptan 50 mg (40% versus 35%, p<0.05); rizatriptan versus 
naratriptan 2.5 mg (33% versus 19%, p<0.01); and rizatriptan versus zolmitriptan 2.5 mg 
(38% versus 30%, p<0.05). 
 
A randomised, multicentre, open-label, five-way crossover study assessed patient preference 
for sumatriptan 50 mg and 100 mg, naratriptan 2.5 mg, zolmitriptan 2.5 mg and rizatriptan 10 
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mg (n = 372). [11, 31] Patients were randomised to treat one migraine attack with each of the 
five triptans in sequence, in a total of 119 possible treatment sequences. Patients assessed 
which triptan they preferred at the end of the study. The results showed that sumatriptan 100 
mg was preferred by 33% of patients, significantly higher than the random preference rate of 
20% (p<0.001). Preference rates for sumatriptan 50 mg, naratriptan, rizatriptan, and 
zolmitriptan were not significantly higher than the random preference rate. The patients’ 
primary reason for preferring a medication was ‘best relief of migraine pain’, and the 
treatment that patients preferred corresponded to the medication that was most likely to 
confer for them a pain-free response 2 hours postdose.  
 
A second small study  (n = 28) conducted in clinical practice compared patient preference to 
sumatriptan 50 mg or 100 mg, naratriptan 2.5 mg or 5 mg and zolmitriptan 2.5 mg or 5 mg. 
[32] Patients were randomised to treat two attacks with each of the triptans. At the end of the 
study, 50% of patients preferred sumatriptan, 32% naratriptan and 18% zolmitriptan. 
 
A retrospective audit of patient data from a secondary care headache clinic (n = 176) 
investigated the pattern of preference for and switching between sumatriptan, naratriptan and 
zolmitriptan in clinical practice. [33] Most patients (68%) had switched between triptans at 
least once in the previous 2 years. No triptan showed a significantly higher level of 
preference, although there were some gender differences. Women tended to prefer 
zolmitriptan over the other two triptans and switched between triptans more often than men. 
Most patients reporting migraine with aura used sumatriptan to treat their attacks. 
 
In a retrospective review of 386 patients who used subcutaneous sumatriptan and were 
switched to a different triptan or formulation, 19.5% returned to subcutaneous sumatriptan. 
[34] For the other triptans/formulations, the percentages for returning were: sumatriptan 25 
mg, 7.8%; sumatriptan 50 or 100 mg, 42.3%; sumatriptan nasal spray, 17.7%; zolmitriptan, 
17.6%; rizatriptan, 16.5%; naratriptan: 9.4%. Of those who used more than three triptans or 
formulations, the last triptan used was: sumatriptan, 29.5%; zolmitriptan, 31.8%; rizatriptan, 
25.0%; naratriptan, 12.5%. Different formulations of sumatriptan were used by 129 subjects 
(33.4%). Of the patients who used sumatriptan as the first triptan and switched to other 
triptans, sumatriptan was also the last triptan used by 53.8% of them. This study involved 
asymmetries of formulations in assessing patient preferences and reasons for switching 
behaviours.  
 
A Swedish study has investigated migraine patients’ preference for zolmitriptan 5 mg nasal 
spray compared with that to oral triptans in a realistic clinical practice setting (n = 83). [35] 
Patients, 96% of whom were currently using a triptan (usually oral), were invited to try 
zolmitriptan nasal spray 5 mg for up to six migraine attacks, to see if efficacy could be 
improved. Initial data indicated that 76% of patients wanted to continue to use zolmitriptan 
nasal spray. The main reasons for this preference were a fast onset of action, a lack of 
adverse events and only needing to take a single dose. The first reason may be intrinsic to a 
nasal spray compared to a tablet; the other two reasons should not have been impacted by 
asymmetry of compared formulations.  
 
Studies comparing different formulations of the same triptan 
 
Sumatriptan, zolmitriptan and rizatriptan are available in different formulations, and a small 
number of studies have compared patient preference for different formulations or doses of 
these drugs.  
 
Sumatriptan 
An open, multicentre, randomised, crossover study with an optional open, parallel-group 
extension (n = 385) investigated the efficacy, safety and patient preference for oral 
sumatriptan 100 mg and subcutaneous sumatriptan 6 mg formulations. [36] Patient 
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preference for the subcutaneous formulation more than doubled from the pre-treatment 
phase to the end of the crossover period in those patients previously naïve to sumatriptan. 
During the optional parallel-group phase of the study, 38% of patients chose to use both 
sumatriptan formulations, treating some attacks with subcutaneous sumatriptan and some 
with oral sumatriptan. The main reason for choosing subcutaneous sumatriptan was speed of 
relief, while convenience was the major reason for choosing the tablet. 
 
An open, randomised, three-attack crossover study compared patient opinions of oral 
sumatriptan 100 mg with subcutaneous sumatriptan 6 mg (n = 124). [37] At the end of the 
study, patient opinion was more often positive after subcutaneous sumatriptan than after oral 
sumatriptan. Subcutaneous sumatriptan was significantly more effective than oral 
sumatriptan, but more adverse events were reported following the subcutaneous formulation. 
 
A telephone survey was conducted in 707 patients who had used sumatriptan tablets and/or 
injection long-term for migraine in clinical practice. [38] Results showed that more patients 
preferred the tablets over the injection, but that more patients reported that the injection was 
the most effective formulation. The most frequently given reasons for the injection being 
superior were efficacy and speed of action. The most frequently given reasons for the tablet 
being superior were fewer side effects and lack of experience with other formulations. Most 
patients (94%) reported that sumatriptan was superior to their previous non-triptan therapies. 
 
An open, randomised, crossover study compared patient preference for sumatriptan 50 mg 
tablets and sumatriptan 20 mg nasal spray. [39] Patients, who were naïve to both 
formulations, preferred both formulations approximately equally (47% for tablets and 53% for 
nasal spray). Patients preferred the nasal spray for its fast onset of action and the tablets for 
their convenience. 
 
Rizatriptan 
Patients (n = 367) taking part in a clinical study of rizatriptan were allowed to continue open-
label treatment with both the film-coated tablet and ODT formulations for a 6-month period. 
[40] At the end of the study, 51.2% preferred the ODT and 48.8% the film-coated tablet. 
Although individual patients had strong reasons for preferring one formulation over the other, 
no group preferences were detected for the individual formulations. 
 
Comparing the different doses of oral sumatriptan 
A multinational, randomised, double-blind, crossover, 8-week study was conducted to assess 
patient dose preference, efficacy and tolerability for oral sumatriptan 25 mg, 50 mg and 100 
mg in the acute treatment of migraine. [41] Patients (n = 257) were randomised to treat three 
migraine attacks, using a different dose for each. At the end of the study, 34.6% of patients 
preferred the 100 mg dose, 30.4% the 50 mg, 20.6% the 25 mg dose and 12.8% expressed 
no preference. Efficacy and speed of action were the two main reasons given for preferring 
the higher doses. However, adverse events were rarely given as a reason for preferring the 
lower doses of sumatriptan. Although the 50 mg dose has been shown to have the optimal 
benefit: risk ratio of the formulations, [42] some patients clearly preferred a higher dose. 
 
Discussion 
 
Patients’ assessments of their preference for, and satisfaction with, their migraine treatments 
may be measures of clinical efficacy relevant to real-life clinical practice, taking into account 
both efficacy and tolerability. We now have considerable clinical data on patient preference, 
allowing the evaluation of the triptans and other acute migraine treatments.  
 
All studies of preference [14–19, 22] and satisfaction [17, 19, 20, 21] for triptans compared 
with patients’ usual non-triptan medications have demonstrated the superiority of the triptans. 
Patients’ most commonly given reasons for preferring triptans were effective relief, speed of 
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relief, restored ability to function and fewer side effects. [16, 18, 19, 22] These are significant 
results, as some controlled clinical trials have shown that sumatriptan was not superior to 
rapid-release tolfenamic acid, [43] paracetamol/domperidone, [44] aspirin/metoclopramide, 
[45, 46] isometheptene/paracetamol/dichlorphenazone, [47] and 
paracetamol/aspirin/caffeine. [48] In contrast, a controlled clinical trial showed that oral 
sumatriptan 100 mg was significantly superior to oral ergotamine plus caffeine. [49] These 
results indicate that patient preference may be a more sensitive and valid measure of 
efficacy and clinical utility than conventional clinical trial endpoints.  
 
Relatively few clinical trials have directly compared patients’ preference for individual 
triptans, and all included sumatriptan. [12, 20, 23, 27] Data from these four studies were 
broadly similar, (Table 3) some patients preferring one triptan and some the other, even 
though fewer patients preferred sumatriptan to the comparator triptan in all cases. The main 
reason for preference was a faster onset of action. Other reasons given included a longer 
duration of effect and fewer adverse events.  Each of these reasons was given for all the 
triptans. The data in these preference studies were broadly similar to those from randomised, 
double-blind comparator studies between these triptans. [50, 51]  
 
Five further studies compared patient preference between multiple triptans. Two studies 
showed that more patients preferred oral sumatriptan 50 mg or 100 mg than other oral 
triptans. [11, 31, 32] Two studies showed few differences between several oral triptans, [33, 
34] and a further study showed that patients preferred zolmitriptan nasal spray over oral 
triptans. [35]  Different study designs and the patients’ initial triptan may have biased the 
results from these studies. 
  
Patient satisfaction data from double-blind, controlled clinical trials showed similar trends to 
those reported above for patient preference. Patients were equally satisfied with the efficacy 
of sumatriptan 100 mg and rizatriptan 10 mg, [24, 25] sumatriptan 100 mg and eletriptan 20 
mg and 40 mg [28] and sumatriptan 50 mg and almotriptan 12.5 mg. [29] In a review of five 
clinical trials, the proportions of patients preferring sumatriptan, zolmitriptan and rizatriptan 
were not markedly different from each other. [30] Patients were also able to express 
preferences between different formulations of the triptans, [36–38, 40] although these data 
are biased due to the asymmetry of the treatment groups. Patients could even distinguish 
between different doses of oral sumatriptan. [41]  
 
There are several limitations to the available analyses of patient preference and satisfaction. 
Many of the studies are published only as abstracts, and much of the desired data is not 
recorded. As secondary endpoints, assessments of patient preference were not subjected to 
rigorous statistical testing, as were the study primary endpoints. The preference and 
satisfaction studies were open-label and bias could therefore occur. Patients may have had 
previous access to one or more of the drugs being investigated. It is interesting that in all 
cases, the triptan preferred most was that of the company sponsoring the study. In the 
double-blind, controlled studies analysed, the patient preference/satisfaction endpoint was a 
secondary or post hoc endpoint, and may therefore not have been powered appropriately. 
Studies involving different formulations are biased by the asymmetries previously discussed 
in this article. The solution is to conduct double-blind, controlled studies with patient 
preference as the primary endpoint, and to investigate which set of triptans in which order, 
scheme, dosage and formulation leads to the fastest effectiveness in a particular patient. In 
such a design, non-responders are switched to another triptan, dosage or formulation to 
reach (in theory) 100% effectiveness. Such a naturalistic design would best serve the needs 
of the clinician who is interested in the best fit of a patient with a triptan. 
 
Clinical implications 
When given the opportunity, most migraine patients are able to distinguish between triptans 
and non-triptan acute therapies for migraine, and between the individual oral triptans. This 
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sophisticated individual preference is not usually seen in controlled parallel design clinical 
trials, where differences between the oral triptans, when statistically present, are small. [4] 
Unfortunately for the physician, patients have very individual preferences for triptans that are 
not predictable in advance. The problem therefore, is to investigate the fastest route to detect 
the right match between patient and triptan (in terms of dose, order of switching and 
formulation). Patients clearly prefer triptans to simple and combination analgesics and 
ergotamine, and thus triptans should be a first-line alternative in most migraine patients. [52] 
In assessing individual triptans in clinical practice, patients are looking for a therapy that 
provides rapid and effective relief of the migraine. [18, 19, 22, 38] and are willing to switch 
between triptans to achieve this goal. [33]  
 
Patient preference is clearly a sensitive and valid overall measure of the clinical profile of 
triptans, encompassing both efficacy and tolerability. In reviewing migraine patients, the 
physician should elicit their preference for, and satisfaction with, their current medication 
before making further treatment decisions. There is no need to change the patients’ 
medication if they are satisfied with their current medications and prefer them to those used 
previously. When the patient’s medication is changed, at review the physician should ask 
about the patient’s preference for the new medication. In addition, physicians should also 
take into consideration patients’ preference for a specific delivery system. For patients with 
attacks of varying severity and/or lifestyle needs, more than one formulation may be 
appropriate.  
 
In conclusion, patient preference is a sensitive and valid clinical trial endpoint and physicians 
should consider using it when reviewing the efficacy of acute migraine medications. 
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3.3 
 
A general practice study on the prevalence of headache, 
depression and bodily pain, and the disability associated with 
headaches occurring inside and outside the menstrual period in 
migraine sufferers* 
 
 
Abstract 
 
Objectives: This study investigated the prevalence of headache, depression and bodily pain 
in women attending a UK general practice. The disability associated with migraine and other 
headache attacks occurring during and outside the menstrual period was assessed in those 
women with migraine.  
Methods: 1,434 of 3,470 female patients (41.3%) aged 14–50 years registered at a UK 
general practice completed two questionnaires. The first questionnaire assessed the point 
prevalence of headache and bodily pain, and the 5-year prevalence of depression in the total 
population. The second questionnaire assessed the disability of all headaches over a 2-
month period (to capture a complete menstrual cycle) for patients reporting migraine who 
were still menstruating. Disability was assessed as the time lost and time spent at less than 
50% productivity in normal activities due to headache, and analyzed as rank sums using the 
Mann-Whitney U Test.  
Results: The first part of the study showed that the prevalence of headache (66.1%), 
depression (55.4%) and bodily pain (40.6%) were high in this population of women. In the 
second part of the study, 30 migraine patients who were still menstruating (11.1% of those 
eligible) reported 89 migraine and 114 non-migraine headache episodes. For migraine, the 
rank order of time at less than 50% productivity was significantly greater for attacks taking 
place inside the menstrual period than for those occurring outside the menstrual period 
(p=0.01). For non-migraine headaches, the time lost appeared to be numerically greater for 
attacks taking place outside the menstrual period than for those occurring inside the 
menstrual period, and the comparison approached significance (p=0.06).  
Conclusions: The patients reported a high prevalence of headache, depression and bodily 
pain. For migraine sufferers, migraine attacks that took place during the menstrual period 
tended to be more disabling than those taking place outside the menstrual period, but the 
opposite was true for non-migraine headache.  
 
 
 
* Edited from the full published paper: Dowson AJ, Kilminster SG, Salt R, Clark M, Bundy 
MJ. Disability associated with headaches occurring inside and outside the menstrual period 
in those with migraine: A general practice study. Headache 2005;45:274–82. Additional 
statistical analyses were conducted by Professor Jan Passchier. 
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Introduction 
 
Headache and depression are two of the commonest conditions that the primary care 
physician has to deal with. Most people suffer from headaches, usually tension-type 
headaches (TTH), migraine or chronic daily headache (CDH). TTH affects over 50% of the 
general population,1 migraine about 12%2 and CDH about 5%.3 Major depression is reported 
to affect up to 12% of the general population.4 Migraine,5 CDH6 and depression4 are all 
disabling conditions to the patient and cause major societal burdens due to the associated 
high direct medical costs of care and indirect costs of lost work productivity.7,8 
 
Although definitive criteria are not available, menstrually-associated migraine attacks tend to 
be defined today as those that begin during the time period from the day prior to the start of 
menstruation and Day 2 of menstruation.9 Such attacks are common, and more than 50% of 
women with migraine report an association between migraine and menstruation, 10 although 
in most cases they also have migraine attacks outside the menstrual period. A population-
based study conducted in the Netherlands provided a prevalence rate of 3% for menstrual 
migraine.11 Studies indicate that menstrually-associated migraine attacks are the result of 
estrogen withdrawal in the late luteal phase of the normal menstrual cycle, but other factors 
such as prostaglandin release have also been implicated.9 Menstrually-associated migraine 
attacks are treated with standard acute therapies and with specific prophylactic treatments 
such as estrogen supplements.9 It used to be widely considered that menstrually-associated 
migraine attacks were more severe and less responsive to treatment than non-menstrually-
associated attacks,9,12 but these suppositions have now been disputed.  A population-based 
epidemiologic study indicated that menstrually-associated migraine attacks were slightly 
more painful, but not more disabling, than attacks occurring at other times in the cycle.13 
Similar results have been reported for TTH attacks occurring inside and outside the 
menstrual period.14 A small study with sumatriptan indicated that the drug was less effective 
for menstrually-associated than for non-menstrually-associated migraine attacks (56% 
versus 81% of patients reporting relief of their migraine headache 4 hours after treatment, 
when treated during and outside the menstrual period, respectively).15 However, more recent 
studies have indicated that triptan drug16 and nondrug treatments17 are equally effective in 
treating migraine attacks occurring inside and outside the menstrual period. In contrast, 
some recent studies indicate that migraine attacks occurring during the menstrual period 
tend to be more frequent, more severe, of longer duration and more resistant to treatment 
than those occurring at other times of the month.11,18 In clinical practice, menstrually-
associated migraine attacks tend to be treated in the same way as non-menstrually-
associated attacks. 
 
This study was set up to investigate two questions related to women’s health issues: 
1. What is the prevalence and severity of headache, depression and bodily pain? 
2. Are migraine and other headache attacks occurring during the menstrual period more 
or less disabling than those occurring outside it in patients with migraine? 
 
The study extends previous research13 into primary care clinical practice. We recorded 
headache characteristics and the disability caused by migraine and other headache attacks 
taking place inside and outside the menstrual period. Disability was assessed by recording 
the time lost from normal activities and the time spent at less than 50% of normal capabilities 
due to headache. Recent research has shown that these assessments form a reliable and 
accurate measure of headache-related disability, when incorporated into the Migraine 
Disability Assessment (MIDAS) Questionnaire.19  
 
Patients and methods 
Patients 
All non-hysterectomized women aged 14–50 years at a health centre in Cranleigh, Surrey, 
UK, were invited to take part in a two-part study. The study was approved by the local 
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investigational review board, the South West Surrey Local Ethics Committee, and all patients 
who took part in the study provided their written informed consent to participate. 
 
Study design 
Part 1 
All patients were asked to complete and return by mail a questionnaire assessing their 
headaches, depression and bodily pain severity (Appendix 1). The point prevalence and 
severity of headache and bodily pain and the 5-year prevalence and severity of depression 
were assessed and patients with frequent headaches, and disabling and non-disabling 
intermittent headaches identified using the questionnaire.  
 
Part 2 
Patients who had disabling intermittent headaches and were still having menstrual periods 
were asked to complete another questionnaire assessing the disability of all headaches that 
occurred inside and outside the menstrual window. Patients were monitored over a 2-month 
period, to ensure that a complete menstrual cycle was covered for all patients.  
 
Questionnaires 
Headache, depression and bodily pain questionnaire 
The questionnaire was developed by the study investigators (Drs Dowson, Kilminster, Clark 
and Bundy). Three questions (Questions 1–3) assessed headache, five assessed depression 
(Questions 5–9) and four assessed bodily pain severity (Questions 10–13).  
 
The answers to Questions 2 (‘How often do they [headaches] occur?’) and 3 (‘Do the 
headaches interfere with your ability to perform normal daily activities?’) were used to 
categorize the patients’ headache. Patients who answered ‘a’ to Question 2, with headaches 
on most days in the month, were categorized as having frequent headaches. Those who 
answered ‘b’, ‘c’ or ‘d’ to Question 2, with up to four or more headaches per month, were 
categorized with non-disabling intermittent headache if the headaches did not interfere with 
their ability to perform normal activities (Question 3a) and with disabling intermittent 
headache if the headaches did interfere with these activities (Question 3b).  
 
The patients’ degree of depression was assessed arbitrarily from Questions 5, 6 and 7, 
covering sleep disturbance, mood disturbance and suicidal ideation. Patients who answered 
‘no’ to all questions were classified as not being depressed. Those who answered ‘yes’ to 
one, two and three of these questions were classified as having mild, moderate and severe 
depression, respectively. Depression is therefore here conceived as a continuous variable. In 
addition, patients who answered ‘yes’ to Question 9 (defined as those who had received 
treatment from a doctor for sleep disturbance, mood disturbance or suicidal ideation) were 
classified as having at least moderate depression, depending on their answers to Questions 
5, 6 and 7 (i.e. none and one ‘yes’ answer = moderate depression; two and three ‘yes’ 
answers = severe depression). 
 
Pain severity in any part of the body was assessed from Questions 10, 12 and 13. Patients 
who responded ‘yes’ to Question 10 but ‘no’ to Questions 12 and 13 were assessed as 
having mild pain. Those who responded ‘yes’ to Questions 10 and 12 but ‘no’ to Question 13 
were assessed as having moderate pain. Those who responded ‘yes’ to Questions 10, 12 
and 13 were assessed as having severe pain. Question 11 was not counted, but provided 
information designed to be useful to the physician. 
 
Menstrual headache questionnaire 
Patients with disabling intermittent headache in Part 1 of the study who were still 
menstruating were eligible to complete Part 2.  Patients reported all their headaches over a 
2-month period, using the menstrual headache questionnaire that was mailed to them 
(Appendix 2). The study investigators developed the menstrual headache questionnaire, 
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based on the International Headache Society (IHS) diagnostic criteria pertaining at the 
time.18 Patients prospectively recorded their menstrual status, time of onset and resolution of 
the headaches and other symptoms (self-selected), headache severity, presence of non-
headache symptoms, time lost from normal activities and the further time spent at less than 
50% of normal capabilities, use of contraceptives and other drugs and any present pre-
menstrual symptoms. 
 
Headaches were diagnosed by the study physicians as migraine or non-migraine using the 
information recorded by the patients in the questionnaire, using their clinical judgment in 
conjunction with reference to the relevant IHS diagnostic criteria.18 Headaches were further 
subdivided into those that started inside and outside the menstrual period. Data were 
analyzed as the number of headache episodes, the time lost from normal activity (total time 
and mean time per attack) and the additional time at less than 50% of normal capability (total 
time and mean time per attack) for migraine and non-migraine headaches.  
 
Endpoints and analyses 
Part 1 
The primary endpoint was the prevalence and severity of headaches, depression and bodily 
pain. Results were recorded as descriptive statistics only; the number and percentage of 
patients with total, mild, moderate or severe symptoms, and subdivided by the age of the 
patient. The relationship between age and headache prevalence was analyzed using Chi-
square tests for independent samples. Similar analyses for depression and bodily pain were 
not carried out given the small differences between the data samples. 
 
Part 2 
The primary endpoint was the disability experienced by the patients, assessed as time lost 
from daily activities. The other components of the questionnaire were recorded, but data are 
not presented here. Non-parametric rank testing with the Mann-Whitney U Test for related 
samples was used to analyze the time lost and time at less than 50% of normal capacity due 
to the migraine and non-migraine headaches, comparing attacks from inside and outside the 
menstrual period. The level of significance was set at p=0.05. 
 
Results 
 
Patient disposition 
Of the 3,470 female patients in the practice who were sent the initial questionnaire, 1,434 
(41.3%) completed and returned it (Table 1). Of these, all but five patients were aged 
between 17 and 54 years. Approximately equal proportions of patients aged 17–24, 25–34, 
35–44 and 45–54 years completed the questionnaire. The proportions of patients in these 
age groups were similar to those in the total population in the practice. 
 
Table 1. Patient demography. Number (and percentage) of women in the general practice 
who took part in the study. 
            
     Number of patients (%) 
 14–16y 17–24y 25–34y 35–44y 45–54y Total 
Patients taking part 
in study 
5 
(0.3) 
234 
(16.3) 
305 
(21.3) 
498 
(34.7) 
392 
(27.3) 
1434 
(100) 
Patients in the 
practice 
79 
(2.3) 
609 
(17.6) 
744 
(21.7) 
979 
(28.2) 
1059 
(30.5) 
3470 
(100) 
 
Prevalence of headache, depression and bodily pain  
Headache 
Overall, 948 patients (66.1%) completing the initial questionnaire reported current headache 
(Table 2). A total of 62 patients (4.3%) reported headache on most days and were 
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categorized as having frequent headache. Two hundred and seventy one patients (18.9%) 
had headache episodes up to more than four times a month that interfered with their ability to 
perform daily activities, and were categorized with disabling intermittent headache. A total of 
615 patients (42.9%) had headache episodes up to more than four times a month that did not 
interfere with their ability to perform daily activities, and were categorized with non-disabling 
intermittent headache. Similar proportions of patients aged 17–24, 25–34, 35–44 and 45–54 
years reported any headache, and disabling and non-disabling intermittent headaches. 
However, frequent headaches were reported significantly more often by patients aged 17–24 
years than by older patients (Chi-square (3) = 22.9, p < 0.001). 
 
Table 2. Headache. Number (and percentage) of women in the general practice who 
reported any headache, frequent headaches*, disabling intermittent headaches** and non-
disabling intermittent headaches***. 
            
     Number of patients (%) 
 17–24y 25–34y 35–44y 45–54y Total 
Patients reporting any headache 158 
(67.5) 
189 
(62.0) 
338 
(67.9) 
263 
(67.1) 
948 
(66.1) 
Patients reporting frequent 
headaches* 
24 
(10.3) 
11 
(3.6) 
15 
(3.0) 
12  
(3.1) 
62 
(4.3) 
Patients reporting disabling 
intermittent headaches** 
38 
(16.2) 
60 
(19.7) 
85 
(17.1) 
88 
(22.4) 
271 
(18.9) 
Patients reporting non-disabling 
intermittent headaches*** 
96 
(41.0) 
118 
(38.7) 
238 
(47.8) 
163 
(41.6) 
615 
(42.9) 
Patients taking part in the study 234 305 498 392 1434 
*Putatively diagnosed as CDH.21 
**Putatively diagnosed as migraine.21,23 
***Putatively diagnosed as TTH.21,23 
 
Depression 
Overall, 794 patients (55.4%) completing the initial questionnaire reported the defined 
depression symptoms in the previous 5 years. Similar proportions of patients aged 17–24, 
25–34, 35–44 and 45–54 years reported depression (Table 3). Approximately 20% of all 
patients reported mild or moderate depression, with 15.3% reporting severe symptoms. The 
distribution of mild, moderate and severe depression was similar among patients aged 17–
24, 25–34, 35–44 and 45–54 years. 
 
Table 3. Depression. Number (and percentage) of women in the general practice who 
reported mild, moderate and severe depression. 
            
     Number of patients (%) 
 17–24y 25–34y 35–44y 45–54y Total 
Patients reporting depression 
(mild, moderate or severe) 
140 
(59.8) 
178 
(58.4) 
265 
(53.2) 
210 
(53.6) 
794 
(55.4) 
Patients reporting mild 
depression 
51 
(21.8) 
72 
(23.6) 
101 
(20.3) 
67  
(17.1) 
292 
(20.4) 
Patients reporting moderate 
depression 
52 
(22.2) 
60 
(19.7) 
92 
(18.5) 
78 
(19.9) 
282 
(19.7) 
Patients reporting severe 
depression 
37 
(15.8) 
46 
(15.1) 
72 
(14.5) 
65 
(16.6) 
220 
(15.3) 
Patients taking part in the study 234 305 498 392 1434 
 
Bodily pain severity 
Overall, 40.6% of patients completing the initial questionnaire reported current pain 
symptoms in any part of the body, with the incidence generally increasing with increasing 
age (Table 4). However, more patients aged 17–24 years reported bodily pain than those 
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aged 25–34 years, with the excess being accounted for by reports of mild pain. Thirteen 
percent of all patients reported mild pain, 5.9% moderate pain and 21.7% severe pain. While 
the incidence of mild and moderate bodily pain was generally similar among the age groups, 
the incidence of severe pain increased with increasing age, from 15.8% for those aged 17–
24 years to 28.6% for those aged 45–54 years. 
 
Table 4. Bodily pain severity. Number (and percentage) of women in the general practice 
who reported mild, moderate and severe pain in any part of the body. 
            
     Number of patients (%) 
 17–24y 25–34y 35–44y 45–54y Total 
Patients reporting pain (mild, 
moderate or severe) 
92 
(39.3) 
94 
(30.8) 
207 
(41.6) 
187 
(47.7) 
582 
(40.6) 
Patients reporting mild pain 42 
(17.9) 
31 
(10.2) 
62 
(12.4) 
49  
(12.5) 
186 
(13.0) 
Patients reporting moderate pain 13 
(5.6) 
17 
(5.6) 
29 
(5.8) 
26 
(6.6) 
85 
(5.9) 
Patients reporting severe pain 37 
(15.8) 
46 
(15.1) 
116 
(23.3) 
112 
(28.6) 
311 
(21.7) 
Patients taking part in the study 234 305 498 392 1434 
 
 
Disability of headaches occurring inside and outside menstruation 
Thirty of the 271 patients (11.1%) with disabling intermittent headache in the first part of the 
study completed the menstrual headache questionnaire. They detailed a total of 203 
headaches that started inside and outside their menstrual periods during the 2-month study 
period. Patients reported slightly fewer migraine attacks (89) than non-migraine headaches 
(114). Migraine attacks were approximately equally frequent inside (47 attacks) and outside 
(42 attacks) the menstrual period. However, non-migraine headache was reported about 
three times more often outside the menstrual period (85 attacks) than inside it (29 attacks). 
 
Meaningful mean or median values could not be calculated for the time lost and time at less 
than 50% productivity data, due to the data being not normally distributed. Floor effects were 
observed as many values were zero. For migraine, the rank order of time lost was 
numerically but non-significantly greater for attacks taking place inside the menstrual period 
than for those occurring outside the menstrual period (1,344.5 versus 1070.5, p=0.23, Figure 
1). The rank order of time at less than 50% productivity was significantly greater for attacks 
taking place inside the menstrual period than for those occurring outside the menstrual 
period (1,453.6 versus 961.5, p=0.01, Figure 1). For non-migraine headaches, the rank order 
of time lost was marginally significantly greater for attacks taking place outside the menstrual 
period than for those occurring inside the menstrual period (5,009.0 versus 1,432.0, p=0.06, 
Figure 2). The rank order of time at less than 50% productivity was numerically but not 
significantly greater for attacks taking place outside the menstrual period than for those 
occurring inside the menstrual period (4,902.5 versus 1,538.5, p=0.37, Figure 2). The rank 
order of data for migraine headaches during menstruation was similar to that of non-migraine 
headache, for both the time lost and time at <50% productivity analyses (Figures 1 and 2). 
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Figure 1. Time lost and time at less than 50% productivity per attack for migraine attacks 
occurring inside and outside the menstrual period for patients with migraine (n = 30): analysis 
of rank sums. 
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Figure 2. Time lost and time at less than 50% productivity per attack for non-migraine 
headache attacks occurring inside and outside the menstrual period for patients with 
migraine (n = 30): analysis of rank sums. 
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Discussion 
 
This study provides a snapshot of headache, depression and bodily pain in women attending 
a primary care clinical practice. While the data are preliminary, they provide an insight into 
clinical issues important to primary care, and suggest future avenues of research. The 
patients recruited to the study came from a single UK primary care practice, with a responder 
rate of 41.3% completing the initial questionnaire. This is a relatively high response rate; 
surveys conducted with the general public more typically elicit a response rate of about 10%. 
Respondents were approximately equally distributed among the different age groups.  
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The patients who completed the initial questionnaire reported high levels of headache, 
depression and bodily pain. About two-thirds of patients reported any headache, with 4.3% 
being categorized with frequent headaches, 18.9% with disabling intermittent headache and 
42.9% with non-disabling intermittent headache. While no formal diagnoses were conducted, 
there are good reasons for categorizing patients with frequent headaches as having CDH, 
those with disabling intermittent headaches as having migraine and those with non-disabling 
intermittent headaches as having TTH. CDH is often defined as daily, or near-daily 
headache.21 Results from the Spectrum and Landmark Studies indicate that a default 
diagnosis of migraine can be given to patients with disabling episodic headaches, and non-
disabling episodic headaches are usually TTH.22,23 Support for this comes from the relative 
prevalence of putative CDH, migraine and TTH in this study, which were similar to those 
reported for women in previous population-based studies (1-year prevalence: TTH = 86%;1 
migraine  = 18%;2 CDH approximately 4–5%3), and were generally consistent across all age 
groups.  
 
Over 50% of the patients reported symptoms indicative of depression, with 15.3% reporting 
severe depression. The prevalence of depression was remarkably similar for all age groups 
and severity levels, but was higher than has been previously reported for the general 
population (about 12%4). The levels of reported bodily pain were also high, with 40.6% of 
patients reporting pain and 21.7% reporting severe pain. Again, all age groups reported a 
high prevalence of bodily pain, but reporting of pain overall and severe pain increased with 
increasing age of the patient. Overall, these results indicate that headache, depression and 
bodily pain are common in the general adult female population.  
 
A low proportion of patients (11.1%) identified with migraine (disabling intermittent headache) 
and still having periods responded to the menstrual headache questionnaire. The reasons for 
this relatively poor response are not clear, although it is well known that less than half of 
migraine sufferers consult with their primary care physicians for care.19 In addition, patients 
find it difficult to complete a diary over a period longer than a few weeks.24 The total number 
of headache episodes reported was also modest (89 migraine and 114 non-migraine 
headache episodes). However, there were some strong trends in the results from the 
questionnaire that have implications for clinical practice.  
 
Migraine headaches were relatively more frequent inside than outside the migraine attack, as 
shown by the roughly equal numbers of attacks in the approximately 1 week of menstruation 
and the 3 weeks outside it. In contrast, non-migraine headaches were approximately equally 
distributed inside and outside the menstrual period. 
 
Migraine attacks that occurred inside the menstrual period scored numerically higher than 
those occurring outside the menstrual period in terms of rank sums of time lost and time at 
less than 50% productivity. These results are in line with a recent study indicating that 
menstrually-associated migraine attacks were slightly more painful than non-menstrually-
associated ones.13 However, the differences between menstrually-associated and non-
menstrually associated migraine attacks was not high in the present study, and significance 
was only reported for the analysis of time at less than 50% productivity. Results for non-
migraine headache were the opposite of those for migraine, with those occurring outside the 
menstrual period scoring numerically, but not significantly, higher than those occurring inside 
the menstrual period in terms of the rank sums of time lost and time at less than 50% 
productivity. Recent data from the Landmark and Spectrum studies indicate that all 
headaches experienced by migraine sufferers with disabling headaches are sensitive to 
triptans and may be part of the overall migraine process.23,25 This raises the possibility that 
both the migraine and non-migraine headaches analyzed in this part of the study were 
essentially migrainous in character, at least in this group of patients with disabling headache.  
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Assessments of disability are important measures, and not only in terms of the response to 
headache treatments. They are key measures in aiding communication between patients and 
physicians,19 assessing headache patients’ illness severity and treatment needs,17 and 
patients’ subjective perceptions of migraine and CDH management.26 
  
Study limitations and suggestions for future research 
Part 1 
The questionnaires used in the study were not validated tools, but were devised by the 
investigators to be simple to use and potentially applicable to primary care clinical practice. 
The questionnaires were not tested for reliability or validity, and additional studies would be 
required for this. Headache subtypes could be diagnosed from the initial questionnaire, as 
described previously in this paper. While the diagnoses were not tested for accuracy, they 
follow criteria developed by the IHS,20,21 and are therefore likely to be valid. However, simple 
diagnostic screening questionnaires for headache have recently been developed and 
validated,27,28 and may therefore be more preferable to use. The initial questionnaire also did 
not provide a clear diagnosis for depression, but simply used clinical markers to guide the 
physician. Again, it would probably be preferable to use a validated depression questionnaire 
in future studies.  
 
The prevalence study design was perhaps not optimal. Additional items that should have 
been taken into account included defining the sample in relationship to the population under 
study, random sampling, defining an acceptable response rate (>50%), and conducting a 
non-response analysis. Despite this, the prevalence of the headache subtypes was close to 
expected values, although depression was probably over-estimated. There was the 
possibility of the responders being a self-selecting population with significant problems. 
 
Part 2  
The menstrual headache questionnaire was based on the IHS diagnostic criteria20 and items 
contained in the MIDAS questionnaire.19 Thus, while this questionnaire was also not 
validated, it contained items with proven reliability and validity. However, the questionnaire 
should be tested for these properties if it is used again. 
 
Some methodological issues were raised by the analyses that have implications for the 
design of future studies. The data were confounded by the fact that some of the events were 
repeatedly measured in individual patients, and that some patients only had one type of 
headache. A much larger sample of patients would be necessary to allow both within and 
between patient group comparisons. In the present study, data were analyzed only between 
the groups for 30 patients experiencing 203 headache attacks. The results should therefore 
be taken with caution. However, non-parametric testing with the Mann-Whitney U Test 
showed one significant and one marginally significant result from only four analyses, which 
indicates that the results were unlikely to have arisen by chance. Analysis of means or 
medians was not a useful measure in the present study because the data were not normally 
distributed (in fact they were seriously skewed). Many headache attacks scored zero on the 
two analyses, leading to floor effects being observed. Such floor effects have been reported 
with use of the MIDAS Questionnaire, on which the analyses were based.29 Future studies 
may benefit from using assessments of headache impact which provide a normal distribution 
of results, such as the Headache Impact Test30 or the Short Pain Inventory.31 
 
Studies of headache in general practice are urgently required, as clinical experience does 
not always follow data from controlled clinical trials.32 We encourage the use of validated 
instruments in these studies, which have become available since the inception of the present 
study. However, despite the methodological deficiencies in the present study, the clinical 
importance of headache, depression and bodily pain were emphasized, and information was 
gleaned on the disability associated with migraine and non-migraine headaches inside and 
outside the menstrual period. We look forward to further studies on this important topic. 
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Conclusions  
This study showed that headache, depression and bodily pain were common in women aged 
14–50 years registered at a UK general practice. For migraine sufferers, migraine attacks 
that took place during the menstrual period tended to be more disabling than those taking 
place outside the menstrual period, but the opposite was true for non-migraine headache. 
These results provide a snapshot of headache, depression and bodily pain in a subset of 
women attending a UK primary care practice. 
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Appendix 1. The headache, depression and bodily pain questionnaire 
 
Please circle the answers that you feel apply to you 
1. Do you suffer from headaches? 
a. No (go to question 4) 
b. Yes 
 
2. How often do they occur? 
a. Most days in the month 
b. More than four times a month 
c. One to four times a month 
d. Less than once a month 
 
3. Do the headaches interfere with your ability to perform normal daily activities, i.e.  
Do you have to stop doing things you would normally do? 
a. No 
b. Yes 
 
4. Do you have periods? 
a. No 
b. Yes 
 
5. In the last five years have you ever suffered from sleep disturbance, such as waking 
in the early hours of the morning regularly or having difficulty getting off to sleep, that 
has lasted for more than two weeks at a time? 
a. No 
b. Yes 
 
6. In the last five years have you ever had an episode of low mood, poor concentration, 
disinterest or tearfulness that has gone on for more than two weeks? 
a. No 
b. Yes 
 
7. In the last five years have you ever had feelings of worthlessness, guilt or suicidal 
ideas that have persisted for more than two weeks? 
a. No 
b. Yes 
 
8. If you answered Yes to any of questions 5, 6 or 7, did you discuss these feelings with 
your doctor? 
a. No 
b. Yes 
 
9. If you saw your doctor, did you receive any treatment? 
a. No 
b. Yes 
 
10. Do you suffer from any other type of pain (other than headaches) that occurs 
regularly? 
a. No 
b. Yes 
 
11. Where do you feel the pain and when you get it how long does it last? 
Site of pain:- 
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Duration of pain:- 
 
12. Have you seen a doctor about this pain: 
a. No 
b. Yes 
 
13. Have you ever received treatment for this pain? 
a. No 
b. Yes 
 
Thank you for taking the time to answer these questions for us. If you answered Yes 
to many of these questions, and especially questions 5, 6 and 7, it may suggest that 
you are suffering from one of these conditions. If you have not discussed these 
symptoms with your doctor we suggest that you contact him/her at the Health Centre 
and he/she may be able to offer you help with your symptoms. 
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Appendix 2. The menstrual headache questionnaire 
 
Date 1 2 3 4 5 6 7 8 9 etc
Menstrual bleeding 
 
          
Time of onset                     - first symptom (specify) 
                                             - headache 
 
          
Time of resolution              - headache 
                                             - last symptom (specify) 
 
          
Maximum intensity of headache (mild, moderate or 
severe) 
 
          
Other symptoms (specify) 
 
          
Time lost from normal activity (hours) 
 
          
Time spent at less than 50% of normal activity 
(hours) 
 
          
Drugs taken 
 
          
Contraceptive drug (if any) 
 
          
Pre-menstrual symptoms or intercurrent illness (if 
any) 
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3.4 
 
Emotional function with tension-type headache, migraine and 
chronic daily headache* 
  
 
Abstract 
 
Background: The Short Pain Inventory (SPI©) is a prospective, validated questionnaire that 
assesses pain severity and mood disturbances for a variety of conditions. 
Objectives: In this prospective, within-group, comparative study, the SPI was used to 
assess how the mood disturbances and coping abilities change over time in patients with 
tension-type headache (TTH), migraine and chronic daily headache (CDH) attending a 
primary care headache centre. The healthcare resource utilisation of these patients was also 
assessed retrospectively. 
Methods: Patients (n = 75) were diagnosed with episodic TTH, migraine or CDH, and 
completed a healthcare utilisation questionnaire. Patients completed the SPI 10 times over a 
7-day period, starting 1 hour after the onset of their next headache. The SPI data were 
analysed statistically as Z scores and coping Z scores for the Total Pain Disturbance, Total 
Mood Disturbance, and individual sub-scores for sedation, social interaction, sadness, 
anxiety and anger. Data from the healthcare resource utilisation questionnaire were analysed 
as descriptive statistics.  
Results: All 75 patients completed the healthcare utilisation questionnaire and 42 (56.0%) 
completed the SPI for the 7-day period. All headache patients showed considerable mood 
disturbances during a headache. In general the disturbances were severe in intensity and of 
the order CDH>migraine>TTH. The pattern of mood disturbance was different for each type 
of headache, as was the patients’ ability to cope with the mood changes. Patients with CDH 
experienced pain and emotional symptoms, particularly sedation, throughout the 7-day 
monitoring period. For TTH and migraine, the pain and emotional symptoms resolved within 
1–2 days after the headache. The level of healthcare resource utilisation was also in the 
order CDH>migraine>TTH, similar to the data reported for the SPI.  
Conclusions: Patients with headache had significant emotional symptoms associated with 
their headaches. These symptoms resolved within 1–2 days for patients with episodic TTH 
and migraine. However, patients with CDH were profoundly affected, and did not improve 
physically or emotionally from their headache over a 7-day period. Headache patients 
generally experienced higher levels of sedation than did patients with other pain conditions. 
 
 
 
 
 
 
* Edited from the full article: Dowson AJ, Bundy M, Kilminster SG. Emotional function with 
tension-type headache, migraine and chronic daily headache. Headache Care 2005; 
manuscript in preparation. 
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Introduction 
 
Three subtypes of headache, tension-type headache (TTH), migraine and chronic daily 
headache (CDH: comprising chronic migraine, chronic TTH, hemicrania continua and new 
persistent daily headache in the new International Headache Society (IHS) classification 
criteria1), comprise the majority of the benign, primary headaches reported in general clinical 
practice. All these headache subtypes are common in the general adult population: 
prevalence rates are >50% for TTH; 12% for migraine; and 4% for CDH.2–4 Physicians’ 
management of these headache subtypes differs markedly in terms of overall strategy, 
selection of treatment modalities and duration of therapy. Also, they may be confused with 
each other on diagnosis. Migraine may present with symptoms typical of TTH,5 and migraine 
may transform to CDH over periods of years or decades.6 Patients with CDH may experience 
headaches characteristic of TTH and migraine in the constellation of their symptoms.7 
Diagnostic procedures may not, therefore, distinguish clearly between the headache types. A 
means of distinguishing the characteristic features, or ‘footprints’ of these headaches would 
be of great value in primary care, where time is limited, and the experience of the physician 
uncertain. 
 
Several tools have been developed to assess headache features, as an aid to clinical 
management. The tools are broadly of three types: scales that specifically measure the 
functional ability of the patient, scales that index the migraine pain experience, including 
functional ability, and more generic measures.8–13 Of the former type, impact questionnaires 
(e.g. the Migraine Disability Assessment [MIDAS] Questionnaire and the Headache Impact 
Test [HIT]) assess the effect headaches have on the patient’s ability to work and function 
normally over 1- or 3-month periods.8,9 Migraine-specific Quality of Life (QOL) tools assess 
the functional status (physical and emotional), well-being and overall health of the patient, 
usually over a 1-month period.10–12 Generic QOL tools measure these values also, and also 
include a social dimension.13 In addition, recently developed questionnaires have 
investigated ways of assessing the efficacy of interventions, using impact-type,14 QOL-type15 
or a combination of different types of questions.16 All of these tools assess retrospective 
data. 
 
A biopsychosocial model has been proposed for chronic pain, whereby physical symptoms 
and emotional distress lead to the suffering that drives the patient to consult a physician.17 
The level of pain and emotional disability are directly linked, while the emotional impact can 
also be expressed as how well the patient is coping with the illness relative to a certain level 
of pain.18 The relationship between pain level, emotional disability and how well the patient 
copes with them is relatively little understood and worthy of investigation. 
 
Whilst the symptomatology of most headache subtypes is well understood, the emotional 
components of headaches are not. Our interest was to learn about how patients suffering 
from TTH, migraine and CDH differ in their pain level and emotional well-being, and the way 
they cope with these headache conditions over time. We also wanted to assess how the 
differences in emotional disturbance and coping may affect healthcare resource utilisation in 
these patient populations.  We chose a prospective tool that has been developed specifically 
to measure the emotional consequences and associations of physical pain, the Short Pain 
Inventory (SPI©).18  
 
In this study, the SPI was used to prospectively assess how the mood disturbances and 
coping abilities change over time in patients with TTH, migraine and CDH attending a 
primary care headache centre. The healthcare resource utilisation of these patients was also 
assessed retrospectively. The study was conducted as part of ongoing use of the SPI in the 
UK National Health Service (NHS), and to investigate the spectrum of primary care patients 
(including those with TTH). 
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Methods  
Patients 
Patients who took part in the study were attending a general practice headache clinic at 
Cranleigh Health Centre, Surrey, UK (Dr Bundy). The study was approved by the South West 
Surrey Local Research Ethics Committee. 
 
Study design 
This was a prospective, within-group, comparative study to assess the emotional ‘footprint’ of 
headaches, measured by the SPI, over 7 days following the onset of a headache. The 
questionnaires were administered by a psychologist (Dr Kilminster). A specialist neurologist 
(Dr Dowson) provided a diagnosis for each patient at the study outset, utilising clinical 
judgement and the IHS criteria then current.19  
 
Patients completed a retrospective healthcare resource utilisation questionnaire at screening, 
covering the previous 6 months. Information was recorded as the number of: consultations 
for headache; prescriptions for headache and other conditions; GP visits; GP services used 
(out-of-hours telephone calls, emergency telephone calls and home visits); and referrals to a 
specialist physician. 
 
Patients had a 6-week window from study onset to experience a headache and complete a 
series of SPI questionnaires. Patients self-completed the SPI at home at the following times 
over a 7-day period:  
• Practise session at the clinic (baseline) 
• Within 1 hour after the first headache started or on waking with a headache (Day 1). 
For CDH, the definition was the onset of a subjective ‘bad headache’. 
• Just after the pain was worst (peak) [Day 1].  
• 1 hour after the headache had resolved or on waking with the headache resolved 
(Day 1) 
• 24 hours after the headache started (Day 2) 
• Evening of Day 2 about 8 pm (Day 2) 
• Days 3–7 inclusive at about 8 pm. 
SPI questionnaires were completed for 7 days, even if the headache lasted for longer than 
this time period. Explanation on how to complete the questionnaires was kept to a minimum.  
 
Instruments: the SPI questionnaire 
The SPI is a 17-item self-rating questionnaire dedicated to measuring any pain, not only 
headache. The questions assess pain intensity, social interaction skills and components of 
emotional function. Patients rate each item on a five-point numerical Likert scale: not at all 
(score 0), a little (1), moderately (2), very much so (3) and extremely (4).  Five subscales 
measure sedation, social interaction, anxiety, sadness and anger, and have been fine-tuned 
by maximising items that are specific to pain. The SPI takes about one minute to complete,18 
and can be accessed via the internet with automatic scoring.20 A scale of Total Mood 
Disturbance (TMD, 14 items) can be summated from the SPI, which measures the subtle 
mood changes that specifically covary with mild to severe pain (including sadness, anger, 
anxiety and sedation scores [social interaction scores are removed because this is a 
cognitive-behavioural parameter]). All 17 items can be summated to form the Total Pain 
Disturbance (TPD) score. As the physical severity of pain worsens, so generally does each 
of the emotional components.21–23 If a patient’s emotional score is exaggerated or flattened 
relative to the normal values, then a coping score can also be given as to how well a patient 
is coping with their pain, relative to others at the same physical level of pain. In this way an 
emotional ‘footprint’ of the headache can be created. Normative coping scores can be 
calculated for all items on the SPI Questionnaire. This can be very useful in the individual 
management of patients. We have found that around 60% of the variance of physical pain is 
explained by the overall mood of the patient.21,22 The SPI has been shown to be far more 
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powerful at discriminating between varying levels of physical pain severity than the McGill 
Pain Questionnaire (used as the gold standard measure), with the majority of the pain 
variance being captured by the SPI.21  
 
A recently published paper showed that the SPI was a reliable and valid measure of 
headache severity, and superior to the HIT. However, the HIT score was better related to 
headache diagnosis than was the SPI score.24 As the pain severity increased from none to 
extreme, there was a highly significant increase in the SPI subscale scores for sedation, 
social interaction, sadness, anxiety and anger, as well as the SPI TMD score. Correlations 
between headache severity and the SPI subscale scores ranged from 0.60 to 0.70, and were 
0.76 for the TMD score and 0.77 for the TPD score. The correlation between SPI sedation 
scores and headache severity was validated in a placebo-controlled, crossover trial of 10mg 
temazepam in 12 healthy volunteers, by analysing Critical Flicker Fusion thresholds.24,25  
 
Other studies have demonstrated that the levels of SPI subscales associated with headache 
exhibited marked differences when compared with those of other pain states such as dental 
pain, osteoarthritis and chronic pain states.22–24 In general, headache patients had the 
greatest level of sedation, while dental patients had the greatest levels of anger, sadness 
and anxiety. Patients with osteoarthritis had the lowest level of mood disturbance of all the 
patient groups. Overall, headache patients had a level of mood disturbance at least as 
severe as patients who were attending a secondary care chronic pain clinic. 
 
Endpoints 
The primary study endpoints were derived from the SPI questionnaire: the pattern of pain 
intensity (assessed as none [Grade 0], mild [Grade 1], moderate [Grade 2], severe [Grade 3] 
and extreme [Grade 4]) and emotional items (sedation, social interaction, sadness, anxiety 
and anger, total TMD and TPD scores) over the 7 days during and following the headache. 
The healthcare utilisation data formed the secondary study endpoint. 
 
Statistical methods 
SPI 
All spoiled SPI forms were included for the intention-to-treat basis. This was done so as to 
reduce the administrator bias and evaluate the SPI as it would be used realistically in clinical 
settings. Statistical analysis was by discriminant function analysis, simple t-tests and test-
retest Pearson product moment correlation coefficients. Statistical analysis was carried out 
on a Power Macintosh G4/400/200 machine with Statistica V4. All data points were double 
validated against source forms. The analysis was carried out by a medical statistician. 
Diagnostic labels derived from the IHS classification criteria19 were dummy coded. Summary 
and derivative SPI measures were then used as dependent variables in simple t-tests. Data 
were 100% validated against source documents. 
 
Simple box plots with mean ± 1 and 1.96 standard errors about the mean were used. 
Elsewhere, graphical information was plotted as Z scores. The SPI raw scores were used for 
the summary and components. SPI disturbance and coping Z scores were computed. With 
the SPI, the extent to which the patient is coping with their pain can be estimated as coping Z 
scores, calculated by removing the effects due to physical pain. Put simply, normative coping 
values of the mood change were computed relative to patients with either no pain, mild, 
moderate, severe and extreme pain. For disturbance score, the normative values were those 
of subjects without pain. The SPI Coping score shows how much emotional upset the patient 
is in relation to the normal ranges expected in each of the five grades of physical pain. A fully 
automated and much simplified electronic version of SPI has been developed and is 
accessible via the internet at www.headachetest.co.uk. Previous studies have shown that the 
analysis of only four patients was sufficient to distinguish between headache subtypes and 
12 were sufficient to assess time of day effects with SPI.20 
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Healthcare resource questionnaire 
Data derived from the healthcare resource questionnaire were analysed by descriptive 
statistics only. 
 
Results 
Patient demography and baseline characteristics 
Seventy five patients took part in the study and completed the healthcare utilisation 
questionnaire. Their mean age was 44.3 years (SD 9.8), and the majority (97.3%) were 
women. At screening, episodic TTH was diagnosed for 15 patients (20%), migraine for 41 
patients (54.7%) and CDH for 19 patients (25.3%). Migraine patients were subdivided into 
those with low-frequency attacks (≤ 3 attacks per month, n = 30) and high-frequency attacks 
(> 3 attacks per month, n = 11). Extreme pain (Grade 4) was reported by 2.6% of patients, 
very much pain (Grade 3) by 8.2%, moderate pain (Grade 2) by 10.5%, a little pain (Grade 1) 
by 34.2% and no pain (Grade 0) by 44.7% of patients.  
 
Forty two of the 75 patients (56.0%) returned the completed SPI questionnaires within 6 
weeks. Six of these patients had TTH (14.3%), 23 had migraine (54.8%) and 13 had CDH 
(31.0%). The major dropout rate was in the TTH group. Due to the low frequency of their 
headaches, many TTH patients did not experience an initial headache over the 6-week 
window. 
 
 SPI: Changes in coping scores during, and for 7 days after, the headache 
Pain severity 
The physical severity of the pain varied considerably over the week following the initial 
headache (Figure 1). At the peak of the headache, patients with episodic TTH presented on 
average with mild to moderate pain (score 1–2), migraine patients with moderate to severe 
pain (score 2–3) and CDH patients with severe pain (score 3). TTH pain largely resolved 
within 24 hours and migraine pain within 2 days, but the CDH pain remained at least mild in 
intensity for the whole 7-day period. 
 
Figure 1. SPI: Physical pain severity during the headache and over the following week for 
patients with episodic TTH, migraine and CDH. 
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Changes in emotional items 
The disturbance in the sedation, social interaction, sadness, anxiety and anger items of the 
SPI over 7 days during and following the headache are shown in Figure 2 as Z scores. 
Coping Z scores for sedation, social interaction, sadness, anxiety and anger items of the SPI 
over 7 days during and following the headache are shown in Figure 3. 
 
Figure 2. SPI: Sedation, social interaction, sadness, anxiety and anger Z scores during the 
headache and over the following week for patients with episodic TTH, migraine and CDH. 
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Figure 3. SPI: Sedation, social interaction, sadness, anxiety and anger coping Z scores 
during the headache and over the following week for patients with episodic TTH, migraine 
and CDH. 
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Sedation disturbance Z scores revealed differences between the patient groups. Although all 
headache groups showed severe sedation at the point of worst pain during their headaches, 
the footprint of sedation over the remaining week was very different. With migraine, the 
sedation had resolved 2 days after the headache. However, patients with CDH and episodic 
TTH showed marked levels of sedation throughout the week. With TTH, this resolved by Day 
7, but the CDH patients were chronically sedated. Analysing the coping Z scores, TTH 
patients appeared to be coping less well than the other groups, with substantial sedation in 
excess of the physical pain they experienced. 
 
Despite the fact that all patients appeared sociable at screening, disturbances in social 
interaction remained above the normal range throughout the 7-day period for CDH patients. 
Two days after their headaches, patients with migraine and TTH had returned to normal 
levels of social interaction. Examining the social interaction coping scores showed that, for 5 
days of the week, the CDH patients had difficulty coping. Patients with migraine and TTH 
returned to normal within 24 hours of the headache. 
  
 104 
 
Disturbances in sadness remained elevated for the CDH patients throughout the 7-day 
assessment period. However, sadness resolved 2 days after the headache in the migraine 
and TTH groups. Coping scores for sadness were not sustained above +0.5Z for any of the 
groups. Therefore, much of the sadness induced is likely to be a direct result of the physical 
pain endured. There was some suggestion that patients with TTH were coping less well 
considering their lower level of pain and lower frequency of headaches compared to the 
other groups. 
 
Disturbances in anxiety remained elevated for the CDH patients throughout the 7-day 
assessment period. However, anxiety had resolved 2 days after the headache in the 
migraine and TTH groups. The SPI anxiety coping Z score showed that patients’ weekly 
anxiety remained within normal coping levels. There was a suggestion from the data that 
TTH patients might be coping less well with anxiety. 
 
The SPI anger disturbance Z scores showed a similar pattern to the pain severity changes 
over the week. Patients with migraine and TTH recovered within 24 hours of the headache, 
but CDH patients remained above normal levels for the whole week of assessments. The 
SPI anger coping Z scores showed that all the headache patients were coping well with 
anger.  
 
Total mood disturbance 
The TMD Z scores and coping Z scores, which include the sedation, sadness, anxiety and 
anger components, are shown in Figure 4. In general, patients with CDH and migraine had 
equivalent and severe mood disturbances during the period of the headache itself. However, 
the mood of CDH patients never returned to normal over the 7-day assessment period, while 
that of TTH and migraine patients did so within 48 hours of the headache. The coping scores 
showed that TTH and CDH patients had mild difficulty coping with their mood disturbances. 
The highest levels were seen temporarily with TTH patients. Migraine patients mostly coped 
well with their mood disturbances. 
 
Figure 4. Total mood disturbance Z scores and coping Z scores during the headache and 
over the following week for patients with episodic TTH, migraine and CDH. 
 
 
 
 
 
  
 105 
 
 
 
The TPD Z score was computed from all 17 SPI subscales. The results closely resembled 
those for the TMD discussed above (Figure 4). As before, the CDH patients did not recover 
over the 7-day assessment period and their pain was typically +2Z above normal. 
 
Healthcare utilisation 
Patients diagnosed with episodic TTH, migraine and CDH showed marked differences in 
their utilisation of healthcare resources (Table 1). Patients with TTH used few resources, and 
did not consult or receive prescriptions for headache. Most patients with migraine had 
consulted for headache, with over three-quarters receiving a prescription for headache from 
their GP. Most patients with CDH had consulted for headache, each receiving, on average, 
more than one prescription for headache. Patients with CDH consulted their GPs (all causes) 
and received more overall prescriptions than patients with migraine or episodic TTH. Out-of-
hours GP services (telephone calls, emergency calls and home visits) were hardly ever used 
by these groups of headache patients. Headache referrals were infrequent for episodic TTH 
patients, but were used for approximately one-third of migraine and CDH patients. Patients 
with low-frequency migraine used fewer resources than those with high-frequency migraine 
and CDH, who had a similar pattern of use.  
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Table 1. Healthcare utilisation by patients in the study, reported at baseline for the previous 
6-month period. 
 
Number of patients (ratio per patient) 
Healthcare 
resource 
Episodic 
TTH 
(n = 15) 
Migraine 
(n = 41) 
Low-
frequency 
migraine 
(n = 30) 
High-
frequency 
migraine 
(n = 11) 
CDH 
(n = 19) 
Headache 
consultations 
0 31 (0.76) 19 (0.63) 12 (1.09) 12 (0.63) 
Prescriptions 
for headache 
0 34 (0.83) 10 (0.33) 24 (2.18) 26 (1.37) 
Total 
prescriptions 
9 (0.6) 143 (3.49) 68 (2.27) 75 (6.82) 131 (6.89) 
GP visits 20 (1.33) 108 (2.63) 67 (2.23) 41 (3.73) 76 (4.0) 
Out-of-hours 
calls 
0 1 (0.02) 1 (0.03) 0 0 
Emergency 
calls 
0 0 0 0 0 
Home visits 0 1 (0.02) 1 (0.03) 0 2 (0.11) 
Referrals  1 (0.07) 13 (0.32) 8 (0.27) 5 (0.45) 6 (0.32) 
 
 
Discussion 
 
This study demonstrates the link between pain, emotional disability and the associated way 
that patients with TTH, migraine and CDH cope with their headaches over time. We have 
previously demonstrated that the SPI is a very discriminating measure of headache 
severity.24 Results from the current study show that it also discriminates the emotional impact 
of different headache subtypes. It is clear that episodic TTH, migraine and CDH leave 
different ‘footprints’ in terms of the emotional experience, associated tiredness, disruption to 
social interactions and the time course of each of these components.  
 
At peak intensity the pain level as assessed by the SPI was mild to moderate for episodic 
TTH, moderate to severe for migraine and severe for CDH. These gradations of intensity are 
similar to those generally reported for the separate headache subtypes.1 Patients with the 
three headache subtypes all exhibited sedation, disturbances in social interaction, sadness, 
anxiety and anger at the peak of the headache. In general, the severity of these emotional 
components was more intense for CDH and migraine than for episodic TTH. However, the 
pattern of these emotions differed between the three groups in the 7-day period following the 
headache. 
 
Analysis of the SPI data demonstrates that CDH is an appropriate term for the condition. 
Physical pain was always present over the 7 days, and fluctuated between mild to moderate 
pain over the post-headache period. Marked levels of sedation, disturbed social interaction, 
sadness, anxiety and anger were also seen over the week following the headache. CDH 
patients are clearly chronically fatigued. For half of the week, their level of sedation was due 
to impaired coping with tiredness above and beyond the level caused by physical pain. This 
may reflect the known association of CDH and Chronic Fatigue Syndrome26 and, certainly, 
tiredness is a major feature of the post-dromal period of headache in CDH. CDH patients 
also showed chronic disturbances in social interaction and sadness that never recovered 
over the 7-day period. For at least part of the week, these disturbances were caused by a 
failure to cope above and beyond the level of physical pain endured. On the other hand, 
coping scores for anxiety and anger were mostly within normal levels, the high levels of state 
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anxiety and anger disturbance being caused by the physical pain severity. Overall, the level 
of emotional disturbance experienced by CDH patients was similar to that seen in patients 
attending chronic pain clinics.22 An unfortunate feature of CDH patients is that their mood 
disturbance never returns to normal and patients obtain no respite from the pain and its 
emotional consequences.  
 
Migraine physical pain improved to mild or no pain within 48 hours of the headache. Although 
marked levels of sedation, disturbed social interaction, sadness, anxiety and anger were 
seen during the headache, these symptoms typically resolved within 2 days. Coping scores 
for these symptoms were at normal levels after the headache. These data indicate that the 
patients were coping well with the emotional symptoms, which resulted from the level of 
physical pain experienced. Unlike CDH patients, migraine patients are not chronically 
sedated.  
 
Physical pain associated with episodic TTH resolved within 24 hours.  Marked levels of 
sedation were seen during the headache and continued for most of the following week. 
Coping scores for sedation were the most disturbed of all the three types of headache, 
seemingly being more severe than those related to CDH. This shows that the sedation was 
probably not related to physical pain, but was exaggerated by it. It may be a feature of a 
delayed recovery from the headache insult or be a precipitating factor for the headache. This, 
perhaps surprising feature considering the relatively mild intensity of TTH, is probably 
underestimated in the management of these patients. Levels of disturbance in social 
interactions, sadness, anxiety and anger were all less intense during the headache than 
those associated with migraine and CDH, and resolved within 1–2 days following the 
headache. Coping scores for social interaction, anxiety and anger demonstrated that these 
symptoms were not above normal ranges, taking into account the level of physical pain.  
Coping scores for sadness were sometimes above the normal range for 3 out of the 7 days 
post-headache. This suggests mood lability in terms of sadness that is not related to the 
physical pain experienced. Coping Z scores for anger tended to be rather low. It is possible 
that episodic TTH is typified by a period of anger repression and extreme tiredness, although 
the study sample was too small to be definite about this.  
 
In this study, the level of mood disturbance was directly related to the level of healthcare 
utilisation in the same group of patients. Direct comparisons cannot be made, as the two 
assessments were not contemporaneous. However, the link is logical. Patients with chronic, 
severe emotional impact are more likely to require medical services than those in which the 
impact is transient. Patients with episodic TTH had a low use of resources, in terms of GP 
consultations and prescription medications. Patients with migraine frequently consulted their 
GP for care and usually required prescription headache medications. Those with high-
frequency migraine had markedly higher patterns of healthcare utilisation than those with 
low-frequency attacks. Patients with CDH consulted their GPs frequently and had high usage 
of prescription medications. Patients with high-frequency migraine are at risk of developing 
CDH,6 and at least some of the patients in this group may actually have been in this situation. 
Mood disturbances may, at least in part, drive patients to consult their GPs for headache 
care.  
 
This work has potential clinical implications to the management of headache. Despite its 
importance to illness severity, the emotional component of headache is likely to be rarely 
elicited by physicians, as it plays no part in the current classification criteria.1 Specialist 
physicians may find that the use of SPI forms a useful additional screening and outcome tool 
for the evaluation of their patients, particularly those who may later develop depression 
and/or anxiety conditions. It may be useful not only to estimate the consequences of pain but 
also stress as a causative trigger to headache. However, should primary care physicians 
may find it too demanding for everyday use, an automated much simplified electronic version 
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has been developed over the internet at www.headachetest.co.uk.20 This has the benefit of 
full electronic delivery of the test and automatic scoring. 
 
The recently developed Migraine Assessment of Current Therapy (Migraine-ACT) 
questionnaire contains one question on emotional response (Are you comfortable enough 
with your medication to be able to plan your daily activities?).16 This question is suitable for 
use in primary care, and ‘no’ answers indicate that the patient has unmet treatment needs. A 
single questionnaire item on mood cannot possibly accurately and comprehensively assess 
mood, and the questionnaire was not set up to do this. Patients with chronic emotional 
problems linked to headache may require referral to a specialist. But one should be mindful 
that mood disturbance can be as much a cause as an effect. 
 
This study has certain limitations. Relatively small numbers of patients took part, and a high 
proportion of patients did not complete a SPI questionnaire in the 6 weeks allowed. A longer 
study duration could have led to a reduction in the drop out rate.  
 
In conclusion, patients with episodic TTH, migraine and CDH all had considerable mood 
disturbances during their headaches. The more pain they experienced, the greater was the 
level of mood disturbance. The pattern of mood disturbance was different for each type of 
headache, as is the patients’ ability to cope with the mood changes. Patients with episodic 
TTH and migraine had significant emotional symptoms associated with their headaches, 
which resolved within 1–2 days. However, patients with CDH were most profoundly affected, 
and did not recover physically or emotionally from their headache over a 7-day period. The 
association of mood disturbances with common headache subtypes may explain in part the 
reported co-morbidity of headache with psychiatric disorders.27 Patients with chronic 
headaches have clear emotional needs, both for their headache and other disorders, which 
may not be currently appreciated or addressed by healthcare services. Future large studies 
with SPI in headache are warranted to further define and quantify the emotional component 
of headache impact.  
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The clinical utility of assessing disability in  
primary care clinical practice  
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4.1 
 
Assessing the impact of migraine and other headaches* 
 
 
Abstract 
 
Migraine is a remarkably disabling condition, although unpredictable and heterogeneous in 
frequency, duration and severity. It can be difficult to manage in primary care, where it is 
under-recognised, under-diagnosed and under-treated. Proposals have been made that 
migraine care could be improved by incorporating assessments of migraine impact into 
management strategies. Research has shown that measuring headache-related disability, 
together with assessments of pain intensity, headache frequency, tiredness, mood 
alterations and cognition can be used to assess the impact of migraine on sufferers’ lives and 
society. From this research two simple and brief impact tools were developed; the Migraine 
Disability Assessment (MIDAS) Questionnaire and the Headache Impact Test (HIT). Both 
tools are scientifically valid measures of headache severity and have the potential to improve 
communication between patients and their physicians, assess headache severity and act as 
outcome measures to monitor treatment efficacy. Each of these tools offers its own 
advantages. For example, HIT was designed for greater accessibility (on the internet at 
www.headachetest.com and www.amIhealthy.com and as a paper-based form known as 
HIT-6) and has a wider coverage of the spectrum of headache than MIDAS. Impact tools are 
also being increasingly recommended as part of generalised headache management 
guidelines to produce an individualised treatment plan for each patient in concert with other 
clinical assessments. It is not possible as yet to unequivocally recommend the optimal impact 
tool for use in primary care, but it should be usable by GPs, pharmacists, nurses and 
patients, and for research purposes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Edited from the full published article: Dowson AJ. Assessing the impact of migraine. Curr 
Med Res Opin 2001;17:298–309. 
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Introduction 
 
Migraine is a common, debilitating neurological disorder that affects about 12% of the 
general population. It is more prevalent in women than in men and in Caucasians than in 
Black and Asian races.1 Migraine attacks consist of moderate to severe headaches, which 
are typically throbbing, one-sided and aggravated by physical activity. The headache is 
usually accompanied by photophobia and/or phonophobia and nausea, and less frequently 
by vomiting and aura symptoms. Attacks occur on average about once or twice a month, last 
for about 24 hours, and are separated by symptom-free intervals.2 Migraine attacks result in 
significant reductions in sufferers’ health-related quality of life (HRQoL) compared with 
normal healthy subjects.3 However, migraine is an unpredictable, heterogeneous disorder 
and attacks vary widely in frequency, duration, severity and reported symptoms.4  
 
Due to this variability, migraine can be difficult to manage in primary care. In clinical practice, 
migraine is under-estimated, under-diagnosed and under-treated, leading to many patients 
dropping out from care (Figure 1). A recent study in the UK showed that 86% of migraine 
sufferers had consulted their physician at some time for treatment. However, 37% of 
sufferers had dropped out, leaving 49% as currently consulting.5 Studies in the USA and 
France indicated that about half of all migraine sufferers who consulted their general 
practitioners did not receive a correct diagnosis.6,7 Patients may not receive appropriate 
treatment even when they do consult and are diagnosed correctly. International and UK 
studies have shown that only a minority of migraine sufferers take prescription medications8,9 
and patient satisfaction with their usual analgesic acute medications is low.9,10  
 
Figure 1. Barriers to migraine care. For effective migraine care, sufferers need to consult 
their physician and be diagnosed, treated and followed-up effectively. Migraine sufferers are 
lost to care through under-consultation, under-diagnosis and under-treatment of their 
attacks.5–10 
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Good
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A range of initiatives has been set up to improve migraine care, by encouraging migraine 
patients to consult their physicians and for physicians to improve their diagnostic and 
treatment strategies. Several of these involve assessing the impact of migraine on sufferers’ 
lives, and using this information to facilitate management strategies. This article reviews the 
rationale for, and development of, tools that assess migraine impact and their potential roles 
in general practice. 
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Research into the impact of migraine 
 
In some instances, the impact of migraine can be considered as the objective effects of the 
illness on sufferers’ lifestyles, including their work and leisure activities, rather than subjective 
effects expressed as symptoms and HRQoL. Impact has great similarities to the World 
Health Organization’s definition of disability: “a restriction or lack (resulting from an 
impairment) of ability to perform an activity in the manner or within the range considered 
normal for a human being”.11 Studies from the USA, Canada and Japan have shown that 
migraine causes significant disability in its sufferers, with two thirds or more reporting at least 
mild disability and one third or more reporting moderate to severe disability.4,12,13 In a UK 
study, two thirds of migraine sufferers reported that migraine disrupted their lives, with three 
quarters having to lie down during attacks (Table 1).14 A second study indicated that between 
one third and two thirds of migraine sufferers in the UK (an estimated 1.9–3.8 million people) 
felt that they were not in control of their migraine and the way it affected their day-to-day 
lives.9 
 
Table 1. Migraine-related disability reported from a study conducted in the United Kingdom.14  
 
Disability Proportion of sufferers 
Physical functioning 
  Always have to lie down 
  Not in control of life 
  Disruption of life 
 
76 
34 
67 
Employment 
  Usually  miss work 
  Difficulty performing work 
  Cancel appointments/meetings 
  Rely on other people 
  Perceived effect on promotion 
 
50 
72 
67 
45 
15 
Unpaid work 
  Postpone household chores 
 
90 
Family and leisure activities 
  Relations with family and friends affected 
 
54 
 
 
The consequences of migraine impact are seen in patients’ lifestyles, including employment, 
unpaid work and family and leisure activities. The loss of these activities has been quantified 
in a series of studies. In the USA, each working migraine sufferer missed an average of 4.4 
days of work per year and the equivalent of 12 further days due to reduced productivity 
during attacks.15 In the UK, half of sufferers reported missing work and over two thirds 
reported difficulty performing work during attacks (Table 1).14 Migraine may even lead to 
unemployment. In a Health Maintenance Organisation in the USA, the unemployment rate 
was 2- to 4-fold higher in severely affected migraine sufferers than in the general 
population.16 School and college work is also affected in young migraine sufferers. In a 
Scottish study, children with migraine were absent from school for significantly longer periods 
than those without migraine (7.8 days versus 3.7 days per year, P<0.0001).17 This personal 
burden of migraine is reflected in an economic burden on society. Indirect costs (due to work 
absence and reduced work productivity) are very large for migraine, being estimated at £1 
Billion or more in the UK.18 These costs are very much higher than the direct costs due to 
medical care, last estimated at £23 million in 1990.19 Although direct medical costs for 
migraine have increased since 1990, partly due to the introduction of the triptan drugs, 
indirect costs still provide the main economic burden of the illness. 
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Migraine also affects unpaid work and family and leisure activities. In a UK study, 90% of 
migraine sufferers reported that they postponed their household work during an attack (Table 
1).14 Several studies have shown that migraine attacks commonly result in the cancellation of 
social events, and affect relationships with partners, children, friends and other people.14,20,21  
 
Migraine is therefore a remarkably disabling condition, with most sufferers reporting 
significant impact associated with their attacks in all areas of their lifestyles. Recent research 
has focused on the use of impact assessments to measure the severity of migraine in 
comparison with other assessments.  
 
Assessing the impact of migraine 
 
Migraine attacks vary in severity from moderate pain, with no activity limitations, to severe 
pain with prolonged incapacitation.4 To measure the impact of migraine, parameters must be 
defined that capture the personal burden on the sufferer and the economic burden on 
society. Following this, a scientifically valid tool needs to be developed to capture this 
information in a way that is simple to use and clinically relevant. 
 
Rationale for using impact tools 
Pain intensity is the most important aspect of migraine to the individual sufferer. Sufferers 
report headache pain more frequently than all other migraine symptoms and most patients 
consulting their physicians do so for pain relief.12 However, economic studies have shown 
that headache-related disability is the most important determinant of migraine’s societal 
impact in economic terms.22 Assessments of pain and disability were therefore included in 
initial studies assessing the impact of migraine. 
 
The Chronic Pain Index (CPI) was developed to measure the severity of a number of pain 
conditions, including headache, in primary care patients.16 Results showed that pain intensity 
and disability measures formed a reliable hierarchical scale whereby pain intensity scaled the 
lower range and disability the upper range of severity. Four severity grades were identified 
that covered the whole pain spectrum. When the CPI was tested on 740 primary care 
headache patients over a 2-year period, the severity grade was directly related to the impact 
of the headache on the individual and the direct and indirect economic costs (Figure 2).16,23 
There was approximately 3–4 fold greater individual impact, direct costs and indirect costs 
(assessed as the unemployment rate) for patients in the highest severity grade compared 
with those in the lowest grade. These results were confirmed in a study conducted in 
migraine patients who assessed the pain and disability associated with their most recent 
attack.4  
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Figure 2. Relationship of the Chronic Pain Index severity grade to the individual and societal 
costs of headache when tested on a group of 740 primary care headache patients over 2 
years. a. Pain impact on the individual assessed as a composite of activity limitations, 
depression and poor-to-fair self-rated HRQoL. b. Impact on society assessed as direct 
medical costs of care per year. c. Impact on society assessed as indirect costs over 2 years 
(assessed as the unemployment rate).16,23 Grade I = low pain intensity and low disability; 
Grade II = high pain intensity and low disability; Grade III = high disability which was 
moderately limiting; Grade IV = high disability which was severely limiting. 
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Using the CPI as a model, the Headache Impact Questionnaire (HImQ) was developed to 
measure headache impact. This was a relatively complex, 16-item questionnaire assessing 
headache frequency, pain intensity and disability, the latter measured as total lost time in 
employment, household work and non-work activities.  Studies showed that the HImQ was a 
scientifically reliable and valid measure of migraine severity. 24,25 However, it was complex to 
score, requiring mathematical equations, and was not intuitive to use as it was based on a 
composite of pain, frequency and disability measures. It was therefore not suitable for use in 
primary care, but has proved to be an excellent research tool.  
 
This research did indicate that it was possible to assess the impact of migraine using 
scientifically valid questionnaires. The next challenge was to develop simple but accurate 
and comprehensive questionnaires that could be used in the primary care setting. 
 
Development of impact tools for use in primary care 
Two tools have been developed to assess the impact of migraine, both partly based on the 
HImQ. However, they use quite different strategies to achieve their goals. The Migraine 
Disability Assessment (MIDAS) Questionnaire assesses impact as a static measure of 
disability, while the Headache Impact Test (HIT) uses a global assessment of impact, 
including headache-related disability. It should be noted that both questionnaires assess 
headache in general, rather than migraine specifically, and so have potential application to 
the whole field of headache management. 
 
The Migraine Disability Assessment (MIDAS) Questionnaire 
MIDAS is a paper-based questionnaire, designed to be accessible at physicians’ surgeries 
and pharmacies. Headache sufferers answer five questions in three activity domains 
covering the previous 3-month period (Figure 3).26 They score the number of lost days due to 
headache in employment, household work and family and social activities. Sufferers also 
report the number of additional days with significant limitations to activity (defined as at least 
50% reduced productivity) in the employment and household work domains. The total MIDAS 
score is obtained by summing the answers to the five questions as lost days due to 
headache. This can sometimes be higher than the actual number of lost headache days due 
to any one day being counted in more than one domain. The score is categorised into four 
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severity grades: Grade I = 0–5 (defined as minimal or infrequent disability); Grade II = 6–10 
(mild or infrequent disability); Grade III = 11–20 (moderate disability); Grade IV = 21 and over 
(severe disability); Two other questions (A and B) are not scored, but were designed to 
provide the physician with clinically relevant information on headache frequency and pain 
intensity. Information on MIDAS can be accessed at www.migraine-disability.net.  
 
MIDAS was tested extensively and shown to have face validity (i.e. meets physicians’ 
conceptions of important clinical criteria) and to be reliable, accurate, easy to use and score 
and intuitively meaningful to physicians.27–29 These features support its suitability for use in 
clinical practice. MIDAS has been proposed as an aid to communication between patients 
and healthcare professionals, as an aid to referral for primary care physicians, as a means of 
specifying treatment by using it to stratify patients according to their treatment needs, as an 
outcome measure and as a public health initiative to coordinate public policies for migraine 
management.8  
 
The MIDAS Questionnaire has several strengths. It has proved to be an effective aid to 
communication between physicians and their migraine patients with regard to disability, a 
subject often overlooked in conventional consultations.30 MIDAS is now widely used for this 
purpose by headache specialists and neurologists. Clinical studies have shown that MIDAS 
is sensitive to change, and can be used as an outcome measure in the follow-up of patients 
with migraine or CDH during treatment.31,32 However, these data require corroboration in 
large scale clinical trials. 
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Figure 3. The Migraine Disability Assessment (MIDAS) Questionnaire.26 The MIDAS Program 
was developed by Innovative Medical Research Inc, with sponsorship and assistance from 
AstraZeneca. 
 
 
 
However, MIDAS also has several weaknesses. It does not assess the full spectrum of 
headache, covering only about 35% of the range between moderate and severe intensity.33 
This may be due to its reliance on a single measure (disability). Additionally, the MIDAS 
grade score may not indicate the true medical need of patients. In the author’s clinical 
practice, many needy patients scored as Grade I, theoretically with little disability. A US study 
has shown that about 10% of MIDAS Grade I headache sufferers had more than six severely 
painful headaches per year.34 On the other hand, patients with frequent headaches, e.g. 
chronic daily headache, tend to all score as Grade IV. Some physicians have suggested that 
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MIDAS is weighted towards the measurement of headache frequency over disability. 
Relatively few physicians currently use MIDAS as a tool to specify treatment according to the 
patient’s disability grade, despite some evidence for this from a large clinical trial.35 
 
The Headache Impact Test (HIT) 
HIT was first developed as a web-based test, designed to be accessible to all physicians and 
headache sufferers through the Internet (at www.headachetest.com and 
www.amIhealthy.com). Questions are not printed on forms in advance. Rather, it is a 
dynamic questionnaire (Figure 4), with items derived from four validated headache 
questionnaires sampling all areas of headache impact (the Headache Disability Inventory 
[HDI], the HImQ, the MIDAS Questionnaire and the Migraine-Specific Quality of Life 
Questionnaire [MSQ]).36 Patients are questioned until clinical standards of score precision 
are met. Internet-HIT matches the questions asked to each patient’s severity level. In 
practice, five questions are sufficient to grade the majority of headache sufferers.36 Clinical 
standards of accuracy were met by 98% of migraine sufferers, and 97%, 87% and 61% of 
people with severe, moderate and mild headaches, respectively, completing five or fewer 
questions. In an extensive testing study in over 19,000 headache sufferers in the USA, 
Internet-HIT was shown to be reliable and valid, and covered the whole spectrum of 
headache.33,37,38 Coverage was similar to that reported for HImQ and much greater than that 
of MIDAS.33 Results showed that migraine had greater impact on sufferers’ lives than most 
other headaches.37 Internet-HIT differentiated sufferers on the basis of diagnosis and 
characteristics such as headache severity and frequency.37 It took only 1–2 minutes to 
complete, and its use motivated headache sufferers to seek medical care and facilitated 
headache-related communication between patients and their physicians.39  
 
Figure 4. The web-based Headache Impact Test (Internet-HIT).36,37 HIT was developed by 
QualityMetric Inc and GlaxoSmithKline. 
 
 
HIT-6 is a paper-based, short-form questionnaire based on the Internet-HIT question pool, 
designed for people without access to the Internet (Figure 5). Six questions cover pain 
severity, loss of work and recreational activities, tiredness, mood alterations and cognition. 
Each question is scored on a five-point scale, with the scores being added to produce the 
final score.40 HIT-6 scores are categorised into four grades, representing minimal, mild, 
moderate and severe impact due to headache. Studies have shown that HIT-6 is reliable and 
valid,40 and can be used to help diagnose headaches and select management strategies 
according to headache severity.41,42 Also, HIT-6 scores were directly related to self-reported 
hours of workplace productivity loss due to headache.43 Internet-HIT and HIT-6 scores 
compared well to each other when the two forms of the questionnaire were tested on a group 
of headache sufferers.44 
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Figure 5. The paper-based short form Headache Impact Test (HIT-6).40 HIT was developed 
by QualityMetric Inc and GlaxoSmithKline. 
 
 
 
 
  
 121 
Both the MIDAS and HIT tools provide scientifically reliable and valid measures of headache 
impact, and show great promise for wide utility in clinical practice. However, both forms of 
HIT appear to have certain advantages over MIDAS. HIT has the brevity of a short-form 
questionnaire but has the accuracy required for measuring individual patients at all levels of 
impact. This may be due to its wider range of questions compared to MIDAS, which scores 
time lost due to headache only. HIT is also more widely accessible than MIDAS, designed to 
be used by everyone through the Internet and as a paper-based form. However, HIT was 
developed more recently than MIDAS and has so far not been used in clinical practice to the 
same extent. So far, only MIDAS has exhibited sensitivity to change and can therefore be 
used to monitor the outcome of therapy.31,32 HIT has not been tested for this, but may be 
expected to also have this feature. Future work will define further the place of each of these 
impact tools in primary care, and such studies are currently underway with HIT. 
 
Strategies for managing migraine using impact measures 
 
Although impact measures for migraine are a recent development, they have been adopted 
widely by many opinion leaders in the field of headache. Both MIDAS and HIT have been 
proposed to have a wide potential for use in clinical practice, to improve communication 
between physicians and their patients, to assess illness severity and as public health 
measures.8,39,41,42 Impact measures have been incorporated in several initiatives to develop 
guidelines for the management of migraine in primary care, including those issued by the 
Migraine in Primary Care Advisors (MIPCA) in the UK45 and the Headache Consortium46 and 
the Primary Care Network47 in the USA. 
 
These three sets of guidelines have several features in common. They use assessments of 
migraine impact or disability in the initial evaluation of patients and recommend that 
treatment should be tailored to the patient’s individual needs. Additionally, patients who have 
disabling migraine are recommended to have access to migraine-specific therapies from the 
outset. Assessing migraine impact has obvious applications in these areas of management 
and future migraine guidelines are likely to incorporate impact tools significantly.  
 
The Migraine in Primary Care Advisors’ (MIPCA) Guidelines 
In 1997, MIPCA was the first organisation to advocate assessing the impact of migraine as 
part of its management strategy, before clinically valid impact tools had been developed. 
Fully revised and evidence-based guidelines were published in 2002,45 and updated in 
2004.48 MIPCA advocates an individualised approach to care, treatment being prescribed 
according to each patient’s needs. Factors considered include the nature of the patient’s 
attacks, the impact of headache on the individual’s life and the demands of the patient’s 
lifestyle. 
 
The MIPCA guidelines are illustrated in Figure 6. At the initial consultation, the physician is 
recommended to conduct a diagnostic assessment and to take a careful history covering the 
nature of the headaches, previous treatments taken and the impact on the patient’s life. 
Patients who experience up to four attacks per month are given acute therapy with a simple 
analgesic, with or without an anti-emetic (for mild-to-moderate migraine) or an oral triptan (for 
moderate-to-severe migraine). Rescue medication is also given for when the initial treatment 
fails. Nasal spray or subcutaneous triptan formulations may be considered if the patient has 
difficulties with oral therapies or requires a fast therapeutic effect due to the demands of their 
lifestyle.  
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Figure 6. The MIPCA management guidelines for migraine in the UK.45  
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If the initial therapy is unsuccessful, an alternative therapy should be provided. For patients 
who fail on multiple acute therapies, and for migraine patients with four or more headaches 
per month, prophylactic treatment is recommended, together with additional acute treatment 
for breakthrough attacks. Migraine patients who fail on this treatment, and those diagnosed 
with chronic daily headache (CDH), may require referral to a specialist physician. 
 
Commentary 
 
Migraine is a remarkably disabling condition, but is not always managed effectively in primary 
care. Barriers to migraine care exist for both general practitioners (GPs) and patients, leading 
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to under-consultation, under-diagnosis and under-treatment. Patients often do not rate non-
headache symptoms as medical and tend not to communicate the disability they suffer. In 
two studies with a total of 105 physicians in North America and Europe, only about one third 
of patients were reported to volunteer information about their headache-related disability.30 It 
can be difficult for the physician to go through protocols with patients. Headache diaries, 
though useful, need reinforcement with other measures and GPs need to know that migraine 
causes disability. In the same North American / European studies discussed above,30 
physicians reported that they recorded symptoms related to diagnosis (e.g. pain intensity and 
associated symptoms) rather than information on headache-related disability. Similar results 
have been reported from the UK. In a recent study of 33 UK GPs, only 54% took the impact 
of migraine into consideration on diagnosis as opposed to 81% who assessed family history, 
93% who assessed symptomatology and 90% who assessed trigger factors (AJ Dowson, 
unpublished results). Only 24% of the physicians felt that migraine always had an impact on 
the patient’s life. Such assessments of impact were subjective, as none of the GPs was 
aware of the MIDAS or HIT impact tools. Overall, measuring the impact of migraine is likely 
to aid the initial assessment of migraine, and improve treatment delivery.  
 
Research has shown that the impact of migraine and other headaches can be measured 
using assessments of some or all of pain severity, headache frequency, limitations to work 
and leisure activities, tiredness, mood alterations and cognition. Tools that address 
headache impact are now available and are being brought into clinical use. The MIDAS 
Questionnaire assesses disability only, as lost time in employment, unpaid work and family 
and leisure activities, whereas HIT assesses a global range of impact, including pain 
intensity, disability and other items, which can be tailored to the individual in Internet HIT.  
 
Neither MIDAS nor HIT is used widely in UK general practice. MIDAS is used in specialist 
practices, where it has proved to be effective in improving communication between 
physicians and their patients, and as a measure of treatment outcome. However, it has not 
proved as useful when tested in UK general practice, partly due to the overlapping nature of 
the questions. Patients too, are unsure of it. Little or no feedback was received from Migraine 
Action Association (MAA: the UK headache patient support group) members when MIDAS 
was published in the MAA Newsletter and tested in pharmacies in the UK. HIT has not been 
used significantly to date in UK clinical practice. 
 
An impact tool can be recommended for the primary care of migraine and its desirable 
attributes identified. It should be a self-administered form that is able to be summarised 
briefly. Open questions should be used, rather than a ‘ticking boxes’ approach. The tool 
should be used in the physician’s initial assessment to aid in the initiation of appropriate 
management strategies. It should also be able to measure the efficacy of medications and 
needs to be discriminating, e.g. impact testing may be used as a tool to measure if a 
treatment is working for a patient, rather than merely if it is not. If the treatment is working, 
the patient should remain on that same treatment. In practice, the impact tool should be 
integrated with other assessments of migraine symptoms. Finally, impact tools need to be 
refined and shown to work in general practice, where they can be used to review patient 
costs and potential cost savings of treatments. From the patients’ viewpoint, it is important to 
ask questions about migraine impact, but this should be taken as part of the whole clinical 
judgement of patients’ needs.  
 
Migraine impact is probably the most important headache assessment for the patient. Impact 
tools should therefore be widely accessible to patients at home, in pharmacies and GPs’ 
waiting rooms and with nurse consultants, e.g. in well woman clinics. They should also have 
positive effects on the GP’s practice, highlighting that migraine is a disabling illness and 
raising its profile in primary care. However, education of both patients and physicians on 
migraine impact and the use of impact tools will be necessary for their successful 
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introduction. The initial launch of impact tools is probably best achieved through headache 
clinics and GPs with an existing interest in treating headache. 
 
Both MIDAS and HIT meet many of the above desirable attributes for an impact tool suitable 
for use in primary care. They are both brief, simple to use and score, and have demonstrated 
scientific validity and clinical utility. HIT has greater accessibility (by design for use on the 
internet and as a paper-based form) and a greater coverage of the spectrum of headache 
patients, irrespective of their illness severity. MIDAS is sensitive to change and is 
increasingly being used as an outcome tool in clinical studies.31,32 However, with MIDAS, 
there is the possibility of patients with infrequent but disabling headache being categorised 
as having minimal disability, and so being overlooked. 
 
Recently published guidelines for the management of migraine have included assessments 
of migraine impact in the evaluation of migraine severity and treatment choice, in conjunction 
with traditional history taking and symptom evaluation. These guidelines advocate an 
individualised approach to care, where patients are managed according to their illness 
severity and lifestyle needs. Patients are educated and encouraged to play a key role in the 
care decisions made. However, previously published guidelines for migraine management in 
many countries, including the UK,49 USA50 and Germany51 make no mention of assessing 
migraine impact in the evaluation of patients. Nevertheless, impact assessments have a 
central role in the management of migraine and should be used in the development of new 
guidelines for primary care in the UK. 
 
In conclusion, the assessment of migraine impact is important in UK primary care. The use of 
impact tools can improve communication between physicians and their patients, aid in the 
assessment of migraine severity and the production of an individualised treatment plan in 
concert with other clinical assessments, and in the monitoring of the response to therapy. In 
the future, impact tools will be used in generalised headache management guidelines for the 
UK. As yet, it is not possible to unequivocally recommend the optimal impact tool, but it 
should be usable by GPs, pharmacists, nurses and patients, and should also be useful for 
purposes of research. 
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4.2 
 
The outcome of headache management following nurse 
intervention: assessment in clinical practice using the Migraine 
Disability Assessment (MIDAS) Questionnaire* 
 
 
Abstract 
 
Objectives: This audit assessed the outcome of a nurse intervention strategy in patients 
presenting with headache to a primary care surgery. 
Methods: All patients aged 18–65 years attending the surgery who reported headache in the 
previous 3 months were assessed by a nurse and completed a Migraine Disability 
Assessment (MIDAS) Questionnaire and a questionnaire investigating headache features 
and physician consultations. All patients were given oral and written advice on headache 
management by the nurse. Patients of MIDAS Grade I/II (minimal-mild disability) with severe 
or frequent headaches and all Grade III–IV (moderate-severe disabling headache) patients 
were also offered an appointment with a headache specialist physician. Patients were 
reviewed after 3 and 6 months with the same questionnaires.  
Results: A total of 195 patients took part in the study. At baseline, 136 (69.7%) were MIDAS 
Grade I/II and 59 (30.3%) were Grade III/IV. Compared with baseline, patients reported 
significant mean reductions at 6 months in: total MIDAS scores (5.9 versus 9.6; p = 0.014); 
headache frequency (MIDAS A score: 7.0 versus 12.6; p = 0.009); headache severity 
(MIDAS B score: 5.0 versus 6.0; p = 0.003); and physician consultations for headache (3-
month period: 0.05 versus 0.30; p = 0.05).  
Conclusions: Advice on headache management given by a nurse can potentially lead to 
significantly improved patient outcomes. MIDAS appeared to be a sensitive outcome 
measure for reduction in disability in headache sufferers. These results warrant further 
investigation in randomised, controlled clinical studies. 
 
 
 
 
 
 
 
 
 
 
 
* Edited from the full published article: Dowson AJ, Salt R, Kilminster S. The outcome of 
headache management following nurse intervention: assessment in clinical practice using 
the Migraine Disability Assessment (MIDAS) Questionnaire. Headache Care 2004;1:177–81. 
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Introduction 
 
Headache management is currently suboptimal in primary care. Migraine patients remain 
under-diagnosed and under-treated, with many patients not consulting a physician for care,1 
and this state has improved little over the past decade or more.2 Patients with chronic daily 
headache (CDH) are frequently not managed in primary care, but are referred to specialist 
headache clinics.3 Sufferers of tension-type headache rarely consult a physician for care.4 
Recently published guidelines for migraine management in the UK advocate a primary care 
team approach to headache management, utilising practice nurses and other healthcare 
professionals, as well as the physician.5 A UK pilot study has suggested that headache 
education provided by nurses can be effective in reducing the severity of headaches.6 
Following advice given by a primary care nurse to a group of headache sufferers, the 
severity of headache and associated disability declined over a 6-month period compared to a 
control group who did not receive this advice. In addition, a retrospective study in the USA 
indicated that the provision of headache advice by Advanced Practice Nurses resulted in 
improved quality of life in adult migraine patients.7 
 
The practice nurse may therefore have a key role to play in the management of headache 
patients. This audit was set up to investigate the outcome of a nurse intervention strategy in 
patients presenting with headache to a primary care clinic. The main outcome measure used 
was the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS assesses the 
disability associated with headache, by measuring the days lost over a 3-month period in 
employment or education, unpaid work and family and leisure activities.8 MIDAS is a reliable 
and valid measure of disability,9 and has been shown to be sensitive to changes in outcome 
in clinical studies.10,11 MIDAS is scored as the number of days of missed activity and scores 
are categorised as Grade I (score 0–5; minimal or infrequent disability), Grade II (score 6–10; 
mild or infrequent disability), Grade III (score 11–20; moderate disability), or Grade IV (score 
over 20; severe disability).9 
 
Patients and methods 
 
All patients aged 18–65 years attending the primary care Merrow Park Surgery in Surrey, UK 
for any reason were interviewed. Those who reported headache in the previous 3 months 
were eligible for inclusion in the audit. Patients were assessed by a primary care nurse with 
experience in headache (RS) and completed a MIDAS Questionnaire and a questionnaire 
investigating headache features and physician consultations (Table 1).  
 
Table 1. Nurse-administered questionnaire investigating patients’ headache features and 
physician consultations. 
 
1. In the last 3 months how many times have you consulted your GP?  
2. How many of these consultations were specifically about headaches?  
3. Do you think your headaches affect your mood?  
4. Do you think your headaches make you tired or lethargic?  
5. Do you feel an improvement in your headaches compared with 3 months ago?  
6. Do you feel that overall you need to see your GP less now? 
 
 
The design of the audit is illustrated in Figure 1.  
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Figure 1. Design of the audit: management decisions during the study. 
IHS = International Headache Society. 
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All patients were given oral and written advice on headache management by the nurse, 
covering trigger factors, use of acute medications, treatment targets, prevention of frequent 
attacks and consulting with a physician if chronic daily headache was suspected. Patients 
were referred to the UK patient support group, The Migraine Action Association, for further 
information. Patients with MIDAS Grades I–II (minimal or mild disability), with infrequent and 
low intensity attacks, received no further specific headache management advice. However, 
patients with MIDAS Grades III–IV (moderate-severe disabling headache), plus those with 
MIDAS Grades I–II and either frequent or severe intensity attacks, were offered an 
appointment with a headache specialist physician (AJD), for diagnosis and appropriate 
interventions. Patients were further reviewed by the nurse after 90 and 180 days, when they 
again completed the MIDAS questionnaire and the questionnaire investigating headache 
features and physician consultations (Table 1). 
 
Endpoints from the audit included: 
• The total MIDAS score (days lost from daily activities over the previous 3-month 
period). 
• MIDAS Question A score (headache frequency over the previous 3-month period). 
• MIDAS Question B score (average headache severity over the previous 3-month 
period, using a 10-point scale where 0 = no pain and 10 = pain as bad as it can be). 
• Patients’ headache features and physician consultation (from the questionnaire in 
Table 1).  
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Summary statistics were calculated as changes from baseline at 90 and 180 days for each 
item and were analysed by t-tests for dependent samples. The definition of significance was 
set at p ≤ 0.05. Additional non-parametric analyses, using Wilcoxon rank tests, were also 
conducted on these data. This was required, as MIDAS data are not necessarily normally 
distributed due to floor effects (patients can score 0 on the questionnaire).12 
 
Results 
Baseline characteristics 
A total of 676 patients were interviewed by the nurse, of whom 477 did not report headaches, 
195 (28.8%) had headaches and took part in the audit, and four declined to participate. At 
baseline, 136 patients (69.7%) were MIDAS Grade I/II with low headache severity and 
frequency and 59 (30.3%) were Grade I/II with high headache severity and frequency or 
Grade III/IV. These 59 patients were offered an appointment with the headache specialist, 
but only 17 actually had the consultation. One hundred and ninety four patients had a 
recorded MIDAS score at baseline, and this number decreased to 87 and 70 patients at 90 
and 180 days, respectively. 
 
Changes in outcome scores at 90 and 180 days 
Figures 2–5 illustrate the changes from baseline in the audit endpoints after 90 and 180 
days. The MIDAS items all cover the 3-month period immediately preceding completion of 
the questionnaire. Compared with baseline, patients reported significant mean reductions in 
total MIDAS score at 180 days (5.9 versus 9.6 days; p = 0.014, Figure 2). Compared with 
baseline, patients reported significant mean reductions in headache frequency (MIDAS 
Question A score) at 180 days (7.0 versus 12.6 headaches; p = 0.009, Figure 3). Compared 
with baseline, patients reported significant mean reductions in headache severity (MIDAS 
Question B score) at 180 days (5.0 versus 6.0; p = 0.003, Figure 4). Similar results were 
reported when the data were analysed non-parametrically. 
 
Compared with baseline, patients reported no significant changes at 90 and 180 days in the 
total number of times they consulted a GP, but did report significant mean reductions in the 
number of consultations for headache in the previous 3-month period at 180 days (0.05 
versus 0.30 consultations; p = 0.05, Figure 5). Similar results were reported when the data 
were analysed non-parametrically. 
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Figure 2. Total MIDAS scores (total activity days lost due to headache in the previous 3 
months) at baseline (n = 194), and 90 (n = 87) and 180 (n = 70) days. Results are presented 
as means, ± SE (boxes) and ± 1.96 SE (bars). 
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Figure 3. MIDAS Question A scores (number of days with headache in the previous 3-month 
period) at baseline (n = 192) and at 90 (n = 86) and 180 (n = 68) days. Results are presented 
as means, ± SE (boxes) and ± 1.96 SE (bars). 
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Figure 4. MIDAS Question B scores (average headache severity in the previous 3 months, 
where 0 = no pain at all, and 10 = pain as bad as it can be) at baseline (n = 194) and at 90 (n 
= 87) and 180 (n = 68) days. Results are presented as means, ± SE (boxes) and ± 1.96 SE 
(bars). 
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Figure 5. Average number of consultations for headache per patient in the previous 3-month 
period: data for baseline (n = 194), and 90 (n = 85) and 180 (n = 70) days. Results are 
presented as means, ± SE (boxes) and ± 1.96 SE (bars). 
 
 
 
 
 
Throughout the study, approximately 90% of patients self-reported that headaches affected 
mood and resulted in feelings of tiredness or lethargy. However, patients reported some 
improvement in headaches and the need to see their GP at 90 and 180 days compared with 
baseline (Table 2). However, no significant changes were reported in any of these items 
during the study (Table 2). 
 
  
 135 
Table 2. Patient perceptions of headaches at baseline, and 90 and 180 days: percentage of 
patients reporting ‘Yes’ to the questions. 
 
Percentage of patients 
Question Day 0 Day 90 Day 180 
Do you think your headaches affect your mood? 91.2 87.8 
(NS) 
90.0 
(NS) 
Do you think your headaches make you tired or 
lethargic? 
 
90.2 87.1 
(NS) 
93.1 
(NS) 
Do you feel an improvement in your headaches 
compared with 3 months ago? 
 
38.2 38.3 
(NS) 
45.6 
(NS) 
Do you feel that overall you need to see your GP 
less now? 
 
NA 48.5 62.5 
(NS) 
NA = Not applicable 
NS = not significant 
 
Discussion 
 
Results from this audit illustrate the positive role that the practice nurse can have in the 
management of headache in primary care. Recent UK guidelines provide clear roles for 
nurses in the screening and follow-up of migraine patients.5,13 Recommendations state that 
nurses should undertake information dissemination and recording of data using headache 
history and impact questionnaires and headache diaries. Previous, small studies have 
indicated that the provision of information by nurses can have a positive effect on headache, 
even when no other interventions are provided.6,7  
 
Patients who took part in the audit were markedly affected by headaches, with approximately 
90% reporting that headaches affected mood and caused tiredness. The baseline mean 
MIDAS score was 9.6, indicating mild to moderate headache-related disability. On average, 
patients experienced about 4 headaches per month. These patients had significantly 
improved headache outcomes at 180 days compared with baseline, in terms of headache-
related disability, headache frequency and severity. Additionally, they perceived an 
improvement in headache and reported a reduced need for consulting a physician for 
headache. As very few patients consulted a physician during the audit, this improvement can 
be attributed with a reasonable degree of confidence to the advice given by the nurse on 
headache management.  
 
MIDAS has been shown to be an accurate measure of headache severity9 and to be 
sensitive to interventions, with drug treatments resulting in significant reductions in total 
MIDAS score.10,11 In this audit, the mean MIDAS score was significantly reduced after 180 
days, indicating headache improvement, which in turn correlated with the patients’ self 
reporting of headache improvement and a reduced need to consult with a GP. MIDAS 
therefore seems to be a sensitive outcome measure for headache sufferers. 
 
The audit does have certain shortcomings. As no control group was included, the reductions 
in MIDAS and other items could be due to a placebo effect. However, there was good 
evidence of significant improvements in MIDAS items and significant reductions in headache 
consultations, as parametric and non-parametric analyses exhibited the same patterns of 
results. Also, the numbers of patients were reduced due to drop outs as the visits proceeded, 
which may have caused some bias. The expected bias would result in an improvement. This 
is because, psychologically, patients are more likely to continue with an investigation if they 
are generally feeling well or better. Overall, this was an interesting exploratory study that 
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provided positive results. It paves the road for future randomised, controlled studies 
investigating the role of nurses in headache management. 
 
In conclusion, this audit indicated that advice on headache management given by a nurse 
could potentially lead to significantly improved patient outcomes. MIDAS appeared to be a 
sensitive outcome measure for reduction in disability in headache sufferers. 
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4.3 
 
Outcome measures compared: Headache Impact Test (HIT) and  
Short Pain Inventory© (SPI)* 
 
Summary 
 
The psychometric properties of the Headache Impact Test (HIT-DYNA®) were compared with 
the 17-item Short Pain Inventory (SPI©) in 75 patients presenting to primary care with 
tension-type headache, migraine or chronic daily headache. Also compared were the abilities 
of the SPI and HIT in terms of discriminating headache severity and diagnosis.  
 
The HIT score correlated 0.28 with the severity of the headaches whereas the SPI correlated 
0.76 on its Total Mood Disturbance score. The correlations of the HIT items with pain 
severity never rose above 0.26 whereas the correlations of the SPI items were all typically 
about 0.7. The SPI significantly discriminated with headache severity levels (none, mild, 
moderate, severe, extreme), with t values of 2–20. The HIT scores were far less powerful at 
discriminating severity, with t test values from 2–5. HIT scores at screening significantly 
discriminated with diagnosis, with the resolution between tension-type headache and chronic 
daily headache reaching 1/100 million. The SPI summary scores and subscales did not 
discriminate with diagnosis. These differences between HIT and SPI were confirmed by 
factor analysis. 
 
The results showed the HIT to be poorly related to the severity of the pain but very closely 
related to the diagnostic label. In contrast to this, the SPI was very closely related to severity 
but not related to diagnosis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Summarised and edited from the published article: Kilminster SG, Dowson A, Bundy M. 
The Headache Impact Test® and the Short Pain Inventory©: Outcome measures compared. 
Int J Pharm Med 2003;17:23–32. 
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Introduction 
 
Pain outcome measures for clinical trials are broadly of two types; scales that measure the 
functional impact of the specific disease entity, and scales that index the general pain 
experience. The Oswestry Back Pain Questionnaire,1 and the Headache Impact Test (HIT®)2 
typify questionnaires of the former type whereas the McGill Pain Questionnaire (MPQ)3 and 
the Short Pain Inventory (SPI©)4 represent the latter. Whatever methods used, and no matter 
how clever and complex their psychometric development, tests must be reliable and valid 
under specified conditions. The basic requirements include published internal reliability in the 
form of Cronbach alpha, split-half reliability, and test-retest reliability under specified time 
intervals. Additionally, the test should state clearly if it measures the here and now (state), 
the general (trait), or the retrospective (over the preceding weeks or months). The test should 
be able to discriminate and resolve fine detail on a scale of what it purports to measure 
(validity). The test data should show empirically whether it is a valid diagnostic or severity 
measure.  
 
The HIT is a retrospective (4-week window) tool to measure the impact headaches have on a 
person's ability to function in their everyday activities.5,6 The Dynamic Headache Impact Test 
(HIT-DYNA®) was designed to be administered via the Internet and was developed from 
questions included in four widely-used measures of headache impact (the Migraine-Specific 
Quality of Life Questionnaire [MSQ]; the Headache Disability Index [HDI]; the Headache 
Impact Questionnaire [HImQ] and the Migraine Disability Assessment Questionnaire 
[MIDAS]) using item response theory psychometric methods.7 The MSQ, HDI, HImQ and 
MIDAS are all well referenced and psychometrically robust tests.8–11 From a dynamic 
computerised HIT scoring system available on the web, in a few minutes the programme 
yields a description of the impact headaches are having on a patient’s life and their ability to 
function.12 Many of the items on the HIT are clearly retrospective, relating to the previous 4 
weeks. In general, only five questions are required to obtain a HIT score. 
  
The SPI is a prospective 17-item self-rating questionnaire dedicated to measuring any pain, 
not only headache. Patients rate each item on a five point Likert scale: not at all, a little, 
moderately, very much so and extremely.  Five subscales measuring sedation, social 
interaction, anxiety, sadness and anger have been fine-tuned by emphasising items that 
were specific to pain.  The SPI takes about one minute to complete and assesses the 
headache as it is at the time of completion. A scale of Total Mood Disturbance (TMD) can be 
summated from the SPI which measures the subtle mood changes that specifically covary 
with mild to severe pain. As the physical severity of pain worsens so generally does each of 
the emotional components.4,13,14 If a patient’s emotional score is exaggerated or flattened 
relative to the normative values, then a coping score can also be given as to how well a 
patient is coping with their pain, relative to others at the same physical level of pain.  This 
can be very useful in the individual management of patients. Testing showed the SPI to be 
psychometrically robust.4,13,14 
 
The psychometric properties of the computerised HIT (HIT-DYNA) were compared with the 
17-item SPI in patients presenting to primary care with headache. Also compared were the 
severity of the headaches and the diagnostic labels given by a specialist neurologist, with the 
ability of the SPI and HIT in terms of discriminating between diagnoses and headache 
severity.  
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Methods 
Patients 
Patients who took part in the study were attending a general practice headache clinic at 
Cranleigh Health Centre, Surrey, UK (Dr Bundy). The study was approved by the South West 
Surrey Local Research Ethics Committee. 
 
Design 
This was a within-group comparative study carried out at one general practice (Cranleigh 
Health Centre headache clinic) comparing the discriminant validity of the computerized HIT 
(HIT-DYNA) and the SPI. The questionnaires were administered by a psychologist (SGK). A 
specialist neurologist (AD) provided a diagnosis for each patient based on the International 
Headache Society (IHS) criteria pertaining at the time,15 and on his own clinical experience. 
The neurologist or his nurse supervised the Internet testing for the HIT evaluation. The SPI 
was self-completed at home at the following times:  
 
1. Practise session at the practice.     Day 0 
2. Within 1 hour after starting headache or on waking.  Day 1 
3. Just after pain is worst (peak)    Day 1 
4. 1 hour after headache has gone or on waking  Day 1 
5. 24 hours after headache started.    Day 2 
6. Evening of Day 2 about 8 pm     Day 2  
7. Days 3–7 inclusive about 8 pm    Days 3-7 
 
Explanation on how to complete the questionnaires was kept to a minimum and all spoiled 
forms were entered into the analysis on an intention-to-treat basis. This was done so as to 
reduce the administrator bias and evaluate the SPI as it would be used realistically in clinical 
screening settings.  
 
Statistical methods 
Analysis was by discriminant function analysis, simple t-tests, and test-retest Pearson 
product moment correlation coefficients. Statistical analysis was carried out on a Power 
Macintosh G4/400/200 machine with Statistica V4. All data points were double-validated 
against source forms. The analysis was carried out by a medical statistician (SGK). 
 
For the discriminant validity analysis, the SPI recorded headache severity (‘pain right now’) 
as no pain (0), mild pain (1), moderate pain (2), severe pain (3), and extreme pain (4). Thus 
pain groups were divided by pain severity as screening samples. The SPI raw scores were 
used for the summary and components. The diagnostic labels derived from the IHS 
classification were dummy-coded. Summary and derivative SPI measures were then used as 
dependent variables in simple t-tests. Discriminant function analysis is the same as simple t-
tests in this case where there is only one independent and one dependent variable.  Factor 
analyses with orthogonal and Varimax rotation of the principal components was carried out to 
examine the structure and redundancy of the two tests.  
 
Results 
Demography 
A total of 75 patients were recruited to the study, diagnosed with episodic TTH (15 patients 
[20%]), migraine (41 patients [54.7%]) and CDH (19 patients [25.3%]). The mean age of the 
patients was 44.3 (SD 9.8).  The majority (73, 97.3%) were women. At screening, extreme 
pain (4) was reported by two patients (2.6%), severe pain (3) by six (8.2%), moderate pain 
(2) by eight (10.5%), mild pain (1) by 26 (34.2%) and no pain by 33 (44.7%). Forty two 
patients returned the completed questionnaires within 6 weeks Six of these patients had TTH 
(14.3%), 23 had migraine (54.8%) and 13 had CDH (31.0%). Drop outs (n = 33) were mostly 
due to patients not experiencing a headache during the 6-week window. 
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Differentiation of pain severity by HIT and SPI 
Figure 1 shows the student t tests computed for headache severity comparisons of all 
headaches for the summary SPI TMD and HIT scores. As headache severity increased from 
none (0) to extreme (4) there was a highly significant increase in SPI TMD ranging from 4–
20. There was a relative diminishment of t for 0 v 4 compared to 0 v 1, 0 v 2 and 0 v 3. This 
is probably explained by the low number of patients with extreme pain (n = 2). Nevertheless, 
the results showed the SPI TMD score had excellent discrimination at resolving the fine 
detail differences in pain severity. The HIT scores were far less powerful at discriminating 
headache severity, with t test values from 2–5 only. 
 
Figure 1. Discriminant t-values of the SPI Total Mood Disturbance (TMD) and HIT at 
resolving the differences in pain severity (0 = no pain; 1 = mild pain; 2 = moderate pain; 3 = 
severe pain; 4 = extreme pain). 
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The best correlation of the HIT with headache severity was 0.28. The relationship was much 
stronger with all of the SPI subscales and the correlation of the TMD score was 0.76.The 
nature of these relationships is also displayed in Figures 2 and 3. Similar results to the SPI 
TMD score were observed for SPI social interaction, sedation, sadness, anger and anxiety 
sub-scores. 
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Figure 2. Dynamic HIT scores relationship to headache pain severity (0 = no pain; 1 = mild 
pain; 2 = moderate pain; 3 = severe pain; 4 = extreme pain).. 
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Figure 3. SPI Total Mood Disturbance (TMD) scores relationship to headache pain severity 
(0 = no pain; 1 = mild pain; 2 = moderate pain; 3 = severe pain; 4 = extreme pain).. 
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Differentiation of diagnosis with HIT and SPI 
There were originally four main groups diagnosed by the neurologist: chronic daily headache 
(CDH), high-frequency migraine (MIG-H), low-frequency migraine (MIG-L) and tension-type 
headache (TTH).  However this was simplified into CDH, TTH and total migraine (MIG) 
groups due to sample size limitations. 
 
The study used t tests to see if the HIT or SPI scores could reveal a statistically significant 
difference between the neurologist-validated diagnoses of CDH, TTH and migraine on the 
initial screening visit. There was significant relationship (p < 0.05) between the HIT score and 
diagnosis (Figure 4), but this was not observed with the SPI. 
 
Figure 4: HIT relationship with diagnosis (CDH = chronic daily headache; MIG = migraine; 
TTH = episodic tension-type headache).  
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Factor structure of the outcome measures and diagnosis  
The independence of the HIT and SPI were checked by Quartimax and Varimax factor 
analyses. Various analyses gave strikingly the same factor structure. The factor structure 
revealed that the major variance was accounted for by the SPI Total Pain Disturbance. All 
the SPI mood subscales also loaded highly on the first factor as did the physical severity of 
the headache, with an explained variance of 58%. The HIT score and the diagnosis (even if it 
included high or low migraine frequency) did not relate to the Total Pain Disturbance.  
 
The second smaller factor which accounted for only 22% of the variance was a diagnostic 
variable and loaded highly with the HIT.  
 
Discussion 
 
The results of this study indicate that the HIT is very good at measuring the diagnosis and is 
superior in this to the SPI. The SPI is very good at indexing the severity of the pain 
experience, while the HIT is relatively poor at this. These data show the HIT and SPI to be 
complementary in measuring headache. 
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Clinicians should be vigilant in conceptualising the difference between a diagnostic and a 
severity scale. The SPI measures the mood disturbance and social interaction associated 
with the physical severity of pain. This 17-item tool is a state-dependent test which measures 
the here and now. It does not rely upon the retrospective recollections of the past as do tests 
like the MIDAS and HIT. The SPI measures the pain now; it does not enquire as to the cause 
of the pain but into its effects. Beyond this, the SPI does not have intentions to give causal 
statements about the medical or biological derivatives of pain. 
 
The HIT is a tool to measure the impact headaches have on a person’s ability to function at 
work, at home, at school and in social situations. It only purports to measure headache as an 
outcome measure and clearly states it is not a diagnostic. As a retrospective view of the 
patient it probably does measure headache outcome, but it is a blunt measure of severity. It 
is perhaps best used before long term anti-migraine treatments are initiated and again at the 
end of an extended treatment session. However, it cannot be used for point assessments of 
efficacy. 
 
The HIT did not correlate well with headache severity nor was it as powerful as SPI at 
resolving differences in the fine gradations of headache severity. The SPI was more closely 
correlated with headache severity and each of the subscales showed excellent discrimination 
between the small changes in severity (Figure 1). The HIT does not capture emotional or 
sedation status of the patient, both of which are important aspects to the patient. The SPI is 
clearly not a diagnostic tool, but is a measure of headache severity. However, the HIT scores 
were closely associated with the headache diagnosis at screening. Various factor analyses 
were carried out to examine the factor structure and redundancy of the SPI and HIT. Two 
factors were identified 
1) Headache severity, best measured by the SPI 
2) Diagnosis, best measured by a neurologist or the HIT.  
 
The study has limitations, mostly related to the relatively small numbers of patients analysed. 
For example, in the analysis of discriminant t values (Figure 1) there was a relative 
diminishment of t for none versus extreme headache as compared to none versus mild, none 
versus moderate and none versus severe, where the relationship was approximately linear. 
This was probably explained by the low number of patients with extreme pain (n = 2). It is 
therefore probably best to consider the statistical analyses as exploratory, requiring 
confirmation in a large study with equivalent numbers of patients in each severity group. 
 
The HIT does discriminate between headache subtypes very well and, should a neurologist 
be not available at screening, this is a rather good diagnostic test. The SPI is not a diagnostic 
test but is a very discriminating outcome measure of headache severity and the 
consequential emotional impact. Accordingly, the data support using the HIT and SPI in 
different ways. As outcome measures, the HIT and SPI are very different and in some sense 
complementary. Clinical trialists should take care choosing and using their outcome 
measures appropriately. 
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4.4 
 
Development and validation of the Headache Diagnostic Screening 
Questionnaire (DSQ): a new questionnaire for the differential 
diagnosis of headache for use in primary care* 
 
Abstract 
 
This prospective, open investigation was set up to validate the 8-item Headache Diagnostic 
Screening Questionnaire (DSQ), containing questions screening for possible sinister 
symptoms, and evaluating headache impact, frequency and duration, the use of symptomatic 
medications and the presence of migraine aura symptoms. Patients completed the DSQ on 
their own and with a pharmacist’s help. The same pharmacist, a GP and a headache 
specialist conducted a differential headache diagnosis according to their usual practices. 
Diagnoses were deduced from the DSQ using an algorithm by a healthcare professional, 
who was blind to the other diagnoses. The primary endpoint was the sensitivity of the DSQ, 
measured as the proportion of correct diagnoses assessed from the patient, pharmacist and 
GP responses, compared with the gold standard of specialist diagnosis, for each headache 
subtype. Eighty seven patients (80.5% women, mean age 52.9 years) completed the study, 
all completing the questionnaire without help within a few minutes. Most patients were 
diagnosed by the specialist with migraine (with or without aura) or chronic daily headache 
(with or without medication overuse headache [MOH]). The overall sensitivity of the patient-
completed DSQ was good (59.3%) and similar to the pharmacist-completed DSQ (66.6%) 
and GP diagnosis (59.4%). The accuracy of the DSQ-derived diagnoses was greatest for 
total migraine, migraine with aura, MOH and migraine without aura. The accuracy of the 
pharmacists’ headache diagnosis was improved markedly when they used the DSQ, 
particularly with regard to diagnosing migraine with and without aura and MOH. In 
conclusion, the Headache DSQ is a brief, rapid to use and accurate diagnostic screening 
questionnaire for headache, and is especially sensitive for migraine and MOH. It can be 
recommended for screening new headache patients at and below the primary care level. 
 
 
 
 
 
 
 
 
* Edited from the published article: Dowson AJ, Turner A, Kilminster S et al. Development 
and validation of the headache Diagnostic Screening Questionnaire (DSQ): a new 
questionnaire for the differential diagnosis of headache for use in primary care. Headache 
Care 2005;2:111–18. 
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Introduction 
 
Despite the many recent advances in drug therapy, management of migraine remains 
suboptimal in primary care. Patients frequently do not consult with a physician for treatment, 
and physicians in turn often fail to make a correct diagnosis and prescribe appropriate 
treatments.1,2 The result is that sufferers end up receiving little medical care, relying on over-
the-counter medications, which are often ineffective.3 This situation has not improved 
markedly over the past decade or so.2,4 
 
Improving the differential diagnosis of headache is one potential way of improving headache 
management. The International Headache Society (IHS) publishes criteria for headache 
diagnosis that are comprehensive, but too lengthy for everyday clinical use.5 Recently, brief 
screening questionnaires for migraine have been developed, which are accurate and rapid 
and easy to use, but are specific for migraine only.6,7 What is needed in primary care is a 
brief, easy to use questionnaire which screens for the constellation of headache subtypes. 
The diagnosis can then be confirmed if necessary by additional questioning. 
 
The UK Migraine in Primary Care Advisors (MIPCA) primary care group have developed 
evidence-based guidelines for migraine and chronic headache management in primary 
care.8,9 As part of these initiatives, a 4-item diagnostic questionnaire was developed to 
screen patients for the common headache subtypes of migraine with and without aura, 
episodic tension-type headache (TTH), chronic daily headache (CDH) and medication 
overuse headache (MOH), while features of potential secondary (sinister) headaches and 
cluster headache are elicited by additional questioning. Figure 1 shows the questionnaire 
and the diagnostic algorithm derived from it. The questions are all based on the IHS 
classification criteria5 and other evidence sources: 
1. Episodic TTH typically has low impact on patients’ daily activities, while migraine and 
CDH have high impact. Studies have indicated that any high-impact, episodic 
headache can be given a default diagnosis of migraine.10 
2. Chronic headaches are defined as those occurring on > 15 days per month, while 
episodic headaches occur on ≤ 15 days per month.5 Chronic headaches of duration > 4 
hours are generally classified as CDH, while shorter-duration headaches may be 
classified in several subtypes (including cluster headache), depending on their duration 
and presenting symptoms.5 CDH is defined arbitrarily as any headache of duration > 4 
hours that occurs on > 15 days per month. In the new IHS classification, these 
headaches equate to chronic migraine, chronic TTH, hemicrania continua and new 
persistent daily headache.5 In practice, patients are often seen with symptoms of mixed 
chronic migraine and chronic TTH. 
3. CDH can be categorised as MOH if it is associated with the overuse of symptomatic 
medications (e.g. analgesics, ergots or triptans) on ≥ 10 days per month.5 
4. Attacks of migraine with aura are associated with reversible sensory symptoms (mostly 
visual) which occur immediately before the headache starts.5 
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Figure 1. The MIPCA diagnostic screening questionnaire for headache and its associated 
diagnostic algorithm.8 
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In an initiative to improve headache diagnosis, MIPCA and the Migraine Action Association 
(MAA: the UK patient support group) have jointly developed a checklist designed for use by 
people with headaches that aims to help the GP diagnose and manage the presenting 
headache subtype. This checklist has been modified slightly for use by pharmacists to help 
them with the diagnosis and processing of patients with headache. However, the first eight 
questions for the patient and pharmacist questionnaires are identical and act as a diagnostic 
screen. The questions are closely based on the MIPCA 4-item questionnaire. This diagnostic 
screen needs to be validated before it can be recommended for use in everyday clinical 
practice. The objective of the current investigation was to validate the 8-item Headache 
Diagnostic Screening Questionnaire (DSQ), comparing data from completions of the 
questionnaire by patients and pharmacists with a conventional GP diagnosis and the gold 
standard of diagnosis by a headache specialist. 
 
Patients and methods 
Patient population 
The aim was to enrol 100 patients with migraine, episodic TTH, CDH (with or without MOH) 
and cluster headache. Patients living local to the Surrey area were recruited from the MAA 
database and from those attending Dr Dowson’s own specialist clinic patients. Patients were 
men or women who had at least a 1-year history of headache. Patients were excluded if they 
had a history of significant psychiatric or any other major illness, or a history of abuse of 
alcohol or other recreational drugs. All patients provided their written consent before 
participating in the investigation, by signing an informed consent form.  
  
Design of the investigation 
This was an open, prospective, single-visit investigation, conducted in a single centre in the 
UK. The investigational design is shown in Figure 2.  
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Figure 2. Design of the investigation. 
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Patients completed the DSQ twice, once on their own and once in conjunction with a 
pharmacist. Patients also underwent a differential diagnosis procedure with the pharmacist 
and a GP. Alternate patients saw the pharmacist first then the GP, or the GP first and then 
the pharmacist, in a non-randomised sequential fashion. Finally, a confirmatory diagnostic 
procedure with a headache specialist was conducted. Table I shows the 8-item Headache 
DSQ, and the algorithm used to define the diagnosis that is deduced from it. 
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Table 1. The MIPCA/MAA 8-item headache diagnostic screening questionnaire (DSQ). 
 
1. Are all the headaches usually similar in their symptoms, frequency and duration?   
Yes / No 
2. Have you had headaches for longer than 6 months? 
Yes / No 
3. Are you aged between 5 and 50 years? 
Yes / No 
 
4. Does the headache interfere to a noticeable extent with your normal daily life (work, 
education and social activities)?  
Yes / No 
5. On average, how many days with headache do you have per month? 
Less than 1 / 1 / 1–4 / 5–15 / 15–30 / Every day 
6. On average, how long do your headaches last? 
Less than 15 minutes / 15 minutes to 1 hour / 1–2 hours / 2–4 hours / 
over 4 hours / My headaches are always there 
7. On average, on how many days per week do you take analgesic medications? 
Less than 1 / 1 / Up to 2 / 2 or more / Every day 
8. Do changes in your senses (sight, taste, smell or touch) occur before the headache 
starts? 
Yes / No 
 
 
NB. If the patient answers No to any of Questions 1, 2, or 3, they may possibly have sinister headache. 
They should be advised to seek immediate medical advice from their GP. 
If the patient answers Yes to questions 1, 2 and 3, they should complete the remainder of the 
questionnaire. 
 
Diagnostic algorithm 
 
• A ‘no’ answer to Questions 1, 2 or 3 indicates the possibility of secondary (or sinister) 
headaches. These patients should be investigated further and do not complete the 
remaining questions. 
 
For patients who answer ‘yes’ to Questions 1–3: 
• Question 4: 
o ‘No’ = episodic tension-type headache 
o ‘Yes’ = migraine or chronic headache 
• Question 5: 
o <1; 1; 1–4 and 5–15 days = migraine 
o 15–30 days and every day = chronic headache 
• Question 6: For patients with chronic headaches only: 
o <15 minutes = investigate further 
o 15 minutes to 1 hour = possible cluster headache 
o 1–2 and 2–4 hours = investigate further 
o Over 4 hours and my headaches are always there = chronic daily headache 
(CDH) 
• Question 7: For patients with CDH only: 
o <1; 1; up to 2 = CDH without medication overuse 
o 2 or more and every day = CDH with medication overuse (MOH) 
• Question 8: For patients with migraine only: 
o Yes = migraine with aura 
o No = migraine without aura. 
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At baseline, patients completed an informed consent form and a demography questionnaire 
(age, gender and race). They then completed the DSQ, without help or any divulging of the 
purpose of the questionnaire (patient-completed DSQ). Each patient was then assigned in a 
1:1 ratio to see a pharmacist or GP. Consecutive patients were assigned to see the 
pharmacist or GP first, before seeing the other healthcare professional. The pharmacist 
conducted a diagnostic assessment of the patient, without using the DSQ (pharmacist 
diagnosis). They then completed the DSQ with the patient, with additional questioning and 
advice where necessary (pharmacist-completed DSQ). The GP conducted a standard 
differential headache diagnostic procedure with the patient (GP diagnosis), and were 
provided with summaries of the IHS criteria for the diagnosis of migraine, episodic TTH, 
CDH, MOH and cluster headache. Finally, the patient consulted with a headache specialist 
(specialist diagnosis), who conducted a confirmatory diagnostic procedure (the gold standard 
diagnosis). The patients remained blind throughout the investigation to the purpose of these 
assessments, and the evaluators were all blinded to the results of each others’ assessments. 
 
Endpoints 
All DSQs and pharmacist, GP and specialist diagnoses were collected. The returned DSQs 
were assessed by a trained healthcare professional, who was blind to the pharmacist and 
physician diagnoses and provided diagnoses according to the DSQ algorithm (Table 1). The 
primary endpoint was the sensitivity of the DSQ, measured as the proportion of correct 
diagnoses assessed from the patient, pharmacist and GP responses, compared with the gold 
standard of specialist diagnosis, for each headache subtype. Sensitivity is defined as the 
proportion of those patients with the illness correctly identified as positive by the test. 
Specificity was not assessed in the investigation. 
 
Statistical analyses 
Introduction 
This investigation was designed to assess the accuracy (validity) of the 8-item DSQ when 
used by the patient alone, or by the patient in consultation with a pharmacist. Diagnostic data 
derived from the completions of the checklist were cross-tabulated with those from diagnoses 
deduced by the pharmacist, GP and headache specialist. All data were 100% triple validated 
against source documents. The analyses were conducted using the Statistica V4 (Tulsa 
USA) statistical package. 
 
Analyses 
Baseline demographic assessments were analysed as descriptive statistics only. The 
deduction of DSQ-based diagnoses was conducted by a trained professional using the 
diagnostic algorithm (Table 2). These diagnoses were formally validated against the gold 
standard diagnosis. The accuracy of diagnoses derived from the DSQ was analysed by 
cross-tabulating diagnostic labels on the following data sets:  
• Patient-completed DSQ versus pharmacist diagnosis 
• Patient-completed DSQ versus pharmacist-completed DSQ 
• Patient-completed DSQ versus GP diagnosis 
• Patient-completed DSQ versus specialist diagnosis 
• Pharmacist diagnosis versus GP diagnosis 
• Pharmacist diagnosis versus specialist diagnosis. 
• Pharmacist-completed DSQ versus pharmacist diagnosis 
• Pharmacist-completed DSQ versus GP diagnosis 
• Pharmacist-completed DSQ versus specialist diagnosis 
• GP diagnosis versus specialist diagnosis. 
 
The different diagnostic sensitivities were compared using the Wilcoxon matched-pairs test, 
as ‘Z’ scores and ‘T’ statistics, with the level of significance set at p < 0.05.  
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The study statistician (SK) calculated that a sample size of 100 patients (assuming 25 per 
diagnostic group [migraine, episodic TTH, CDH and cluster headache]) was appropriate to 
assess sensitivity, as it is similar to the numbers used in other studies of this design.   
 
Results 
Patient characteristics 
Eighty seven patients took part in the investigation, 44 who saw the pharmacist first and 43 
who saw the GP first. All patients completed the five diagnostic procedures. Most patients 
were women (n = 70, 80.5%), all were Caucasian in racial origin and the mean age was 52.9 
years (range 23–77 years). The vast majority of the patients were diagnosed by the specialist 
with migraine (with and without aura; n = 48, 55.2%) or CDH (with and without MOH; n = 32, 
36.8%). Only four patients were diagnosed with cluster headache and one with TTH. All 
patients completed the DSQ without help within a few minutes. 
 
Sensitivity analysis 
Sample sizes were adequate for the patients with migraine (n = 48) and total CDH (n = 32), 
but were very small for those with episodic TTH (n = 1) and cluster headache (n = 4). The 
sensitivity analyses are shown in Table 2. Overall, the pharmacist diagnoses had the poorest 
sensitivities across all diagnostic groups (29.3% sensitivity). However, the pharmacist-
completed DSQ sensitivity was markedly higher, at 66.6%, and similar to that of the patient-
completed DSQ (59.3%) and GP diagnoses (59.4%). The diagnostic sensitivity for ‘total 
migraine’ was high in all groups (83.3%–93.8%) and similar, although lower, for ‘total CDH’ 
(43.8–50.0%). The sensitivity for diagnosing migraine with aura, migraine without aura and 
MOH was substantially higher in the DSQ groups (patient-completed and pharmacist-
completed) than in the pharmacist and GP diagnosis groups. There were too few patients in 
the episodic TTH and cluster headache categories for analysis. 
 
Table 2. Sensitivity of each diagnostic assignment analysed from the patient-completed 
DSQ, pharmacist-completed DSQ, pharmacist diagnosis and GP diagnosis for episodic TTH, 
CDH, MOH, migraine and cluster headache compared with the gold standard specialist 
assignment. 
 
        Sensitivity 
Number of patients (%) 
Diagnosis Number 
of 
patients 
Patient-
completed 
DSQ 
Pharmacist-
completed 
DSQ 
Pharmacist 
diagnosis 
GP 
diagnosis 
TTH 1 1 (100.0) 1 (100.0) 0 (0) 1 (100.0) 
CDH 17 2 (11.8) 2 (11.8) 4 (23.5) 5 (29.4) 
Migraine 
with aura 
11 9 (81.8) 10 (90.9) 1 (9.1) 7 (63.6) 
Migraine 
without aura 
32 19 (59.4) 21 (65.6) 0 (0) 16 (50.0) 
MOH 15 9 (60.0) 11 (73.3) 0 (0) 2 (13.3) 
Total CDH 
(CDH + 
MOH) 
32 15 (46.9) 16 (50.0) 14 (43.8) 16 (50.0) 
Total 
migraine* 
48 43 (89.6) 44 (91.7) 40 (83.3) 45 (93.8) 
Cluster 
headache 
4 1 (25.0) 2 (50.0) 3 (75.0) 3 (75.0) 
Mean  59.3 66.6 29.3 59.4 
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* The ‘migraine with aura’ and migraine without aura’ groups do not add up to the ‘total 
migraine’ group because a group labelled ‘migraine’ was only identified by the specialist, GP 
and pharmacist diagnoses, and was included in the overall ‘total migraine’ group. 
 
Analysis of the Wilcoxon matched-pairs tests of the different diagnostic groups is shown in 
Table 3. The data was organised so as to match pairs of diagnostic groups, validated with 
the specialist diagnosis. The diagnosis from the patient-completed DSQ was significantly 
less accurate than that from the pharmacist-completed DSQ (p = 0.03). However, there were 
no significant differences between the patient-completed DSQ and the pharmacist and GP 
diagnoses. Both were equally good by reference to the gold standard (specialist). The only 
variation to this was that CDH was diagnosed less accurately on the pharmacist-completed 
DSQ.  
 
Table 3. Analysis of the Wilcoxon matched-pair tests for accuracy from the patient-completed 
DSQ, pharmacist-completed DSQ, and pharmacist, GP and specialist diagnoses. 
 
Wilcoxon comparison Wilcoxon 
T statistic
Wilcoxon  
Z score 
p-value 
Patient-completed DSQ versus 
pharmacist diagnosis 
7.00 1.54 0.12 
Patient-completed DSQ versus 
pharmacist-completed DSQ 
0.00 2.20 0.03 
Patient-completed DSQ versus GP 
diagnosis 
12.50 0.25 0.80 
Pharmacist-completed DSQ versus 
pharmacist diagnosis 
5.00 1.82 0.07 
Pharmacist-completed DSQ versus GP 
diagnosis 
6.50 0.84 0.40 
GP diagnosis versus pharmacist 
diagnosis 
0.00 2.37 0.02 
Specialist diagnosis versus patient-
completed DSQ 
0.00 2.37 0.02 
Specialist diagnosis versus pharmacist-
completed DSQ 
0.00 2.37 0.02 
Specialist diagnosis versus pharmacist 
diagnosis 
0.00 2.52 0.01 
Specialist diagnosis versus GP diagnosis 0.00 2.20 0.03 
 
There was a trend for the pharmacist-completed DSQ to be more accurate than the 
pharmacist diagnosis, although the difference did not reach statistical significance  
(p = 0.07). The pharmacist-completed DSQ was of similar accuracy to that of the GP 
diagnosis. The GP diagnosis was significantly more accurate than the pharmacist diagnosis 
(p = 0.02). The patient-and pharmacist-completed DSQ (p = 0.02 for both analyses), the 
pharmacist diagnosis (p = 0.01) and the GP diagnosis (p = 0.03) were all significantly less 
accurate than the specialist diagnosis (the gold standard used in this study).  
 
Discussion 
 
The 8-item DSQ was designed to be a diagnostic aid for headache to be used at the patient’s 
first consultation with a healthcare professional, who may be a GP, nurse, pharmacist or 
other practitioner (e.g. opticians and dentists often see people with headache). Its principal 
use is proposed to be an aid to deciding the appropriate first management decisions. The 
questionnaire was designed to be brief and simple to use, so that patients could complete it 
on their own. Although the design of the DSQ was based on sound theoretical criteria,5 it had 
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to be demonstrated to be accurate in terms of diagnostic sensitivity before being 
recommended for general use. 
 
The patients who took part in the investigation were mostly women, and were somewhat 
older than those recruited in most migraine studies.11 This may be due to the high proportion 
of CDH sufferers recruited, whose age distribution tends not to be skewed as is the typical 
young to middle-aged migraine sufferer.12,13 Both migraine and CDH are more prevalent in 
women than in men.12,13 All the patients completed the initial patient-completed DSQ with  
little difficulty within a few minutes, and all questions were answered. This demonstrates the 
general ease of use of the questionnaire. 
 
Overall, both the patient- and pharmacist-completed DSQs exhibited good sensitivity, of 
around 60% for both measures, values very similar to that of the GP diagnosis. The best 
sensitivity was demonstrated for total migraine (about 90%), migraine with aura (about 80–
90%), MOH (about 60–75%) and migraine without aura (about 60–65%). The sensitivity for 
total CDH (CDH with and without MOH) was somewhat lower at about 50%, driven by a poor 
sensitivity for CDH without MOH (about 12%). Results for episodic TTH and cluster 
headache could not be interpreted due to the small number of patients with these conditions. 
These results indicate that the DSQ is an effective tool for the differential diagnosis of 
headache. Interestingly, the accuracy of the pharmacists’ headache diagnosis was improved 
markedly when they used the DSQ, particularly with regard to diagnosing migraine with and 
without aura and MOH. It would be interesting to see if GPs’ diagnostic accuracy could 
improve to the specialist level if they had access to the DSQ. 
 
As would be expected, all groups were significantly less accurate in diagnosis than the 
headache specialist diagnoses. However, when pharmacists had access to the DSQ, their 
diagnostic accuracy was significantly greater than that of patients using the DSQ and 
approached that of the GP diagnosis. These results indicate that, with this aid, pharmacists 
can diagnose headache accurately, which is of clinical importance as they may see more 
headache sufferers than do GPs.1 Use of the DSQ therefore has the potential to improve 
headache management in the pharmacy setting, from which many effective medications are 
available without a prescription. In turn, the burden of managing headache on busy GPs may 
be relieved. 
 
Some weaknesses were observed in the results. The study was not properly randomised, 
with consecutive patients being openly assigned to seeing the pharmacist or GP first. The 
study was not large enough to determine whether the order of seeing these healthcare 
professionals had any effect on the results. However, the pharmacists and GPs were blind to 
each other’s assessments. The entry criteria for numbers of patients with episodic TTH and 
cluster headache were not met by the patients recruited from the databases of the MAA and 
Dr Dowson. For this reason the specificity of the DSQ was not assessed. The lack of patients 
with TTH and cluster headache is perhaps not surprising bearing in mind what we know 
about these headaches. Cluster headache is an uncommon condition, affecting < 0.5% of the 
population,14 and is not seen often in general practice. Episodic TTH is very common, but 
sufferers rarely consult for the condition, preferring to self-treat with OTC medications.3 Such 
sufferers are, however, very likely to consult pharmacists. It would be useful to repeat this 
validation exercise in a specialist headache clinic (where cluster headache patients are more 
common) and in a pharmacy (where episodic TTH sufferers may be encountered frequently). 
The accuracy of the DSQ for CDH without MOH was poor, and patients tended to 
underestimate the duration and/or the frequency of their headaches. Additionally, migraine 
patients sometimes confused aura symptoms with prodromes when answering question 8. 
Based on feedback from patients who took part in the study, we suggest that the following 
small changes to the questions may help to improve the accuracy of the DSQ: 
• Question 1: Has the pattern of your headaches been generally stable (i.e. no change 
or only small changes in frequency and severity) over the past few months? 
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• Question 6: On average how long do your headaches last, if left untreated? 
• Question 8: Do changes in your senses (sight, taste, smell or touch) occur in the 
period immediately before the headache starts? 
Table 4 shows the revised DSQ, including these changes. Future testing of the DSQ for 
sensitivity and specificity should use this version of the questionnaire. 
 
 
Table 4. The revised 8-item headache diagnostic screening questionnaire (DSQ) produced 
following completion of the investigation. 
 
1. Has the pattern of your headaches been generally stable (i.e. no change or only small 
changes in frequency and severity) over the past few months? 
Yes / No 
2. Have you had headaches for longer than 6 months? 
Yes / No 
3. Are you aged between 5 and 50 years? 
Yes / No 
4. Does the headache interfere to a noticeable extent with your normal daily life (work, 
education and social activities)?  
Yes / No 
5. On average, how many days with headache do you have per month? 
Less than 1 / 1 / 1–4 / 5–15 / 15–30 / Every day 
6. On average, how long do your headaches last, if left untreated? 
Less than 15 minutes / 15 minutes to 1 hour / 1–2 hours / 2–4 hours / 
over 4 hours / My headaches are always there 
7. On average, on how many days per week do you take analgesic medications? 
Less than 1 / 1 / Up to 2 / 2 or more / Every day 
8. Do changes in your senses (sight, taste, smell or touch) occur in the period 
immediately before the headache starts? 
Yes / No 
 
 
NB. If the patient answers No to any of Questions 1, 2, or 3, they may possibly have sinister headache. 
They should be advised to seek immediate medical advice from their GP. 
If the patient answers Yes to questions 1, 2 and 3, they should complete the remainder of the 
questionnaire. 
 
The DSQ has considerable potential clinical utility in the management of headache in primary 
care. Patients should be able to obtain a copy at their first point of care, whether a GP 
surgery, pharmacist, optician, dentist or other provider. They can complete the DSQ, either at 
home by themselves or with the help of the practitioner. Both patients and pharmacists find 
the questionnaire easy to complete. The practitioner should review the DSQ and provide 
appropriate advice. Episodic TTH can usually be managed successfully by the sufferer or by 
a pharmacist.15 Patients with migraine and CDH probably need to be advised to see a GP for 
care, although the pharmacist may be able to manage those with uncomplicated, mild-to-
moderate migraine symptoms.8,9 Using the questionnaire, there is the potential for earlier and 
better headache diagnoses. Following pharmacist intervention, patients should be 
empowered to obtain help from the GP sooner rather than later. Improved migraine 
management has the potential to reduce the high economic cost of the illness to society.16 
 
It is interesting to compare the DSQ with other screening questionnaires that have been 
recently developed for headache. Migraine was diagnosed sensitively and specifically using 
three questions on headache-related disability, nausea and sensitivity to light,6 or three 
questions on disability, headache duration and the lack of new-onset headaches in the 
previous 6 months.7 Both these questionnaires restricted themselves to diagnosing migraine 
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only. Maizels and Burchette have developed the Brief Headache Screen to diagnose 
different headache subtypes.17 Migraine, daily headache syndromes and medication overuse 
could be distinguished using three questions: the frequency of disabling headache, the 
presence of other, mild headaches and the use of symptomatic medications. There is 
considerable overlap between the DSQ and these other questionnaires in terms of assessing 
disability, headache frequency and duration, and the use of headache medications, which 
reinforces the validity of these assessments.  
 
In conclusion, the headache DSQ is a brief, rapid to use and accurate diagnostic screening 
questionnaire for headache, and is especially sensitive for migraine and MOH. It can be 
recommended for screening new headache patients at and below the primary care level. 
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4.5 
 
Identifying patients who require a change in their current acute 
migraine treatment: the Migraine Assessment of Current Therapy 
(Migraine-ACT) questionnaire* 
 
Abstract 
Background: Currently available measures of the efficacy of acute migraine medications are not 
frequently used in primary care. They may be too burdensome and complicated for routine use. 
Objectives: To design and test a new, easy to use, 4-item assessment tool, the Migraine Assessment 
of Current Therapy (Migraine-ACT) questionnaire for use by clinicians, to quickly evaluate how a 
recently prescribed acute medication is working, and to identify patients who require a change of their 
current acute treatment.  
Methods: A 27-item Migraine-ACT questionnaire was developed by an international advisory board of 
headache specialists. Questions were formulated in four domains: headache impact, global 
assessment of relief, consistency of response and emotional response. All these are clinically 
important measures of migraine severity and treatment outcome. All questions were dichotomous and 
answered by yes or no. Patients (n = 185) attending secondary care headache clinics who were 
diagnosed with migraine according to International Headache Society criteria entered a multinational, 
prospective, observational study to investigate the test-retest reliability and construct validity of the 27-
item Migraine-ACT. Patients completed the Migraine-ACT on two occasions, separated by a 1-week 
interval, and test-retest reliability was assessed by Pearson product moment and Spearman rank 
measures. Construct validity was assessed by correlating patients’ answers to the 27-item Migraine-
ACT with those to other questionnaires (individual domains and total scores) conceptually related to it; 
the Short-Form 36 quality of life questionnaire (SF-36), the Migraine Disability Assessment (MIDAS) 
questionnaire and the Migraine Therapy Assessment Questionnaire (MTAQ). Discriminatory t-tests 
were used to identify the four Migraine-ACT questions (one in each domain) which discriminated best 
between the domains of the SF-36, MIDAS, and MTAQ.  These four items constituted the final 4-item 
Migraine-ACT. 
Results: The test-retest reliability of the 27 Migraine-ACT questions ranged from good to excellent, 
and correlation coefficients were highly significant for all items. The consistency of reporting the yes 
and no answers was also excellent. Correlations of Migraine-ACT items with SF-36 and MIDAS items 
and SF-36, MIDAS and MTAQ total scores indicated that the following were the most discriminating 
items, in the respective four domains, and constitute the final Migraine-ACT questionnaire: 
• Consistency of response - Does your migraine medication work consistently, in the 
majority of your attacks? 
• Global assessment of relief - Does the headache pain disappear within 2 hours? 
• Impact - Are you able to function normally within 2 hours? 
• Emotional response - Are you comfortable enough with your medication to be able to 
plan your daily activities 
The 4-item Migraine-ACT was shown to be highly reliable (Spearman / Pearson measure r = 0.82). 
The individual questions, and the total 4-item Migraine-ACT score, showed good correlation with items 
of the SF-36, MIDAS and MTAQ questionnaires, particularly with the total MTAQ and SF-36 scores.  
Conclusions: The 4-item Migraine-ACT questionnaire is an assessment tool for use by primary care 
physicians to identify patients who require a change in their current acute migraine treatment. It is brief 
and simple to complete and score, and has demonstrated reliability, accuracy and simplicity. Migraine-
ACT can therefore be recommended for everyday clinical use by clinicians. 
 
 
* Edited from the published article: Dowson AJ, Tepper SJ, Baos V, Baudet F, D’Amico D, 
Kilminster S. Identifying patients who require a change in their current acute migraine 
treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr 
Med Res Opin 2004;20:1125–35. 
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Introduction 
The Migraine Assessment of Current Therapy (Migraine-ACT) is designed to be a brief 
assessment tool used in initial assessments and follow-up to help the clinician determine 
quickly and easily whether a change in the acute therapy of their migraine patients is 
required. The 27-item version was developed by an advisory board of headache specialists 
from the UK, Germany, Italy, Spain and the USA. This paper describes an international study 
designed to assess the test-retest reliability and construct validity of the items constituting the 
27-item Migraine-ACT, and use these data to select the four items that will constitute the final 
questionnaire.  
  
Several recent initiatives have resulted in the development of novel questionnaires that can 
be used to assess the efficacy of migraine therapies: 
• Impact tools, e.g. the Migraine Disability Assessment (MIDAS) Questionnaire1 and 
the Headache Impact Test (HIT).2 
• Quality of Life (QOL) questionnaires, which can be generic or migraine-specific.3 
• Disease management tools, e.g. the Migraine Therapy Assessment Questionnaire 
(MTAQ).4 
 
All these questionnaires have been shown to be reliable and valid tools in populations of 
headache sufferers, and all have potential in assessing the outcome from interventions.4–6 
However, experience from clinical practice has demonstrated some problems with the 
questionnaires that have that limited their uptake there: 
• Patients often find them too complicated to use without supervision. 
• Physicians are frequently unaware of the questionnaires, and find them too long and 
unwieldy for everyday use.  
• Both MIDAS ands HIT-6 are brief questionnaires,1,2 but both patients and physicians 
require education for their use, which is generally not available.  
• When asked, many physicians state that they prefer to ask a single question on 
impact, rather than a series of questions. 
 
There is a clear need for a brief, simple, patient-friendly, re-evaluation tool to be used in 
triage and as a good means of evaluating the efficacy of medications used for the 
management of migraine in primary care. Such simple screening tools have proved valuable 
in other therapy areas. The CAGE alcohol dependence questionnaire contains only four 
yes/no type questions, with two ‘yes’ responses constituting a positive screening test result.7 
A three-question yes/no type questionnaire was developed for asthma to provide the patient 
and physician with a rapid assessment of outcome, and as a trigger for intervention.8 We set 
out to develop a similar questionnaire  for migraine, the Migraine Assessment of Current 
Therapy (Migraine-ACT). As originally developed by an international advisory board (AJD, 
SJT and VB), Migraine-ACT consisted of 27 questions (Table 1) in four domains selected 
from a much larger question pool on the basis of consensus and the group’s extensive 
clinical experience to be of significant importance on the basis of clinical evidence: impact;9,10 
global assessment of relief;11,12 consistency of response;12,13 and emotional response.14 
Questions are answered by the patient as yes or no. The aim is to produce a 4-item test, with 
one question in each of the four domains above.  
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Table 1. The initial 27-item Migraine Assessment of Current Therapy (Migraine-ACT) 
questionnaire.  
 
Each question starts with the text ‘When you take your treatment’ 
Impact 
Question Code Yes No 
When you take your treatment: 
Is the impact of the headache significantly relieved within 2 hours?  
 
IMP 1 
  
Is the disability caused by the headache significantly relieved within 2 hours? IMP 2   
Are you able to resume your normal activity (i.e. work or family-leisure-social 
activity, etc.) within 2 hours? 
IMP 3   
Are you able to function normally within 2 hours? IMP 4   
Do you usually not need to lie down after 2 hours? IMP 5   
Can you get back to what you were doing within 2 hours? IMP 6   
Are you able to experience normal enjoyment of your daily life within 2 hours? IMP 7   
Are you able to cope normally with everyday life within 2 hours? IMP 8   
Are you able to concentrate normally within 2 hours? IMP 9   
Do you feel that your sense of emotional well-being returns to normal within 2 
hours? 
IMP 10   
Have any feelings of tiredness, irritability, sadness, anger and anxiety 
disappeared within 2 hours? 
IMP 11   
 
Global assessment of relief 
Question Code Yes No 
When you take your treatment: 
Does the headache pain disappear within 2 hours?  
 
GAR 1 
  
Is the headache pain relieved after 2 hours? GAR 2   
Does the headache pain disappear within 2 hours and not return within 24 
hours? 
GAR 3   
Does the headache pain disappear within 2 hours and not return within 48 
hours? 
GAR 4   
Does the headache pain start to disappear within 30 minutes? GAR 5   
Do your non-headache symptoms (e.g. nausea and sensitivity to light, sound or 
smells) disappear within 2 hours? 
GAR 6   
Are your non-headache symptoms (e.g. nausea and sensitivity to light, sound 
or smells) relieved within 2 hours? 
GAR 7   
Are you clear of all your symptoms within 2 hours? GAR 8   
Does your migraine headache pain stop within 2 hours? GAR 9   
 
Consistency of response 
Question Code Yes No 
When you take your treatment: 
Does your migraine medication work attack after attack?  
CONS 1   
Does your migraine medication work reliably in the majority of your attacks? CONS 2   
Does your migraine medication work consistently, in the majority of your 
attacks? 
CONS 3   
 
Emotional response 
Question Code Yes No 
When you take your treatment: 
Does your migraine medication work consistently enough that you can plan 
your future activities? 
EMOT 1   
Are you confident that the migraine medication you are taking will treat the next 
attack effectively? 
EMOT 2   
Are you comfortable enough with your medication to be able to plan your daily 
activities? 
EMOT 3   
Do you feel in control of your migraine enough so that you feel there will be no 
disruption to your daily activities? 
EMOT 4   
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Patients and Methods 
Patients 
Patients at five secondary care headache centres, in the UK, Spain, Germany, Italy and the 
USA, took part in the study. All patients were attending the centres for migraine treatment. 
Each centre enrolled 40 patients with migraine diagnosed according to the International 
Headache Society (IHS) criteria.15,16 Eligible patients were men or women aged between 18–
65 years, with at least a 1-year history of migraine, experiencing on average 1–4 attacks per 
month, and a minimum of 24 hours between each attack. Patients were able to distinguish 
migraine attacks from other types of headache. Patients were excluded from the study if they 
had a history of significant psychiatric illness, or any other illness that could affect the 
interpretation of the results, e.g. major depression or anxiety disorder, or had a history of 
abuse of alcohol, or other recreational drugs.  
 
Study design 
This was an open, prospective, multinational, observational, two-visit study, conducted in the 
UK, Spain, the USA, Germany and Italy, using questionnaires which were translated into the 
local languages. Patients were assessed at baseline and completed a series of outcome 
questionnaires; the 27-item Migraine-ACT, the Short Form-36 (SF-36) quality of life (QOL) 
questionnaire,3 the MIDAS Questionnaire1 and the MTAQ Questionnaire.4 The validity of the 
Migraine-ACT Questionnaire was assessed from the responses to these questionnaires. 
Additionally, we evaluated test-retest reliability, thus the same patients completed the 27-
item Migraine-ACT Questionnaire again 1 week later. 
 
Patients provided their written consent before participating in the study, by signing a consent 
form. The study was conducted in accordance with the Declaration of Helsinki, as revised by 
the most recent meetings of the World Medical Assembly. The study was conducted in the 
spirit of, and according to, the principles of Good Clinical Practice (GCP), as embodied in the 
ICH Harmonised Tripartite Guideline for GCP.  
 
Study procedures 
Migraine patients (n = 200; 40 per centre) attended the clinic, or were contacted by 
telephone, for demography baseline assessments (age, gender, race, weight and height) and 
completion of the outcome questionnaires: 27-item Migraine-ACT; SF-36 QOL questionnaire; 
MIDAS Questionnaire; and the MTAQ Questionnaire (Visit 1). All patients (n = 40 per centre) 
who completed the 27-item Migraine-ACT attended the clinic or were contacted by telephone 
1 week later to complete the Migraine-ACT Questionnaire for a second time (Visit 2). During 
this time, no changes were allowed in the patients’ migraine treatments. Any patients who 
withdrew from the study were recorded, and the reasons for withdrawal noted. Patients who 
withdrew were included in the analyses of results. 
 
Endpoints 
The primary study endpoints were test-retest reliability (a comparison of the Migraine-ACT 
data from the 27 individual questions from Visits 1 [baseline] and 2 [1 week]), and construct 
validity (a comparison of the Migraine-ACT data from the 27 individual questions with 
relevant data from the SF-36 and MIDAS (domains and total scores) and MTAQ 
questionnaires (total score only) at Visit 1 [baseline]). The construct validity data were used 
to identify the four items (one in each domain) to be contained in the final Migraine-ACT 
questionnaire. 
 
Statistical analyses 
Introduction 
This study was designed to assess the test-retest reliability and construct validity of the 27 
items constituting the original Migraine-ACT questionnaire. These data were then used to 
construct the final 4-item version of the questionnaire. Test-rest reliability was assessed by 
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comparing patients’ responses to the individual Migraine-ACT questions when completed at 
baseline (Visit 1) and 1 week later (Visit 2). Validity was assessed by comparing patients’ 
responses to the individual Migraine-ACT questions at baseline (Visit 1) with those to 
components of questionnaires related to the conception of Migraine-ACT, i.e. the SF-36, 
MIDAS and MTAQ questionnaires. All analyses were conducted with Statistica (Tulsa, USA) 
software with statistical hypotheses tested for two-tailed tests of type 1 error at 0.05. Data 
were 100% validated against source documents. 
 
Baseline analyses 
All baseline demographic assessments were analysed as descriptive statistics only (means 
and standard deviations). 
 
Test-retest reliability 
Test-retest reliability of the individual Migraine-ACT questions was assessed using Pearson’s 
product moment and Spearman rank measures. A minimum test-retest product moment of r 
= 0.30 (detected statistically at alpha2 p = 0.05) would be n = 40 per centre. A test–retest or r 
statistic of 0.75 or over represents excellent agreement, 0.40 to 0.75 represents intermediate 
to good agreement, and below 0.40 represents poor agreement.17 The whole process was 
repeated and confirmed on the summed 4-item score. 
 
Construct validity 
To assess the construct validity of the individual Migraine-ACT questions, the associations 
were determined between patients’ responses to the individual Migraine-ACT questions and 
instruments related conceptually to the Migraine-ACT questionnaire. Correlations were made 
between Migraine-ACT and the MIDAS, SF-36 and MTAQ questionnaires (criterion 
variables). Discrimination was analysed by simple t-tests of means from dichotomised 
Migraine-ACT item scores. Factor analysis was used to identify and score the key features of 
the criterion variables and the Migraine-ACT questions were correlated and discriminated 
with these factors. Separate analyses checked for centre effects (i.e. within each centre 
[country]), and for the total scores derived from all countries combined (i.e. overall analysis).   
 
Item selection 
The questions to be included in the final 4-item Migraine-ACT questionnaire were identified 
from the correlation coefficients and discrimination of all 27 questions with summary and 
derived subscale scores and factor analysed criterion scores from MIDAS, MTAQ and SF36. 
In addition, the questions all had to exhibit at least good test-retest reliability. Regression was 
used to compare the summation of the individual final four items versus weighted items. 
Summation of the best four items was made after various analyses to find the best structure 
and redundancy of terms from the MIDAS, MTAQ and SF36.  
 
Orthogonal and Oblique rotations of the principal components derived the maximum variance 
factors associated with a reduced data set. Regression-derived new composite variables 
were constructed from the factor analyses.  
 
Results 
 
Demography and baseline characteristics 
One hundred and eighty five patients took part in the study. All patients were assessed at 
Visit 1, with 143 (77%) completing the questionnaire on both occasions. The majority of the 
patients (68%) were women. All but one of the patients was of white racial origin. The mean 
age was 44 years (range 14 to 87 years), with the vast majority (172, 93%) aged 18–65 
years. 
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Test-retest reliability 
Spearman rank order measures for all 27 Migraine-ACT items are shown in Table 2. The 
analyses were nonparametric and pairwise deleted. There were few dropouts; between 176 
and 185 of the 185 patients taking part in the study provided data at Visits 1 and 2. 
Spearman rank order measures ranged from 0.54 to 0.79 for the individual 27 Migraine-ACT 
items, indicating good-to-excellent reliability. Summated Spearman measures for the impact 
(IMP1–11), global assessment of relief (GAR1–9), consistency of response (CONS 1–3) and 
emotional response (EMOT1–4) items exhibited excellent reliability, and the total summation 
of all 27 items was extremely reliable, at r = 0.99 (Table 2). 
 
Table 2. Test-retest reliability of the 27-item Migraine-ACT Questionnaire. Spearman rank 
order measures are shown below for all 27 Migraine-ACT items. Analyses were 
nonparametric and pairwise deleted. 
 
Migraine-ACT questions n  r   t (n - 2)  p-value 
IMP1     184  .68   12.67    <.0001 
IMP2     182  .61   10.23    <.0001 
IMP3     182  .77   16.25    <.0001 
IMP4     185  .72   13.96    <.0001 
IMP5     183 .54   8.61    <.0001 
IMP6     181  .79   16.96    <.0001 
IMP7     184  .73   14.31    <.0001 
IMP8     182  .70   13.10    <.0001 
IMP9     182  .74   14.76    <.0001 
IMP10     183  .62   10.66    <.0001 
IMP11     183  .62   10.64    <.0001 
GAR1     181  .58   9.44    <.0001 
GAR2     183  .63   11.04    <.0001 
GAR3     179  .61   10.18    <.0001 
GAR4     179  .58   9.44    <.0001 
GAR5     183  .60   10.15    <.0001 
GAR6     182  .60   10.15    <.0001 
GAR7     182  .62   10.56    <.0001 
GAR8     179  .58   9.53    <.0001 
GAR9     177  .72   13.68    <.0001 
CONS1    182  .68   12.43    <.0001 
CONS2    184  .70   13.15    <.0001 
CONS3    182  .61   10.30    <.0001 
EMOT1    180  .74   14.76    <.0001 
EMOT2    179  .77   16.04    <.0001 
EMOT3    178  .78   16.40    <.0001 
EMOT4    176  .62   10.56    <.0001 
Total IMPACT (IMP 1–11) 168  1.00   137.78   <.0001 
Total GAR (GAR 1–9)  164  .78   16.08    <.0001 
Total CONS (CONS 1–3) 180  .73   14.33    <.0001 
Total EMOT (EMOT 1–4) 172  .80   17.41    <.0001 
TOTAL Migraine-ACT  143  .99   75.62    <.0001 
(27 items) 
 
Analyses of consistency of response were conducted to investigate the reliability data further. 
The proportion of patients who consistently answered ‘yes’ or ‘no’ at both Visits 1 and 2 is 
shown in Table 3. The consistency of response was excellent for all 27 Migraine-ACT items. 
Similar consistency was shown in the distribution of ‘yes’ and ‘no’ answers over the two 
visits. 
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Table 3. The consistency of the ‘yes’/‘no’ responses between Visit 1 and Visit 2 for the 27 
Migraine-ACT items: proportion of patients who responded ‘yes’ or ‘no’ at Visit 1 who had the 
same responses at Visit 2. 
 
Consistency of response (% patients) 
Migraine-ACT item ‘No’ answers ‘Yes’ answers 
IMP 1 76.74 90.28 
IMP 2 75.00 84.00 
IMP 3 87.14 87.07 
IMP 4 83.15 85.86 
IMP 5 66.67 83.04 
IMP 6 77.78 93.50 
IMP 7 84.85 84.27 
IMP 8 80.49 85.58 
IMP 9 88.07 81.82 
IMP 10 80.00 78.21 
IMP 11 88.43 69.23 
GAR 1 79.75 73.83 
GAR 2 83.33 88.89 
GAR 3 90.43 62.32 
GAR 4 86.07 67.21 
GAR 5 83.58 75.47 
GAR 6 77.91 79.80 
GAR 7 71.43 88.81 
GAR 8 86.40 66.10 
GAR 9 85.06 82.11 
CONS 1 82.54 83.06 
CONS 2 78.79 93.78 
CONS 3 70.00 86.86 
EMOT 1 84.75 85.83 
EMOT 2 83.08 81.36 
EMOT 3 84.00 89.55 
EMOT 4 79.79 75.56 
 
Construct validity and item selection 
Discriminatory t-test scores between the individual 27 Migraine-ACT questions and 15 items 
contained within the SF-36, MIDAS and MTAQ questionnaires are shown at the end of the 
article in Table 4. Eleven items related to the SF-36 questionnaire (physical function, role-
physical, bodily pain, general health, vitality, social functioning, role-emotional, mental heath, 
total physical, total mental and total SF-36 scores). Three items related to the MIDAS 
questionnaire (MIDAS A score [headache frequency], MIDAS B score [headache severity] 
and total MIDAS score [time lost for everyday activities]) and one item related to the MTAQ 
score (total MTAQ score). Finally, the total score from all 15 variables was correlated with the 
four best Migraine-ACT items. A t-discrimination score of ≥ 2 indicates a significant 
correlation. 
 
Correlations of Migraine-ACT items with SF-36 and MIDAS items and SF-36, MIDAS and 
MTAQ total scores indicated that the most discriminating items in the four domains of the 
Migraine-ACT questionnaire were IMP 4, GAR 1, CONS 3 and EMOT 3. The discriminating 
factors for these four items were all highly significant. The best correlation was observed 
between the Migraine-ACT items and the MTAQ total score. These data indicate that the four 
items constituting the final Migraine-ACT questionnaire should be: 
• Impact:  Are you able to function normally within 2 hours? (IMP 4) 
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• Global assessment of relief: Does the headache pain disappear within 2 hours? 
(GAR 1) 
• Consistency of response: Does your migraine medication work consistently, in 
the majority of your attacks? (CONS 3) 
• Emotional response: Are you comfortable enough with your medication to be 
able to plan your daily activities? (EMOT 3) 
 
The results showed that the four items in the Migraine-ACT discriminated most with the 
MTAQ score, and to a slightly lesser degree with the total SF-36 score. Factor analysis 
showed that four items described most of the variance in the data: the total SF-36 score 
described 42.01%; the SF-36 role emotional score described 9.49%; the total MTAQ score 
described 8.93%; and the MIDAS B score (pain severity) described 6.96%. Mean t-
discrimination scores from the 15-item analysis above were compared with those from the 
factor analysis (Table 5), and were very similar, indicating a high level of correlation. 
 
Table 5. Discrimination analysis (discriminatory t-tests) of the four items constituting the final 
Migraine-ACT Questionnaire: comparison of t-test values calculated from all 15 items 
contained within the SF-36, MIDAS and MTAQ questionnaires, and the four items derived 
from factor analysis. 
 
Mean t-discrimination 
Migraine-ACT item Total score derived from all 
15 SF-36, MIDAS and 
MTAQ items 
Total score derived from 
factor analysis 
IMP 4 3.07 3.97 
GAR 1 2.70 3.14 
CONS 3 2.08 2.71 
EMOT 3 3.16 4.18 
 
Analysis of the 4-item Migraine-ACT questionnaire 
The 4-item Migraine-ACT questionnaire was further analysed in several ways. The individual 
questions, and the total Migraine-ACT score, were correlated with subscales and total scores 
of the SF-36, MIDAS and MTAQ questionnaires using Pearson product moment measures 
(Table 6). The Migraine-ACT items and total score correlated well with the other items, 
particularly so with the total MTAQ and SF-36 domain and total scores. Regression of MTAQ 
and total SF-36 on Migraine-ACT were both highly significant (MTAQ: beta = -0.58, SE = 
0.06, p < 0.0001; SF-36: beta = 0.36, SE = 0.07, p < 0.0001). The 4-item Migraine-ACT 
questionnaire was examined for test-retest reliability, and was shown to be very reliable by 
the Pearson and Spearman measures (r = 0.82 for both calculations).  
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Table 6. Analysis of the 4-item Migraine-ACT questionnaire: calculation of Pearson product 
moment measures with the SF-36, MIDAS and MTAQ questionnaires. 
 
Pearson product moment measures 
 IMP4 GAR1 CONS3 EMOT3 Total 
Migraine-
ACT score 
SF-36 Bodily Pain   0.345 0.24 0.25 0.33 0.38 
SF-36 General 
Health 
0.18  0.15 0.25 0.24 
SF-36 Vitality   0.22 0.25  0.22 0.28 
SF-36 Social 
Functioning  
0.31 0.30 0.21 0.34 0.38 
SF-36 Mental 
Health 
0.20 0.21  0.21 0.25 
SF-36 Total 
Physical 
0.31 0.25 0.20 0.29 0.34 
SF-36 Total Mental 0.27 0.27 0.18 0.29 0.33 
SF-36 Total    0.31 0.28 0.20 0.31 0.36 
MIDAS B score   -0.24 -0.20 -0.18 -0.18 -0.26 
Total MIDAS score -0.28 -0.29  -0.31 -0.32 
Total MTAQ score  -0.50 -0.39 -0.38 -0.59 -0.60 
 
In scoring the Migraine-ACT questionnaire, it is desirable to produce simple cut-off points 
that facilitate interpretation and use. The simplest scoring method is to score all ‘yes’ 
answers as ‘1’ and all ‘no’ answers as ‘0’, and sum the answers. This produces a 5-item 
score, ranging from 0–4. A score of ‘4’ might indicate that the patient has no medication 
needs, while a score of ‘0’ may indicate very high medication needs. Alternatively, the items 
can be individually weighted, resulting in a more complex scoring scheme. However, 
regression analysis indicated that weighting the scoring only increased its discriminatory 
power by 3% as compared to the MTAQ questionnaire. The simpler method was therefore 
practically as good as a more complicated weighting method. Table 7 shows how the simple 
version Migraine-ACT scores compare with those of MIDAS, MTAQ and SF-36 total scores. 
A decreasing Migraine-ACT score (indicating increased medication needs) correlated with 
increasing MIDAS and MTAQ scores (indicating increased management needs) and a 
decreasing SF-36 score (indicating reduced quality of life). The mean Migraine-ACT score for 
patients (n = 181) participating in this study was 2.55 (SE = 0.11).  
 
Table 7. Interpretation of the total Migraine-ACT score: relation to MIDAS, MTAQ and SF-36 
scores 
  
Migraine-ACT score MIDAS score MTAQ score SF-36 score 
4 16 2.25 54 
3 22 2.95 48 
1 34 4.37 46 
0 40 5 44 
 
MIDAS scores range from 0 to over 100. There are four grades: I = no or minimal disability 
(score 0–5); II = mild disability (score 6–10); III = moderate disability (score 11–20); and IV = 
severe disability (score > 20). Most migraine sufferers score as Grade III or IV.1 
MTAQ scores range from 0–8, with a higher score indicating an increasing number of 
management issues.4 
SF-36 scores range from 0–100, with increasing score correlating with better health. A score 
of 50 is the average for the US population.23 
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Discussion 
 
Any new tool assessing clinically important endpoints needs to exhibit good test-retest 
reliability and validity before it can be recommended for use. Good test-retest reliability 
means that the tool assesses the data consistently over time. Validity denotes the accuracy 
of the tool in assessing what it is meant to measure. Validity is commonly assessed by 
criterion (gold standard) or construct validity (comparing the accuracy of the new tool 
compared to other tools that are related to the same disease area). Additional attributes are 
necessary if a tool is designed for use in primary care. The tool needs to be brief, and simple 
to complete and score. It should also exhibit face validity, being intuitively meaningful to the 
target audience. All these factors were included in the design and testing of the Migraine-
ACT questionnaire. 
 
Migraine-ACT was designed from the outset to have high face validity. The question domains 
were chosen to be clinically relevant. Migraine impact, the global response to medication, 
consistency of response and the emotional component of the headache are all important in 
assessing the severity of illness and the response to treatment.9–14 The questionnaire was 
also designed to be brief, with only four questions, one in each domain. Simplicity was 
assured by ensuring that all questions were answered by ‘yes’ or ‘no’.  
 
The individual 27 Migraine-ACT questions all exhibited good-to-excellent test-retest 
reliability. However, additional analyses of reliability were required due to the variables being 
dichotomous (yes/no) rather than continuous, with resultant low degrees of freedom in the 
analyses. We therefore analysed the consistency of response in the patients’ answers at the 
two study visits. Analyses of consistency (the proportion of patients who answered ‘yes’ or 
‘no’ at both study visits and the proportion of ‘yes’ and ‘no’ answers for each question at the 
study visits) provided a high consistency in the responses (typically over 80% agreement). 
Taken together with the good test-retest reliability data, it can be concluded that the 
Migraine-ACT questions are highly reliable. While the 1-week gap between the first and 
second completions of the questionnaire may be considered to be short, this was done to 
minimise potential changes in the patients’ migraine attacks, which could have altered the 
results. 
 
For the assessment of construct validity, the 27 items constituting the original Migraine-ACT 
were correlated with a series of questionnaires that have been shown to be sensitive to 
outcome in headache. SF-36 is a generic QOL questionnaire that can be used for any illness 
state. It has been shown to accurately assess the severity of migraine, and effective 
treatment results in an increased score, indicating improved QOL.18 MIDAS is a headache-
specific questionnaire that assesses disability as time lost from daily activities, as well as the 
headache frequency and severity.1 It is a reliable1,19 and valid20 measure, and is a sensitive 
outcome measure in migraine and other headaches.21,22 MTAQ is a migraine-specific 
questionnaire that is a reliable and valid screening tool,4 although its utility as an outcome 
measure has not yet been demonstrated. Discriminatory t-tests showed that many of the 
Migraine-ACT items correlated well with the total SF-36 score and some of its subscales, the 
MIDAS total score and MIDAS B scores, and the total MTAQ score. Of all these items, 
Migraine-ACT items correlated best with the total SF-36 and MTAQ scores. The four items 
constituting the final Migraine-ACT questionnaire were selected on the basis of those items 
(one in each domain) that correlated best with the total score from all 15 items from the SF-
36, MIDAS and MTAQ variables. Factor analysis confirmed these data.  
 
The four-item Migraine-ACT questionnaire is shown in Figure 8 at the end of this article. The 
order of the questions is designed so that migraine and headache items are introduced first, 
while the more generic questions are answered later. Each ‘yes’ answer is scored as ‘1’ and 
each ‘no’ answer as ‘0’. The total Migraine-ACT score is achieved by summing the answers 
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to the four items. We suggest that a score of 4 corresponds to the physician not needing to 
re-evaluate the patient while 0 corresponds to a very high need for re-evaluation. However, 
further studies are required to confirm this relationship and define the cut-off point that 
indicates the need for evaluation and/or a change in treatment. Regression analysis showed 
that there was no significant advantage in weighting the answers, which would have 
increased the complexity of the questionnaire markedly. The result is a questionnaire that is 
intuitive and simple to complete and score, yet correlates highly with both generic (SF-36) 
and disease-specific (MTAQ) measures of health status. Further testing showed that the 4-
item Migraine-ACT is highly reliable and valid. 
 
We envisage the main use of the Migraine-ACT as a rapid and accurate screener to identify 
patients whose current acute treatment regimen needs to be changed. It is intended for use 
by the primary care physician or clinician in everyday clinical practice. Currently-used tools 
do not fulfil this role because they are too complex for routine use.1–4 There were clear but 
opposite relationships between the 4-item Migraine-ACT with the SF-36 general health 
measure, and the headache-specific MIDAS and the highly migraine-specific MTAQ. This 
would be expected, as illness and health are opposite constructs. The 4-item Migraine-ACT 
score ranges from 0–4 and indexes a window into the total SF-36 score ranging from 44–54. 
The higher the score, the better off is the patient. Similarly the specific MIDAS and MTAQ 
measure illness with higher scores being worse for the patient. The 4-item 0–4 score indexes 
a window into MIDAS from 16–40 and into MTAQ ranging from 2–5. The MIDAS scores, 
ranging from mid-Grade III to high Grade IV are what would be expected in a population of 
secondary care patients having significant headache-related disability.1 The 4-item Migraine-
ACT is appreciably shorter, simpler and easier to complete than any of the three other 
questionnaires above.  
 
Further studies are required to define the clinical utility of Migraine-ACT, to define the score 
that indicates a change in treatment is needed, and to investigate its sensitivity to change for 
use as an outcome tool in comparison to changes in SF-36, MIDAS and MTAQ. This study 
was conducted in secondary care referral centres. Studies in primary care practice are 
therefore particularly needed to demonstrate its utility in the everyday management of 
migraine. However, we believe that the main use of Migraine-ACT will be in clinical practice, 
and naturalistic studies conducted in this domain will determine the true utility of the 
questionnaire.  
  
Conclusions 
 
The 4-item Migraine-ACT questionnaire is a rapid, reliable, brief, simple to complete and 
score assessment tool, which can be recommended for everyday clinical use by the clinician 
to identify patients who require a change in their current acute migraine treatment. 
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Figure 1. The 4-item Migraine-ACT questionnaire recommended for use in primary care. 
 
Please answer all four questions below, as ‘yes’ or ‘no’, by placing a tick in the relevant box. 
 
Question Yes No 
When you take your treatment: 
Does your migraine medication work consistently, in the 
majority of your attacks? 
 
  
When you take your treatment: 
Does the headache pain disappear within 2 hours?  
 
  
When you take your treatment: 
Are you able to function normally within 2 hours? 
 
  
When you take your treatment: 
Are you comfortable enough with your medication to be 
able to plan your daily activities? 
 
  
Migraine-ACT Score 
 
 
 
Scoring the Migraine-ACT questionnaire 
One or more ‘no’ answers may indicate the need to change treatment. An increasing number of 
‘no’ answers indicates increasing treatment needs.  
 
 
© Practical Solutions in Medicine Ltd. 2004. Permission is freely given for the use of the 
Migraine-ACT questionnaire by individuals for the purposes of research and to improve 
treatment of migraine patients. As a courtesy, researchers and commercial parties are 
asked to inform the copyright holder in advance before using the questionnaire. 
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4.6 
 
The Migraine Assessment of Current Therapy (Migraine-ACT) 
questionnaire: investigation of reliability, validity and clinical utility in 
a multinational study* 
 
 
Abstract 
 
The 4-item Migraine-ACT questionnaire is an assessment tool for use by primary care 
physicians to identify patients who require a change in their current acute migraine treatment. It 
has been shown to be easy to use, and to be reliable and accurate in its assessments. The 
Migraine-ACT study database was analysed further, providing additional information on the 
reliability, validity and potential clinical utility of the questionnaire.  
Reliability was assessed by recording the distribution of Migraine-ACT scores recorded at 
baseline and 1 week later (test-retest reliability). Analyses of consistency of Migraine-ACT 
scores were conducted on the total sample of patients and for the five separate centres 
(Germany, Italy, Spain, UK and USA), using Pearson and Spearman correlations. Validity was 
assessed by comparing the t-discrimination values for clinically-relevant questions within 
domains of the original 27-item questionnaire. Reliability and validity were also assessed by 
constructing an ‘alternative’ (Form B) Migraine-ACT questionnaire, derived from an analysis of 
the second best items in each domain in the original study data. Clinical utility was assessed 
using Pearson pairwise correlations to compare Migraine-ACT scores with clinically-defined 
criteria as analysed by the SF-36 Quality of Life questionnaire, the Migraine Disability 
Assessment (MIDAS) questionnaire and the Migraine Therapy Assessment (MTAQ) 
questionnaire. 
The distribution of Migraine-ACT scores between the two completions of the questionnaire was 
consistent for the total sample (test-retest reliability r = 0.81) and between the individual 
countries (r = 0.61–0.92). In this study, the validity (assessed as t-discrimination) of the 
Migraine-ACT ‘impact’ and ‘global assessment of relief’ questions were markedly higher than 
those of other endpoints used in migraine clinical studies. The Form B Migraine-ACT 
questionnaire was almost as reliable and accurate as the original Form A questionnaire. The 
distribution of Migraine-ACT scores was: 0 = 12.6%, 1 = 13.7%, 2 = 14.7%, 3 = 20.5% and 4 = 
38.4%. The change in Migraine-ACT score correlated with, and had a linear relationship with 
changes in SF-36, MIDAS and MTAQ scores, and indicated that a Migraine-ACT score of ≤ 2 
corresponded with a need to consider changing the patient’s acute medication. About 40% of 
the migraine patients in the study scored ≤ 2 and may have had significant unmet treatment 
needs.  
These data confirm the good reliability and validity of the Migraine-ACT questionnaire and 
provide further evidence for its utility in clinical practice. 
 
 
 
*Summarised from the article: Kilminster S, Dowson AJ, Tepper S, Baos V, Baudet F, D’Amico 
D. The Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire: investigation of 
reliability, validity and clinical utility in a multinational study. Headache 2005; Submitted for 
publication. 
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Introduction 
 
A 4-item questionnaire was developed, the Migraine Assessment of Current Therapy (Migraine-
ACT) questionnaire (see Chapter 3.5 and Table 1) as a means to identify patients attending 
primary care clinics who require a change in their current acute migraine treatment. Four 
clinically important domains of the migraine experience were assessed: consistency of 
response,1,2 global assessment of relief,2,3 headache impact4,5 and emotional response.6 A 
multicentre, international study was conducted with Migraine-ACT (the original Migraine-ACT 
questionnaire was developed in English then translated into Spanish, German and Italian for use 
in the study. The translations were verified by blind back-translation into English). The study 
demonstrated that Migraine-ACT was easy to use, and was reliable and accurate in its 
assessments and suitable for use by the primary care physician. Scoring the questionnaire is by 
simple summing of the ‘yes’ scores (range 0–4).7 This article describes further analyses of the 
Migraine-ACT study database, providing additional information on the reliability, validity and 
clinical utility of the questionnaire.  
 
Table 1. The 4-item Migraine-ACT questionnaire recommended for use in primary care (Form 
A).7 
 
Please answer all four questions below, as ‘yes’ or ‘no’, by placing a tick in the relevant box. 
Question Yes No 
When you take your treatment: 
Does your migraine medication work consistently, in 
the majority of your attacks? 
 
  
When you take your treatment: 
Does the headache pain disappear within 2 hours?  
 
  
When you take your treatment: 
Are you able to function normally within 2 hours? 
 
  
When you take your treatment: 
Are you comfortable enough with your medication to 
be able to plan your daily activities? 
 
  
Migraine-ACT Score 
 
 
 
Scoring the Migraine-ACT questionnaire 
One or more ‘no’ answers may indicate the need to change treatment. An increasing number of 
‘no’ answers indicates increasing treatment needs.  
 
© Practical Solutions in Medicine Ltd. 2004. Permission is freely given for the use of the Migraine-
ACT questionnaire by individuals for the purposes of research and to improve treatment of 
migraine patients. As a courtesy, researchers and commercial parties are asked to inform the 
copyright holder in advance before using the questionnaire (email address: migraineact@psim-
limited.com).  
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Methods 
Patients and design 
Details of the patient inclusion and exclusion criteria and the overall study design are described 
in Chapter 3.5. 
 
Reliability 
Test-retest reliability was previously assessed by Pearson and Spearman measures.7 Further 
analyses of reliability were conducted in terms of the distribution of Migraine-ACT scores 
recorded at baseline and 1 week later for the total sample of patients and the individual 
countries. Results were expressed as the proportion of patients at each score. Test-retest 
reliability was assessed as the Pearson correlation and the Spearman rank correlation for 
comparisons of data from the total patient sample and the individual countries. 
 
Validity  
Construct validity of Migraine-ACT was previously assessed7 using discriminatory t-tests to 
relate dichotomous ‘yes’ and ‘no’ responses scored 1 and 0 in patients’ answers to the 27-item 
Migraine-ACT with those to the Short-Form 36 quality of life questionnaire (SF-36),8 the Migraine 
Disability Assessment (MIDAS) questionnaire9 and the Migraine Therapy Assessment 
Questionnaire (MTAQ) [see ‘Methods’ chapter].10 Further analyses of validity were conducted in 
terms of correlating the t-discrimination values for clinically-relevant questions within domains of 
the original 27-item questionnaire. t-discrimination values were compared for the following items: 
• Impact: Are you able to function normally within 2 hours (IMP 4)?; Do you usually not 
need to lie down after 2 hours (IMP 5)?; Are you able to concentrate normally within 2 
hours (IMP 9)?; Have any feelings of tiredness, irritability, sadness, anger and anxiety 
disappeared within 2 hours (IMP 11)?. 
• Global assessment of relief: Does the headache pain disappear within 2 hours (GAR 
1)?; Is the headache pain relieved after 2 hours (GAR 2)?; Does the headache pain 
disappear within 2 hours and not return within 24 hours (GAR 3)?; Does the headache 
pain disappear within 2 hours and not return within 48 hours (GAR 4)?; Does the 
headache pain start to disappear within 30 minutes (GAR 5)?; Do your non-headache 
symptoms (e.g. nausea and sensitivity to light, sound or smells) disappear within 2 
hours (GAR 6)?; Are you clear of all your symptoms within 2 hours (GAR 8)? 
  
An ‘alternative’ Migraine-ACT questionnaire was also constructed, derived from an analysis of 
the second best items (Form B) for each domain in the original study data. This questionnaire 
was examined for reliability (Spearman rank correlations) and validity (t-discrimination scores). 
The overall reliability of the original questionnaire (Form A) and the Form B questionnaire were 
compared using Pearson pairwise correlations.  
 
Clinical utility 
The clinical utility of the Migraine-ACT questionnaire was examined in several ways to relate 
Migraine-ACT scores to medical need. Firstly, the distribution of Migraine-ACT scores recorded 
above in the reliability analysis was examined. Secondly, the Migraine-ACT score was correlated 
to the total scores obtained for the SF-36, MIDAS and MTAQ questionnaires, using Pearson 
pairwise correlations. Following this, Migraine-ACT scores were compared to clinically-defined 
criteria as analysed by the SF-36, MIDAS and MTAQ questionnaires.  
 
Results 
Reliability 
The distribution of Migraine-ACT scores at baseline and 1 week later for the different countries 
and the total patient population are shown in Table 2. Analyses of these data and the Pearson 
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and Spearman test-retest correlations (Table 3) showed that the data between the two 
completions of Migraine-ACT were consistent for the total population and for the individual 
countries. All correlations were significant to p < 0.01. Pearson correlations ranged from 0.61 to 
0.92, and similar values were reported for the Spearman rank correlations. The correlation for 
the total patient population was r = 0.81 for both analyses.  
 
Table 2. Consistency of the 4-item Migraine-ACT questionnaire: proportion of patients assigned 
to each Migraine-ACT score during the two completions of the questionnaire (total sample and 
data for each country). Scores range from 0 (all answers are ‘No’) to 4 (all answers are ‘Yes’). 
 
Total sample 
   1st completion (n = 190)  2nd completion (n = 185) 
Migraine-ACT 
score 
n Patients (%) n Patients (%) 
4 73 38.4 68 36.8 
3 39 20.5 30 16.2 
2 28 14.7 36 19.5 
1 26 13.7 26 14.1 
0 24 12.6 25 13.5 
 
UK 
1st completion (n = 40)  2nd completion (n = 39) 
Migraine-ACT 
score 
n Patients (%) n Patients (%) 
4 16 40.0 16 41.0 
3 9 22.5 6 15.4 
2 5 12.5 7 17.9 
1 4 10.0 4 10.3 
0 6 15.0 6 15.4 
 
Spain 
1st completion (n = 40)  2nd completion (n = 40) 
Migraine-ACT 
score 
n Patients (%) n Patients (%) 
4 15 37.5 14 35.0 
3 6 15.0 7 17.5 
2 3 7.5 7 17.5 
1 5 12.5 3 7.5 
0 11 27.5 9 22.5 
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USA 
1st completion (n = 40)  2nd completion (n = 40) 
Migraine-ACT 
score 
n Patients (%) n Patients (%) 
4 20 50.0 18 45.0 
3 8 20.0 5 12.5 
2 7 17.5 10 25.0 
1 5 12.5 5 12.5 
0 0 0 2 5.0 
 
Germany 
1st completion (n = 30)  2nd completion (n = 26) 
Migraine-ACT 
score 
n Patients (%) n Patients (%) 
4 7 23.3 9 34.6 
3 7 23.3 3 11.5 
2 7 23.3 4 15.4 
1 8 26.7 6 23.1 
0 1 3.3 4 15.4 
 
Italy 
1st completion (n = 40)  2nd completion (n = 40) 
Migraine-ACT 
score 
n Patients (%) n Patients (%) 
4 15 37.5 11 27.5 
3 9 22.5 9 22.5 
2 6 15.0 8 20.0 
1 4 10.0 8 20.0 
0 6 15.0 4 10.0 
 
 
Table 3. Test-retest reliability of the Migraine-ACT questionnaire: Pearson and Spearman rank 
correlations for the completions of the Migraine-ACT questionnaire at baseline and 1 week later: 
analysis by country and for the whole patient sample. 
 
 
Country  Pearson  Spearman rank 
   correlation  correlation 
UK    0.91     0.90 
Spain    0.92    0.92 
USA    0.61    0.65 
Germany  0.74    0.74 
Italy    0.75    0.77 
Total   0.81   0.81 
patient sample 
 
All comparisons were significant to p < 0.01 
 
  176 
Validity 
Figure 1 shows the analysis of t-discrimination scores for assessments of impact and the global 
assessment of relief. In examining the relative discriminatory value of measures of migraine 
impact, the ability to function normally within 2 hours (IMP 4) was markedly more discriminatory 
than not needing to lie down after 2 hours (IMP 5), being able to concentrate normally within 2 
hours (IMP 9) and the disappearance of emotional symptoms within 2 hours (IMP 11). In 
examining the relative discriminatory value of measures of global assessment of relief, the 
assessment of headache pain disappearance at 2 hours (GAR 1) was markedly more 
discriminatory than that of headache relief at 2 hours (GAR 2), sustained pain-free rates over 24 
hours (GAR 3) or 48 hours (GAR 4), early onset of pain disappearance (GAR 5), disappearance 
of non-headache symptoms (GAR 6) and disappearance of all symptoms (GAR 8).  
 
Figure 1. Comparison of t-discrimination values for Migraine-ACT items equivalent to commonly-
used endpoints in migraine studies. a. Impact: ability to function normally within 2 hours (IMP 4), 
no need to lie down after 2 hours (IMP 5), able to concentrate normally within 2 hours (IMP 9) 
and symptoms of tiredness, irritability, sadness, anger and anxiety disappear within 2 hours (IMP 
11). b. Global assessment of relief. pain-free at 2 hours (GAR 1), 24 (GAR 3) and 48 (GAR 4) 
hours, headache relief at 2 hours (GAR 2), start of headache relief within 30 minutes (GAR 5), 
free of non-headache symptoms at 2 hours (GAR 6) and clear of all symptoms within 2 hours 
(GAR 8). 
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b.
0
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1.5
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2.5
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Table 4 shows the ‘alternative’ (Form B) 4-item questionnaire that was derived from the original 
27-item Migraine-ACT by selecting the second most discriminatory question in each domain. 
Calculated values for reliability (Spearman rank correlation) and validity (t-discrimination scores) 
for each question were similar to those of the original 4-item questionnaire. Pearson pairwise 
correlations showed that the overall test-retest reliability of the Form B questionnaire was high, (r 
= 0.81) and was virtually the same as that of the original Form A questionnaire (r = 0.82). The 
correlation was significant to p < 0.01. 
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Table 4. An ‘alternative’ (Form B) 4-item Migraine-ACT questionnaire and its reliability and 
validity, compared with those of the original questionnaire. Values in parentheses show the 
equivalent data for the original Migraine-ACT questionnaire (Form A7). 
 
Question Reliability 
(Spearman 
rank 
measure) 
Validity 
(t-discrimination) 
When you take your treatment: 
Does your migraine medication work attack 
after attack?  
 
 
0.68 
(0.61) 
 
2.06 
(2.08) 
When you take your treatment: 
Are you clear of all your symptoms within 2 
hours? 
 
 
0.58 
(0.58) 
 
2.33 
(2.70) 
When you take your treatment: 
Are you able to resume your normal activity 
(i.e. work or family-leisure-social activity, etc.) 
within 2 hours? 
 
 
0.77 
(0.72) 
 
2.96 
(3.07) 
When you take your treatment: 
Do you feel in control of your migraine enough 
so that you feel there will be no disruption to 
your daily activities? 
 
 
0.63 
(0.78) 
 
3.12 
(3.16) 
 
Clinical utility 
The distribution of Migraine-ACT scores for the total population was: 0 = 12.6%, 1 = 13.7%, 2 = 
14.7%, 3 = 20.5% and 4 = 38.4%. The distribution of scores between the two completions of the 
questionnaire was consistent between countries (Table 2). 
 
Pearson pairwise correlations for the comparison of Migraine-ACT scores with the total SF-36, 
MIDAS and MTAQ scores are shown in Table 5. All correlations were significant at p < 0.05. The 
data showed that Migraine-ACT closely correlated with SF-36, MIDAS and MTAQ total scores 
both times it was completed (at baseline and after 1 week). The tendency was for a greater 
correlation (stronger relationship) with MTAQ > MIDAS > SF-36. The pattern of correlations 
showed great construct consistency.  
 
Table 5. Pearson pairwise correlations for the comparisons of Migraine-ACT, SF-36, MIDAS and 
MTAQ total scores: comparisons of data at baseline and 1 week. 
 
 Total SF-36 score Total MIDAS score Total MTAQ score 
Migraine-ACT 
score (baseline) 
0.36 -0.32 -0.60 
Migraine-ACT 
score 
(1 week) 
0.34 -0.39 -0.58 
 
All correlations were significant at p < 0.05. 
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Figure 2 shows how the Migraine-ACT scores corresponded to SF-36, MIDAS and MTAQ 
scores. The relationship was essentially linear in all cases. As the Migraine-ACT score 
decreased from 4 to 0, the SF-36 score deceased from 53.6 to 44.0, the MIDAS score increased 
from 16.0 to 39.3 and the MTAQ score increased from 2.3 to 5.0. 
 
Figure 2. Relationship of Migraine-ACT scores to clinically-defined criteria as analysed by scores 
on the SF-36, MIDAS and MTAQ questionnaires.  
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Discussion 
 
The aims of this post hoc analysis of the original Migraine-ACT study were to provide further 
data on the robustness of the results, and to give the physician insights into the clinical utility of 
the questionnaire and how it might best be used in the clinic. To do this, new analyses of 
reliability and validity were conducted and examined for clinically relevant data. 
 
The original assessments of test-retest reliability used appropriate statistical methodology 
(Pearson product moment and Spearman rank measures). This methodology has been used in 
examining the reliability of, among others, the MIDAS Questionnaire, both in its original English 
version,5 and in scientific translation into other languages.11 The 27 items of the original 
Migraine-ACT questionnaire all exhibited good-to-excellent reliability over 1 week, and the final 
4-item Migraine-ACT was a highly reliable measure (r = 0.82).7 Data presented here 
demonstrate that there was high consistency in the Migraine-ACT scores reported from the 
individual countries and the total population. Test-retest reliability ranged from 0.61–0.92 
according to country. Additionally, an ‘alternative’ 4-item Form B questionnaire derived from the 
same 27 questions was also highly reliable (r = 0.81). These data reinforce the good reliability of 
the 4-item Migraine-ACT questionnaire.  
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The assessment of construct validity (accuracy) commonly involves the comparison of data from 
a new tool with those from standard existing tools (‘gold standard’ measures).12 In the original 
study, Migraine-ACT was compared with the SF-36 QOL questionnaire, the MIDAS disability 
questionnaire and the MTAQ disease management questionnaire, and was shown to correlate 
well with these questionnaires, especially with the total MTAQ and SF-36 scores.7 Data 
presented here showed that a second Form B 4-item questionnaire could be derived from the 
original 27 questions in which the questions were almost as accurate as the 4-item Migraine-
ACT questionnaire. The two sets of questions exhibited considerable redundancy, indicating that 
they accurately measured the same specific domains. Additionally, three of the original 
questions assessing global assessment of relief (GAR 1, 4 and 8) and three of the impact 
questions (IMP 4, 9 and 11) showed similar levels of discrimination.  
 
This conclusion is reinforced when examining the t-discrimination scores associated with 
different types of questions used in the ‘impact’ and ‘global assessment of relief’ domains. 
Migraine is associated with different areas of impact, including:  
• The ability to function normally, which can be assessed with the MIDAS questionnaire.13 
• The need to lie down during attacks, which was assessed as important in the studies that 
developed the Headache Impact Test.14 
• Cognitive changes, which are frequently reported during attacks, and have been 
assessed in one study.15 
• Emotional changes, which have been identified as important components of migraine, 
tension-type headache and chronic daily headache.6,16 
The results reported here indicate that assessing the ability to function normally after treatment 
is markedly more discriminating in assessing impact that the other three measures. Numerous 
studies have indicated that the disruption of patients’ everyday activities is the key measure of 
illness severity in migraine patients.4,5,13,17,18 
 
Over the years, much research has attempted to define the optimal measure of relief of migraine 
symptoms, usually using a 2-hour endpoint:  
• The disappearance of the headache, which is used as the gold standard measure by the 
International Headache Society.3 
• The relief of headache, defined as an improvement from severe or moderate to mild or 
none, and used as the primary endpoint in most migraine studies to this day.19 
• Disappearance of the headache which is sustained for 24 or 48 hours after treatment.2,20  
• Onset of headache disappearance, usually defined as within 30 minutes after 
treatment.21 
• Disappearance of non-headache symptoms of the migraine attack.19 
• Disappearance of all symptoms of the migraine attack.20 
The results reported here indicate that assessing the disappearance of the headache at 2 hours 
after treatment is markedly more discriminating in assessing relief than any of the other 
measures above. The results therefore agree with recent studies that have indicated the pain-
free measure is the most important clinical endpoint in migraine studies.2,3,20 Migraine-ACT 
therefore contains two highly valid measures for assessing the efficacy of treatment. Domains of 
consistency of response and emotional response have not been assessed to anything like the 
same extent as impact and global response, but are both clinically relevant in assessing the 
constellation of migraine symptoms.2,6  
 
The clinical relevance of these data is considerable. The original Migraine-ACT questionnaire 
was developed in English then translated into Spanish, German and Italian for use in the study. 
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The translations were verified by blind back-translation into English. The high values obtained 
for consistency and reliability in the distribution of the Migraine-ACT grade scores attest to the 
robustness of the questionnaire for use in different countries. Migraine-ACT has since been 
translated into Dutch (Appendix 1) and its use is advocated in the Netherlands.22 
 
The relationship of Migraine-ACT scores to scores on the SF-36, MIDAS and MTAQ 
questionnaires provides further evidence of clinical utility. Pearson pairwise correlations 
confirmed that the Migraine-ACT score was closely related to SF-36, MIDAS and MTAQ total 
scores. The linear relationship between the range of Migraine-ACT scores and scores for the 
three other questionnaires is noteworthy and demonstrates an even gradation of Migraine-ACT 
scoring. The mean SF-36 score in the US population is 508 and patients with Migraine-ACT 
scores of 2, 1 and 0 would therefore seem to have lower quality of life than the general 
population (SF-36 scores of 48.9, 46.5 and 44.0, respectively). The MIDAS scores ranged from 
16.0 (Migraine-ACT score 4) to 39.3 (Migraine-ACT score 0). MIDAS scores of 11–20 (Grade III) 
equate with moderate disability, while scores of > 20 (Grade IV) equate to severe disability.9 The 
mean MIDAS score for migraine patients is typically in the Grade III range.9 MTAQ scores 
ranged from 2.3 (Migraine-ACT score 4) to 5.0 (Migraine-ACT score 0). MTAQ scores range 
from 0–8 depending on the number of management issues identified for the patient. A score of ≥ 
2 is used as the threshold for when follow up is warranted.10  
 
From these data, it can be deduced that a Migraine-ACT score of 2, 1 and 0 identifies patients 
for whom a change in acute treatment may be warranted. These patients have reduced quality 
of life, severe headache-related disability and a considerable number of outstanding 
management issues. In this study, 41.0% of patients met this criterion, and the results were 
relatively similar between the countries (UK = 37.5%, Spain = 47.5%, USA = 30.0%, Germany = 
53.3%, Italy = 40.0%, Table 2). It might be expected that the proportion of patients presenting to 
primary care physicians with Migraine-ACT scores of ≤ 2 would be even higher, due to the 
likelihood of them having received suboptimal care.23–27  
 
The general limitations of the Migraine-ACT study are described in Chapter 3.5. From the 
analyses described here, further work is desirable to investigate the clinical significance of the 
Migraine-ACT scoring scheme. In addition, further studies are warranted to investigate Migraine-
ACT as an outcome tool to monitor the effect of interventions. 
 
In conclusion, these data confirm the good reliability and validity of the Migraine-ACT 
questionnaire and provide further evidence for its utility in clinical practice. It is suggested that a 
score of ≤ 2 may indicate that a change in the patient’s acute medication is warranted and a 
score of ≤ 1 may indicate that the change is mandated.  
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5 
 
General discussion 
 
 
The main aim of these studies was to investigate the clinical significance of headache-related 
disability and impact; the clinical importance of assessing disability, the means of recognising 
the patients with severe disability and the development of new ways to assess headache-related 
disability and their utility in clinical practice. The main methodology used in the thesis was critical 
reviews of the literature and open, naturalistic studies designed to mimic the situation in 
everyday primary care clinical practice. In this chapter the main study findings are discussed and 
related to the published clinical literature. The research and clinical implications deduced from 
the data are outlined. Finally, the methodology of the studies is criticised and future studies and 
directions for further research outlined. 
 
5.1 Main results 
Clinical importance of assessing headache-related disability 
For evidence-based medicine, the randomised, double-blind, controlled clinical study remains 
the gold standard for evaluating the clinical profile of drugs.1,2 However, as discussed in Chapter 
3.1, several criteria need to be met before the study can be categorised as high quality Grade A 
clinical evidence. Studies need to be randomised, double-blind and to contain enough patients in 
each treatment group to allow for sufficient power for the statistical analyses. Patient withdrawals 
should be low (≤ 10%) and equivalent in the separate treatment groups. Outcome measures 
should be quantifiable and clinically meaningful, and statistical tests should be appropriate for 
the populations and endpoints studied.3 These criteria should be mandatory for all controlled 
studies (Figure 1). Additionally for headache, a placebo group should always be included to 
control for the variable placebo response that characterises the condition.4  
 
Figure 1. Criteria for the design of Grade A clinical studies. 
 
Randomised, 
double-blind design
Placebo / comparator 
controlled
Appropriate patient 
group selected
Diagnosis by 
defined criteria
Study powered 
appropriately
Validated, clinically 
relevant endpoints
Tolerability / 
safety assessed
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Not surprisingly, these stringent conditions are not always met, and post hoc and meta-analyses 
are sometimes used if clinical evidence is inconclusive and when comparisons between drugs 
are desired but a proper controlled study has not yet been conducted. For headache, such 
analyses have generated controversy, rather than contributing substantially to understanding the 
efficacy of acute migraine therapies (with inconsistencies in the studies included and analyses 
conducted).5–8 Their chief utility should be to suggest avenues for future clinical studies and they 
should not be used on their own as a means of selecting acute treatments for migraine.3 
 
However, even results from double-blind, controlled clinical trials may not always be optimal in 
terms of reflecting the situation in clinical practice. For example, in migraine controlled clinical 
studies show only small differences between the oral triptans, whereas patients describe clear, if 
individual, preferences between them.3 The conundrum is that individual patients respond 
differently to medications that have similar efficacy profiles, and reinforce the need for an 
approach to care that is tailored to the needs of each patient. The basis for these differences in 
effect may be due to biological (e.g. neuroreceptor profile) and/or clinical (e.g. co-morbidities and 
the presence of single or multiple headache conditions) factors. Patients differ in how they cope 
with pain, their sensitivity to pain and in other ways that lead to headache being a 
heterogeneous rather than an isolated condition. Only very large studies using vast numbers of 
patients can detect statistically significant differences between treatments in such a 
heterogeneous environment. However, the differences are often small and not necessarily 
clinically relevant. This fundamental methodological problem is encountered in other medical 
fields, e.g. palliative care and psychiatric disorders. 
 
The development of new, more sensitive endpoints to assess migraine relief may therefore be 
needed. Proposed new endpoints tend to be global measures that combine assessments of 
efficacy and tolerability, including assessments of patient preference and satisfaction, the impact 
on patients’ daily lives and the patient’s quality of life. Of these three types of endpoints, patient 
preference / satisfaction and headache impact can provide simple and intuitive assessments,9,10 
while quality of life is a more complex measure wherein the units of assessment do not relate 
directly to clinically meaningful measures.11 Such endpoints may be more valid and sensitive 
than the traditional headache-based ones, although this has to be demonstrated in clinical 
studies. 
 
Assessing patient preference 
Chapter 3.2 reviews and discusses the data on using patient preference / satisfaction as an 
outcome measure in migraine studies.9 Many studies have used patient preference as 
secondary analyses of efficacy. Overall, the results show that patients can distinguish 
differences in efficacy between the triptans and non-triptan medications for migraine, and also 
between the different triptans.9 These data are remarkable, as it has proved difficult to show 
significant differences between acute migraine medications using the usual primary endpoint of 
relief of headache.12–20 More limited data for patient satisfaction show similar trends.9 A limitation 
of these data is that, as secondary analyses, they were not subject to rigorous statistical 
analyses. 
 
Patients’ assessment of their preference for their migraine treatments may therefore be a valid 
and sensitive measure of clinical efficacy that is relevant to real-life clinical practice, taking into 
account both efficacy and tolerability. The results also indicate that patient preference may be a 
more sensitive measure of efficacy and clinical utility than conventional clinical trial endpoints, 
although this remains to be proven in rigorously designed clinical studies. Another limitation of 
the data is that patients’ preferences are individual and not predictable beforehand, possibly 
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being based on individual biological and/or clinical factors.9 Despite this, physicians should 
consider using assessments of patient preference when reviewing the efficacy of acute migraine 
medications, based on the author’s clinical experience. It is important that new instruments to 
assess preference/ satisfaction are appropriately developed and tested. It would be good to 
have a standard instrument that is used in all studies to make the findings more easily 
comparable. 
 
Assessing headache-related disability 
Headache can be a significantly disabling condition, as defined by the World Health 
Organization as a condition resulting in limitations to daily activities.21 Migraine is particularly well 
categorised as being disabling. Numerous studies (reviewed in Chapter 4.1) demonstrate that 
migraine results in sufferers being unable to conduct their everyday daily activities (employment, 
household tasks and family and leisure activities) during their attacks.22 The studies of Lipton, 
Stewart and colleagues elegantly demonstrate that disability rather than pain severity is the key 
measure of migraine severity.23 Tension-type headache (TTH) is generally thought to be a 
relatively non-disabling condition in terms of pain and headache-related disability.24 The study 
assessing emotional impact of headache with the SPI questionnaire (Chapter 3.4) indicated that 
the pain associated with TTH was indeed transient and mild-to-moderate intensity. However, the 
results showed a marked chronic sedation associated with TTH25 that has been noted once 
before.26 These data may indicate that the disability associated with TTH is currently under-
estimated. The same study showed that chronic daily headache (CDH) was associated with 
chronic pain and emotional impact that was severe in intensity.25 These data confirm the well-
recognised severe disability associated with CDH,27 but extend the impact into the emotional 
domain. From all these data, it is clear that physicians should ask headache patients about their 
level of disability before deciding on a management plan, although it seems that few currently do 
so.28 In fact, information on disability does change the physician’s perception of illness severity 
and subsequent handling of management.28 
 
There are currently limited data on the use of disability or impact tools as endpoints in clinical 
studies. However, two studies have shown that the MIDAS questionnaire is sensitive to change, 
and can be used to monitor patients with migraine or CDH in the clinic.29,30 The HIT 
questionnaire has been much less studied in this regard and, as described in Chapter 4.3, may 
be more useful as a diagnostic tool than as a measure of headache severity.31 Both MIDAS and 
HIT capture retrospective data, over 3 months and 1 month, retrospectively.22 The SPI 
questionnaire collects prospective data,32 and may therefore be a better clinical study endpoint 
than either MIDAS or HIT, although this can only be demonstrated with further studies. 
 
Recognising headache-related disability 
As already described, assessing headache-related disability is important in the clinical 
evaluation of headache. It is therefore important that the physician is able to recognise patients 
who are disabled and to manage them accordingly. The level of disability also needs to be 
monitored over time, and this aspect of recognising disability was assessed in two studies in this 
thesis: 
• Investigating the level of disability associated with headaches occurring inside and 
outside the menstrual period 
• Investigating the emotional impact of different headache subtypes over time.  
 
Disability associated with headaches occurring inside and outside the menstrual period  
The study described in Chapter 3.3 provided a snapshot of headache in women attending a 
primary care clinical practice, and also provided information on their level of depression and 
bodily pain.33 Patients who completed an initial questionnaire reported high levels of headache, 
  186 
depression and bodily pain. About two-thirds of patients reported headache, over 50% 
symptoms indicative of depression, and about 40% bodily pain. The symptoms were reported 
across all age groups. Overall, the results indicate that headache, depression and bodily pain 
are common in the general adult female population and that many patients clearly have multiple 
symptoms. Physicians would benefit from asking patients about their levels of pain and mood 
disturbance. Headache is frequently co-morbid with psychiatric disorders (particularly major 
depression and anxiety),34 and patients with multiple co-morbidities are likely to require more 
care than those with a single condition. 
 
Migraine sufferers in this study were invited to complete a disability questionnaire encompassing 
some of the items now contained in the MIDAS questionnaire over a 2-month period, covering at 
least a full menstrual period. However, this was not a MIDAS study, being designed before the 
full development of the MIDAS questionnaire. The data showed that migraine headaches were 
relatively more frequent inside than outside the menstrual period, while non-migraine headaches 
were approximately equally distributed inside and outside the menstrual period. This data for the 
distribution of migraine attacks is in line with recently published data.35 The study also showed 
that migraine attacks that occurred inside the menstrual period were somewhat more disabling 
than those occurring outside the menstrual period in terms of rank sums of the MIDAS items of 
time lost and time at less than 50% productivity. These results are in line with a recent study 
indicating that menstrually-associated migraine attacks were only slightly more painful than non-
menstrually-associated ones,36 but not with another study indicating that attacks during 
menstruation were markedly more disabling than those occurring outside the menstrual period.35 
Results for non-migraine headache were the opposite of those for migraine, with attacks 
occurring outside the menstrual period scoring numerically, but not significantly, higher than 
those occurring inside the menstrual period in terms of the rank sums of time lost and time at 
less than 50% productivity. These data indicate that the pattern of headache-related disability 
can differ at different time periods in the patient’s life and also with respect to the different 
headache subtypes experienced by the patient. They emphasise the importance of a correct 
diagnosis (or diagnoses) and the monitoring of patients over time with a headache diary or other 
form of questionnaire. 
  
The emotional impact of different headache subtypes over time 
The study described in Chapter 3.4 categorised the emotional impact of episodic TTH, migraine 
and CDH with the SPI questionnaire.25 This allowed the analysis of the emotional ‘footprint’ of 
each headache subtype in terms of the emotional experience, associated sedation, disruption to 
social interactions and the time course of each of these components. Patients recorded their 
headaches with the SPI at peak intensity and at intervals for 7 days afterwards. 
 
At peak intensity the pain level was mild-to-moderate for episodic TTH, and patients exhibited 
sedation, disturbances in social interaction, sadness, anxiety and anger. These symptoms all 
resolved within 24 hours, except for sedation, for which marked levels persisted for most of the 
following week. Coping scores for sedation were the most disturbed of all the three types of 
headache, even including CDH. This is surprising, considering the relatively mild intensity of 
TTH. Sedation may be a precipitating factor for TTH or a feature of the recovery process that is 
unrelated to the headache severity. Also, coping scores for sadness were sometimes above the 
normal range for 3 out of the 7 days post-headache. The results indicate that TTH patients have 
mood lability and may mean that the illness severity of patients is currently underestimated by 
physicians.  
 
At peak intensity the pain level was moderate-to-severe for migraine and patients exhibited 
sedation, disturbances in social interaction, sadness, anxiety and anger. In general, the severity 
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of these emotional components was more intense for migraine than for TTH. All these symptoms 
typically resolved within 2 days of the headache and coping scores were at normal levels after 
the headache. These data indicated that the patients coped well with the emotional symptoms, 
which resulted from the level of physical pain experienced.  
 
At peak intensity the pain level was severe for CDH and patients exhibited sedation, 
disturbances in social interaction, sadness, anxiety and anger. In general, the severity of these 
emotional components was more intense for CDH than for TTH. However, these symptoms were 
maintained over the 7-day period following the headache. Pain remained at a mild-to-moderate 
level. Marked levels of sedation, disturbed social interaction, sadness, anxiety and anger were 
also seen during this period. The coping scores for sedation, social interaction and sadness 
were above the level caused by the pain. The result is that CDH patients are chronically 
fatigued. CDH is associated with Chronic Fatigue Syndrome37 and sedation is a major feature of 
the post-dromal period of CDH. Overall, the level of emotional disturbance experienced by CDH 
patients was similar to that seen in patients attending chronic pain clinics.38 An unfortunate 
feature of CDH patients is that their mood disturbance never returns to normal and patients 
obtain no respite from the pain and its emotional consequences. This pattern of emotional 
impact associated with CDH is similar to that reported in a qualitative study.39 
 
Overall, patients with TTH, migraine and CDH all had considerable mood disturbances during 
their headaches. The more severe the pain they experienced, the greater was the level of mood 
disturbance. The level of mood disturbance was also directly related to the healthcare utilisation 
of the patients. The pattern of mood disturbance was different for each type of headache, as 
was the patients’ ability to cope with the mood changes. The association of mood disturbances 
with common headache subtypes may explain in part the reported co-morbidity of headache 
with psychiatric disorders.34 Physicians should elicit the emotional needs of their headache 
patients, which may not be currently appreciated or addressed by healthcare services, as they 
play no part in the current classification criteria for headache.24  
 
Assessing headache-related disability 
Chapters 3.3 and 3.4 show that disability is a key feature of headache, and can differ in intensity 
and quality in different headache subtypes and in individual patients over time.25,33 Assessing 
headache-related disability should therefore have utility in monitoring patients, as an outcome 
measure and possibly for other assessments. A review of the methodological robustness and 
clinical utility of disability and impact questionnaires was conducted for the thesis (Chapter 4.1)22 
as well as a series of studies investigating the utility of disability questions in diagnosis 
(Chapters 4.3 and 4.4)31,40 and as outcome measures for patient assessment (Chapters 4.2, 4.5 
and 4.6).41–43  
 
Reviewing disability measures for headache 
Research (reviewed in Chapter 4.1) has shown that headache-related disability and impact can 
be measured using assessments of some or all of pain severity, headache frequency, limitations 
to work and leisure activities, tiredness, mood alterations and cognition. Disability-based 
measures include the MIDAS, HIT and SPI questionnaires, all of which are now available for 
clinical use.22  
 
The MIDAS questionnaire retrospectively measures headache-related disability as time lost (as 
the number of days) in employment, unpaid work and family and leisure activities. Numerous 
studies have shown that it is reliable,10 valid,10 sensitive to change29,30 and exhibits considerable 
clinical utility in the clinic.44 HIT (either in the Internet45 or paper-based HIT-646 forms) 
retrospectively assesses a global range of impact, including pain intensity, disability and other 
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items. HIT is also reliable and valid,45,46 and has some evidence of clinical utility for assessing 
diagnosis and headache severity in the clinic.47,48 Chapter 4.3 of this thesis indicates that HIT is 
a good diagnostic tool but a relatively poor tool for assessing headache severity.31 The SPI 
questionnaire prospectively assesses pain intensity and emotional impact of the headache over 
time.32 It is also reliable and valid,49 and can distinguish the emotional components of different 
pain states50 and, as shown in Chapter 3.4, those of different headache subtypes.25 Synthesising 
the available evidence, it would seem that HIT can be used for headache diagnosis, and MIDAS 
and SPI for assessing headache severity and as outcome measures in clinical studies. MIDAS 
has been shown to be a useful outcome tool in different headache disorders,29,30 and we await 
similar evidence from studies with SPI. 
 
The assessment of headache-related disability is a key item of recently published migraine 
guidelines in the USA1 and migraine and CDH guidelines in the UK.51,52 It is used to improve 
communication between physicians and their patients and, with other measures, to assess 
headache severity to tailor treatment to each patient’s individual needs. However, although used 
a lot in specialist clinics, disability tools have not yet penetrated significantly into primary care. 
They seem to be relatively unknown and the clinical experience of the author shows them to be 
too complex for patients to complete unaided. Clearly, educational initiatives are needed to 
promote the use of disability tools in primary care. However, physicians should enquire about 
disability and a simple question such as: How do your headaches interfere with your normal 
daily activities? may be sufficient to start a discussion and obtain relevant clinical information 
from the patient. 
 
Utility of disability questions in headache diagnosis 
Already discussed are the results from Chapter 4.3 investigating the clinical utility of the HIT and 
SPI questionnaires. The results showed that the Internet version of HIT is very good at 
differentiating the diagnosis of TTH, migraine and CDH.31 HIT was not designed to be a 
diagnostic tool, but to measure the impact headaches have on a person’s ability to function at 
work, at home, at school and in social situations. Indeed, the developers state that HIT is not a 
diagnostic tool.45 We can only speculate on the factors within the HIT questionnaire that are 
associated with diagnosis. HIT assesses a constellation of factors: headache-related pain 
severity and disability, the need to lie down, tiredness and mood alterations. As SPI assesses 
emotional function and is not a diagnostic tool, it seems unlikely that tiredness and mood 
alterations correlate with diagnosis. However, pain severity24 and disability27,47 do differ between 
the three headache subtypes, and these seem the most likely drivers of diagnosis, at least in the 
HIT questionnaire. Whatever the case, HIT does discriminate between headache subtypes very 
well and, should a neurologist be not available, is a good diagnostic test.  
 
Chapter 4.4 describes the development and testing of the 8-item DSQ, designed to be an 
inclusive diagnostic aid for headache to be used at the patient’s first consultation with a 
healthcare professional.40 The items assessed were headache frequency, duration and related 
disability, together with frequency of use of analgesic medications, prevalence of aura symptoms 
and a series of questions eliciting potential sinister headaches. The study showed that the DSQ 
was simple to complete, either by the patient on their own or in concert with a healthcare 
professional. Overall, the DSQ exhibited good diagnostic sensitivity (of about 60%) when 
completed by the patient or the pharmacist, especially for total migraine, migraine with and 
without aura and MOH. These results indicate that the DSQ is an effective inclusive tool for the 
differential diagnosis of headache. Interestingly, the accuracy of the pharmacists’ headache 
diagnosis was improved markedly when they used the DSQ, providing evidence of clinical utility.  
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Again, it was not possible to identify the DSQ items that correlated best with diagnosis. 
Compared with the HIT questionnaire, an item on disability was present, while one on pain 
severity was not. It is tempting to speculate that the assessment of headache-related disability, 
in concert with other headache features, is the main predictor of diagnosis. Such a pattern is 
seen in other recently-developed diagnostic questionnaires for headache. With the inclusive 
Brief Headache Screen, migraine, daily headache syndromes and medication overuse were 
distinguished using three questions: the frequency of disabling headache, the presence of other, 
mild headaches and the use of symptomatic medications.53 Migraine exclusively could be 
diagnosed sensitively and specifically using three questions on headache-related disability, 
nausea and sensitivity to light,54 or three questions on disability, headache duration and the lack 
of new-onset headaches in the previous 6 months.55 There is considerable overlap between the 
DSQ and these other inclusive and exclusive questionnaires in terms of assessing disability, 
together with other headache features and symptoms, which reinforces the content and external 
validity of the DSQ questionnaire.23 
 
The DSQ is therefore a useful headache screening questionnaire for use when the patient first 
seeks care for the condition from a healthcare professional, who may be a GP, nurse, 
pharmacist or other practitioner (e.g. opticians and dentists often see people with headache). Its 
principal use is proposed to be an aid to deciding the appropriate first management decisions. It 
may be particularly suitable for use by pharmacists, which is of clinical importance as they may 
see more headache sufferers than do GPs.56  
 
Utility of disability questions as outcome measures for patient assessment 
Two studies are included in this thesis investigating the use of disability questions to assess 
patient outcome. 
1. Chapter 4.2: the clinical utility of the MIDAS questionnaire when used by nurses 
at patient screening41 
2. Chapters 4.5 and 4.6: the methodological robustness and clinical utility of the 
Migraine-ACT questionnaire, which contains two items on disability.42,43 
 
In Chapter 4.2, the MIDAS questionnaire was used to monitor new patients with mild-to-
moderate headache at baseline and for 6 months after being provided with headache advice by 
a specialist nurse.41 The patients had significantly improved headache outcomes 6 months later 
in terms of headache-related disability, headache frequency and severity, all assessed with 
MIDAS. Additionally, they perceived an improvement in headache and reported a reduced need 
for consulting a physician for headache. As very few patients consulted a physician during the 
study, this improvement could be attributed to the advice given by the nurse on headache 
management, despite the absence of a control group. The study also adds to the published data 
indicating that MIDAS may be a sensitive outcome measure for headache sufferers.29,30 
 
It is worth noting that the simple provision of advice can lead to a sustained significant 
improvement in headache, although previous small studies have suggested the same effect.57,58 
Recently published headache guidelines have advocated the provision of advice and information 
to patients at headache screening,51,52 and this study illustrates how effective this strategy can 
be. The practice nurse has a positive role in the management of headache in primary care, 
particularly with respect to screening and follow-up, and guidelines dedicated for nurse use have 
been published.59 These recommendations state that nurses should undertake information 
dissemination and recording of data using headache history and impact questionnaires and 
headache diaries.  
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Chapters 4.5 and 4.6 outline the development of a new outcome questionnaire, Migraine-ACT, 
to assess the need to change a migraine patient’s acute medication.42,43 This somewhat limited 
functionality is, however, clinically important due to the fact that acute medications are usually 
under-used, despite the availability of effective treatments today.60–63 Four clinically-relevant 
domains were included in the questionnaire: impact,23,54 global assessment of relief,5,64 
consistency of response5,65 and emotional response.25,31 Twenty seven questions were 
developed and reduced to four (one in each domain) by testing for reliability and validity. The 
tool was designed from the outset to be brief, and simple to complete and score by yes/no 
answers. The use of clinically-relevant domains provides prior evidence of face validity.  
 
The individual 27 Migraine-ACT questions all exhibited good-to-excellent test-retest reliability in 
the total population and within the five countries taking part in the study. Assessment of 
construct validity demonstrated that many of the 27 Migraine-ACT items correlated with the SF-
36 QOL questionnaire,11 the MIDAS questionnaire10 and the MTAQ disease management 
questionnaire66 and allowed selection of the best four items in the final questionnaire. The four-
item Migraine-ACT questionnaire was highly reliable and valid. In assessing the impact items, 
the ability to function normally after treatment (a measure of headache-related disability) was 
markedly more discriminating than other measures. Numerous studies have previously indicated 
that the disruption of patients’ everyday activities is the key measure of illness severity in 
migraine patients.23,54,55,67,68 In addition, the resolution of headache at 2 hours provided a more 
discriminating assessment of global response than other items tested, agreeing with data from 
other studies.5,64,69 
 
The total Migraine-ACT score is achieved by summing the answers to the four items without 
weighting (‘yes’ = 1 and ‘no’ = 0). A score of 4 corresponds to the physician not needing to re-
evaluate the patient while 0 corresponds to a very high need for re-evaluation. Scores of 2, 1 
and 0 correlated with lower than average quality of life,11 MIDAS scores equivalent to severe 
disability10 and MTAQ scores above the threshold for when follow up is deemed warranted.66 
From these data, it was deduced that a Migraine-ACT score of 2, 1 and 0 identifies patients for 
whom a change in acute treatment may be warranted. These patients have reduced quality of 
life, severe headache-related disability and a considerable number of outstanding management 
issues. It was suggested that a score of ≤ 2 may indicate that a change in the patient’s acute 
medication is warranted and a score of ≤ 1 may indicate that the change is mandated.43 
 
The 4-item Migraine-ACT questionnaire is therefore a rapid, reliable, brief, simple to complete 
and score assessment tool, which can be recommended for everyday clinical use by the clinician 
to identify patients who require a change in their current acute migraine treatment. Table 1 
summarises the key features of the questionnaire. 
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Table 1. Features of the Migraine-ACT questionnaire. 
 
Property Feature of Migraine-ACT questionnaire 
Objective  Assess the need to change a migraine 
patient’s acute medication 
Questions  Four yes/no questions on headache-
related disability, global response, 
consistency of response and emotional 
impact 
Scoring  5-point scale (0–4), with a score ≤ 2 
indicating that a change in acute 
medication is warranted 
Reliability, validity and potential clinical 
utility 
Good 
Who conducts the questionnaire  Physician (primary care or specialist) 
 
5.2 Implications: methodological, research and clinical 
 
The importance of assessing headache-related disability was first identified by Lipton, Stewart 
and colleagues several years ago. This research led to the understanding that disability is the 
key driver of headache severity,23 and to the development of the MIDAS questionnaire.10 The 
literature searches and studies outlined in this thesis have extended the knowledge of disability 
assessments and expanded their potential use in research and in the clinic in several areas: 
Methodological 
1. The type of naturalistic, longitudinal clinical studies used in this thesis are suitable for use 
in primary care and produce clinically-meaningful results, as described above. The 
potential advantages of this type of study over the conventional controlled or open-label 
clinical study are:  
a. Real-life patients are more representative of the general patient population than 
the selected groups of patients seen in conventional clinical studies, where 
children, women pregnant or wishing to become pregnant, patients with some co-
morbidities and older people are usually excluded. 
b. Fewer patients may be required in order to achieve the clinical effect. 
c. Commercially-available drugs, doses and formulations are used according to 
everyday clinical practices, allowing real-life comparisons. 
d. The long-term effectiveness of treatment is investigated, rather than the efficacy 
at a point in time. 
 
Research 
1. Conventional clinical study endpoints for headache may be relatively insensitive.3 MIDAS 
is now frequently used as an endpoint and we now have the Migraine-ACT 
questionnaire, based on disability and symptom relief, which shows promise as a new 
study endpoint. 
2. There is an emotional component associated with headache-related disability, 
encompassing sedation, poor social interaction, sadness, anger and anxiety. The pattern 
of the emotional disturbances varies in different headache subtypes. 
3. All disability and impact measures are not the same. HIT is more a diagnostic tool than a 
severity tool. MIDAS and SPI are tools that assess headache severity and not diagnosis. 
Clinical  
1. The pattern of disability related to headaches can differ at different time periods in the 
patient’s life and also with respect to the different headache subtypes experienced by the 
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patient. This emphasises the importance of the physician’s correct diagnosis (or 
diagnoses) and their prospective monitoring of patients over time. 
2. Physicians should assess headache-related disability when they evaluate their headache 
patients. One of the available questionnaires (MIDAS, HIT or SPI) can be used, or just a 
simple question about the disturbance to daily activities may help to start discussions and 
reveal clinical information. 
3. Assessments of disability play key roles in the management of headache: 
a. Improving communication between the healthcare professional and the patient. 
b. As part of the diagnostic procedure. Perhaps few physicians will use HIT alone for 
diagnosis, but HIT, or a general question on disability can provide valuable 
diagnostic information and is useful for case finding.  
c. As part of the assessment of headache severity, helping to tailor treatment to 
each patient’s individual needs. 
e. As an integral part of primary care guidelines for headache, so guiding treatment 
choice. 
f. Assessing disability is a suitable job for the practice nurse, and forms a key part 
of their role in headache management. 
4. The DSQ is a sensitive inclusive tool for the screening of headache sufferers when they 
first present for care. It contains one question on disability, together with other questions 
on different headache features. It has considerable potential clinical utility in the 
management of headache in primary care. Patients should be able to obtain a copy at 
their first point of care, whether a GP surgery, pharmacist, optician, dentist or other 
provider. They can complete the DSQ, either at home by themselves or with the help of 
the practitioner. The practitioner then reviews the DSQ and provides appropriate advice. 
Using the questionnaire, there is the potential for earlier and better headache diagnoses. 
The DSQ may be particularly useful to pharmacists. Following pharmacist intervention, 
patients can either be treated immediately or, if appropriate, be empowered to obtain 
help from the GP sooner rather than later.  
5. The MIDAS questionnaire is also suitable for first-line use in the clinic. Patients identified 
with a marked level of disability can have improvements in their headaches simply by 
receiving appropriate information from a nurse or other healthcare professional.  
6. The Migraine-ACT questionnaire has been developed as a rapid, reliable and accurate 
screener to identify patients whose current acute treatment regimen needs to be 
changed. It contains four questions on headache-related disability, emotional impact, and 
response to treatment. It is intended for use by the primary care physician in everyday 
clinical practice. A score of 2, 1 or 0 is suggested as being indicative of the need to 
change medications. 
 
5.3 Methodological issues and suggestions for future research 
 
As well as advantages, the naturalistic studies conducted for this thesis have several potential 
disadvantages that need to be taken into account when evaluating the results: 
1. The studies were relatively small in terms of numbers of patients and sometimes in 
duration. 
2. The open design means that results could not be unequivocally assigned to the 
intervention used. Other factors, e.g. a placebo response, could bias the results.  
3. The studies may not have been powered appropriately. 
4. Asymmetries of design may have occurred. 
5. Some of the questionnaires used were not validated. 
Each study is now considered in turn for its methodological robustness and the potential for 
future research. 
  193 
 
Chapter 3.3: Disability associated with headaches occurring inside and outside the 
menstrual period 
This study investigated the prevalence of headache, depression and bodily pain in women 
attending a UK general practice. The disability associated with migraine and other headache 
attacks occurring during and outside the menstrual period was assessed in those women with 
migraine. Results showed that the patients reported a high prevalence of headache, depression 
and bodily pain. For migraine sufferers, migraine attacks that took place during the menstrual 
period tended to be more disabling than those taking place outside the menstrual period, but the 
opposite was true for non-migraine headache.  
 
The questionnaires (headache, depression and bodily pain) used in the first part of this study 
were not validated tools, but were devised by the investigators to be simple to use and 
potentially applicable to primary care clinical practice. They were not tested for reliability or 
validity, and additional studies would be required for this. Despite this, headache subtype and 
the severity of depression and bodily pain were identified for each patient. The prevalence of the 
headache subtypes was close to expected values, although depression was probably over-
estimated. Future work on this topic should probably use validated diagnostic questionnaires for 
headache (e.g. the DSQ)40 and depression (e.g. the Beck Depression Inventory).70  
 
The design of this prevalence study was also not optimal. Additional items that should have 
been taken into account included defining the sample in relationship to the population under 
study, random sampling, defining an acceptable response rate (> 50%), and conducting a non-
response analysis. There was the possibility of the responders being a self-selecting population 
with significant problems, although the similarities in age range between the responders and the 
total population argues against this. 
 
Part 2  
The menstrual headache questionnaire used in Part 2 of the study was also not validated. 
However, it was based on the IHS diagnostic criteria pertaining at the time71 and contained items 
now used in the MIDAS questionnaire.10 It therefore contained items with proven reliability and 
validity. However, the questionnaire should be tested for reliability if it is used again. This in fact 
seems unlikely to happen, as the MIDAS questionnaire could be used in its place. 
 
Some methodological issues were raised by the study analyses that have implications for the 
design of future studies. The data were confounded by the fact that some of the events were 
repeatedly measured in individual patients, and that some patients only had one type of 
headache. A much larger sample of patients would be necessary to allow both within and 
between patient group comparisons. The results should be taken with caution as data were 
analysed between the groups for only 30 patients experiencing 203 headache attacks. However, 
non-parametric testing with the Mann-Whitney U Test showed one significant and one marginally 
significant result from only four analyses, which indicates that the results were unlikely to have 
arisen by chance. Analysis of means or medians was not a useful measure in the present study 
because the data were not normally distributed. Many headache attacks scored zero on the two 
analyses, leading to floor effects being observed. Such floor effects have been reported with use 
of the MIDAS Questionnaire, on which the analyses were based.72 Future studies may benefit 
from using assessments of headache impact which provide a normal distribution of results, such 
as the Headache Impact Test45,46 or the Short Pain Inventory.32 
 
This study is best considered a pilot investigation of questionnaires to assess headache, 
depression, bodily pain and the disability associated with headache. While the methodology 
  194 
used has been superseded by more recent developments, it served to investigate new ways to 
measure headache-related disability at a time when validated questionnaires were not available 
for headache. Such studies are necessary in the development of new tools and their publication 
serves scientific accountability.  
 
Chapter 3.4: the emotional impact of different headache subtypes over time 
In this prospective, within-group, comparative study, the SPI was used to assess how the mood 
disturbances and coping abilities change over time in patients with episodic TTH, migraine and 
CDH attending a primary care headache centre. The healthcare resource utilisation of these 
patients was also assessed retrospectively. The results showed that patients with headache had 
significant emotional symptoms associated with their headaches. These symptoms resolved 
within 1–2 days for patients with episodic TTH and migraine. However, patients with CDH were 
profoundly affected, and did not improve physically or emotionally from their headache over a 7-
day period. Headache patients generally experienced higher levels of sedation than did patients 
with other pain conditions. 
 
The limitations to this study are discussed below in the text on Chapter 4.3 
 
Chapter 4.3: comparison of HIT and SPI 
This sub-analysis of study 3.4 above compared the psychometric properties of the Headache 
Impact Test (HIT-DYNA®) with the 17-item Short Pain Inventory (SPI©) and the abilities of the 
SPI and HIT in terms of discriminating headache severity and diagnosis. The results showed the 
HIT to be poorly related to the severity of the pain but very closely related to the diagnostic label. 
In contrast to this, the SPI was very closely related to severity but not related to diagnosis.   
 
In the two chapters based on this study (3.4 and 4.3), relatively small numbers of patients took 
part, and a high proportion of patients did not experience a headache (especially those with 
TTH) and hence did not complete a SPI questionnaire in the 6 weeks allowed. A longer study 
duration could have led to a reduction in the drop out rate. The healthcare utilisation analysis 
was performed with retrospective collected data, for practical reasons. Of course, a prospective 
design would have been more powerful. Patients from a primary care headache centre were 
recruited so that, as far as possible, criteria for a naturalistic study were met. 
 
SPI is now a well-established questionnaire that can be used to assess any pain state.32,38,50 It is 
available to interested healthcare professionals at www.headachetest.co.uk and can be 
completed on-line. Future studies should include SPI as an endpoint in controlled studies of 
headache treatments, in comparison to more conventional endpoints (including other disability 
questionnaires).  
 
Chapter 4.2: the clinical utility of the MIDAS questionnaire when used by nurses at patient 
screening  
This audit assessed the outcome of a nurse intervention strategy in patients presenting with 
headache to a primary care surgery. The results showed that advice on headache management 
given by a nurse led to significant improvements in the patients’ outcomes. MIDAS appeared to 
be a sensitive outcome measure for reduction in disability in headache sufferers.  
 
The main shortcoming of this study was that it was uncontrolled. As no control group was 
included, the reductions in MIDAS and other items could have been due to a placebo effect. 
Nevertheless, there was good evidence of significant improvements in MIDAS items and 
significant reductions in headache consultations, as parametric and non-parametric analyses 
exhibited the same patterns of results.  
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A further shortcoming was that the numbers of patients reduced as the visits proceeded due to 
drop outs. This could have caused some bias, leading to an improvement in the patients’ 
condition. This is because, psychologically, patients are more likely to continue with an 
investigation if they are generally feeling well or better than if they are deteriorating or have no 
change in their condition. However, the results were promising enough to pave the way for 
future randomised, controlled studies investigating the role of nurses in headache management. 
 
Chapter 4.4: utility of disability questions in headache diagnosis 
This prospective, open investigation was set up to validate the 8-item Headache Diagnostic 
Screening Questionnaire (DSQ), containing questions screening for possible sinister symptoms, 
and evaluating headache impact, frequency and duration, the use of symptomatic medications 
and the presence of migraine aura symptoms. The results showed that the Headache DSQ is a 
brief, rapid to use and accurate diagnostic screening questionnaire for headache, and is 
especially sensitive for migraine and MOH. It can be recommended for screening new headache 
patients at and below the primary care level. 
 
Some weaknesses were observed in this study. The study was not properly randomised, with 
alternate patients being openly assigned to seeing the pharmacist or GP first. The study was not 
large enough to determine whether the order of seeing these healthcare professionals had any 
effect on the results. However, the pharmacists and GPs were blind to each other’s 
assessments. The entry criteria for numbers of patients with episodic TTH and cluster headache 
were not met by the patients recruited into the study. For this reason the specificity of the DSQ 
could not be assessed.  
 
The accuracy of the DSQ for CDH without MOH was poor, and patients tended to underestimate 
the duration and/or the frequency of their headaches. Additionally, migraine patients sometimes 
confused aura symptoms with prodromes when answering question 8 (Do changes in your 
senses (sight, taste, smell or touch) occur before the headache starts?). Small changes were 
made to the questionnaire to rectify these points, as part of its ongoing development. A follow-up 
randomised study with the modified DSQ is warranted to assess its sensitivity and specificity. 
Further studies with the DSQ could also be conducted in specialist headache clinics (where 
cluster headache patients are more common and could be assessed) and in pharmacies (where 
episodic TTH sufferers may be encountered frequently and could be assessed). In addition, it 
would be interesting to see if GPs’ diagnostic accuracy could improve to the specialist level if 
they had access to the DSQ. 
 
However, the value of this study is that the Headache DSQ as developed is a brief, rapid to use 
and accurate diagnostic screening questionnaire for headache, and is especially sensitive for 
migraine and MOH. The DSQ, and other questionnaires, demonstrate the utility of incorporating 
assessments of disability into diagnostic questionnaires. It is recommended for screening new 
headache patients at and below the primary care level, although future studies will more fully 
define its place in the clinic. 
 
Chapters 4.5 and 4.6: development and testing of the Migraine-ACT questionnaire 
This study designed and tested a new 4-item assessment tool, the Migraine Assessment of 
Current Therapy (Migraine-ACT) questionnaire for use by clinicians, to quickly evaluate how a 
recently prescribed acute medication is working, and to identify patients who require a change of 
their current acute treatment. The results showed that Migraine-ACT, containing four questions 
on headache impact (measured as headache-related disability), global response and 
consistency of response to therapy and emotional impact, was reliable, valid, easy to use and 
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score, and exhibited considerable potential clinical utility. Migraine-ACT can be recommended 
for everyday clinical use by clinicians. 
 
The Migraine-ACT study used rigorous methodology to confirm the reliability and validity of the 
questionnaire. The result is a robust questionnaire that is suitable for use in research and in the 
clinic. However, additional studies are required to further examine the clinical utility of Migraine-
ACT, to define the score that indicates a change in treatment is needed, and to investigate its 
sensitivity to change for use as an outcome tool in comparison to other endpoints. The study 
was conducted in secondary care referral centres. Studies in primary care practice are 
particularly needed to demonstrate the utility of Migraine-ACT in the everyday management of 
migraine. The main use of Migraine-ACT is likely to be in primary care, and naturalistic studies 
conducted in this domain will determine the true utility of the questionnaire. Pharmacists and 
nurses may also find the questionnaire useful and studies with these professionals would also 
be valuable. 
 
5.4 Final remarks 
 
The research and studies contained in this thesis have confirmed the clinical importance of 
assessing disability when managing headache patients. Disability assessments play key roles in 
the screening, diagnosis and treatment of these patients. While there is no definitive method to 
measure disability, several tools are available and have utility in diagnosis (HIT), assessing 
headache severity and monitoring treatments (MIDAS) and in assessing emotional disability 
(SPI). Disability assessments also play key roles in the development of other questionnaires. 
The DSQ sensitively screens for diagnosis using questions on disability and other headache 
features, features consistent with those of other diagnostic questionnaires. Migraine-ACT 
assesses the need to change acute medications using questions on headache-related disability, 
emotional impact, and overall response and consistency of response. While these 
questionnaires require further development, physicians are now closer to the goals of having 
definitive diagnostic and outcome measures in their armamentarium. 
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6 
 
Summary 
 
 
Introduction 
The main aim of this thesis is to investigate the clinical significance of headache-related 
disability; the clinical importance of assessing disability, the means of recognising the patients 
with severe disability and the development of new ways to assess headache-related disability 
and their utility in clinical practice. The main methodology used in the thesis was critical reviews 
of the literature and open, naturalistic studies designed to mimic the situation in everyday 
primary care clinical practice.  
 
Clinical significance of headache-related disability 
In Chapter 3.1, the factors involved in the understanding of clinical study evidence are reviewed, 
and new study endpoints discussed that may be relevant to headache clinical practice. Large, 
randomised, double-blind, controlled clinical trials form the gold standard of clinical evidence for 
evaluating new medications. Meta-analyses and post hoc analyses of existing trials are 
increasingly used to compare therapies, but should not be used on their own to evaluate 
therapies. Controlled clinical trials evaluating triptans in the acute treatment of migraine 
demonstrate clear superiority of the drugs over placebo, but only small differences are reported 
in studies comparing individual triptans and triptans with non-triptan medications. In contrast, 
patients can clearly distinguish between triptans and non-triptans and between different triptans 
in clinical practice. This incongruity may be due to the relative insensitivity of the standard 
clinical trial endpoint, relief of headache. New and more sensitive clinical trial endpoints are 
required for use in clinical studies that reflect everyday general practice (naturalistic studies). 
Among the potential endpoints are assessments of patient preference, impact on the patient’s 
daily life and quality of life. However, novel endpoints should be developed, in collaboration with 
patients, which can summarise the whole migraine experience. 
 
Chapter 3.2 reviews the evidence that patient preference may be a clinical study endpoint that 
is useful in headache clinical practice. Patient preference assesses a global measure of efficacy 
and tolerability, and may be a valid and sensitive means of distinguishing between the triptans. 
In a series of studies, patients consistently expressed a clear preference for triptans over their 
usual non-triptan acute medications, e.g. analgesics and ergotamine. Direct comparator studies 
of patient preference with oral triptans showed that patients could distinguish between different 
triptans, and between different formulations of the same triptan. Patients could even distinguish 
between the three oral doses of sumatriptan. The most frequently provided reasons for 
preference were speed of response and overall effectiveness. Patient preference may therefore 
be a sensitive and valid clinical trial endpoint and physicians should consider using it when 
reviewing the efficacy of acute migraine medications. 
 
Chapter 3.3 describes a study that investigated the prevalence of headache, depression and 
bodily pain in women attending a UK general practice. The disability associated with migraine 
and other headache attacks occurring during and outside the menstrual period was also 
assessed in those women with migraine. Women aged 14–50 years completed two 
questionnaires. The first questionnaire assessed the point prevalence of headache and bodily 
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pain, and the 5-year prevalence of depression in the total population. The second questionnaire 
assessed the disability of all headaches over a 2-month period (to capture a complete menstrual 
cycle) for patients reporting migraine who were still menstruating. Disability was assessed as the 
time lost and time spent at less than 50% productivity in normal activities due to headache, and 
analysed as rank sums using the Mann-Whitney U Test. The first part of the study showed that 
the prevalence of headache (66.1%), depression (55.4%) and bodily pain (40.6%) were high in 
this population of women. In the second part of the study, for migraine, the rank order of time at 
less than 50% productivity was significantly greater for attacks taking place inside the menstrual 
period than for those occurring outside the menstrual period (p=0.01). For non-migraine 
headaches, the time lost appeared to be numerically greater for attacks taking place outside the 
menstrual period than for those occurring inside the menstrual period, and the comparison 
approached significance (p=0.06). In conclusion, the patients reported a high prevalence of 
headache, depression and bodily pain. For migraine sufferers, migraine attacks that took place 
during the menstrual period tended to be more disabling than those taking place outside the 
menstrual period, but the opposite was true for non-migraine headache.  
 
Chapter 3.4 describes a prospective, within-group, comparative study, in which the Short Pain 
Inventory (SPI©) was used to assess how the mood disturbances and coping abilities changed 
over time in patients with episodic tension-type headache (TTH), migraine and chronic daily 
headache (CDH) attending a primary care headache centre. The healthcare resource utilisation 
of these patients was also assessed retrospectively. 
Patients completed the SPI 10 times over a 7-day period, starting 1 hour after the onset of their 
next headache. The SPI data were analysed statistically as Z scores and coping Z scores for the 
Total Pain Disturbance, Total Mood Disturbance, and individual sub-scores for sedation, social 
interaction, sadness, anxiety and anger. Data from the healthcare resource utilisation 
questionnaire were analysed as descriptive statistics. Seventy five patients completed the 
healthcare utilisation questionnaire and 42 (56.0%) completed the SPI for the 7-day period. All 
headache patients showed considerable mood disturbances during a headache. In general the 
disturbances were severe in intensity and of the order CDH>migraine>TTH. The pattern of mood 
disturbance was different for each type of headache, as was the patients’ ability to cope with the 
mood changes. Patients with CDH experienced pain and emotional symptoms, particularly 
sedation, throughout the 7-day monitoring period. For TTH and migraine, the pain and emotional 
symptoms resolved within 1–2 days after the headache. The level of healthcare resource 
utilisation was also in the order CDH>migraine>TTH, similar to the data reported for the SPI. In 
conclusion, patients with headache had significant emotional symptoms associated with their 
headaches. These symptoms resolved within 1–2 days for patients with episodic TTH and 
migraine. However, patients with CDH were profoundly affected, and did not improve physically 
or emotionally from their headache over a 7-day period. Headache patients generally 
experienced higher levels of sedation than did patients with other pain conditions. 
 
Assessing headache-related disability 
Chapter 4.1 reviews the disability caused by migraine and other headache disorders. Migraine 
is a remarkably disabling condition, although unpredictable and heterogeneous in frequency, 
duration and severity. It can be difficult to manage in primary care, where it is under-recognised, 
under-diagnosed and under-treated. Proposals have been made that migraine care could be 
improved by incorporating assessments of disability into management strategies. Research has 
shown that measuring headache-related disability, together with assessments of pain intensity, 
headache frequency, tiredness, mood alterations and cognition can be used to assess the 
impact of migraine on sufferers’ lives and society. From this research two simple and brief 
impact tools were developed; the Migraine Disability Assessment (MIDAS) Questionnaire and 
the Headache Impact Test (HIT). Both tools are scientifically valid measures of headache 
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severity and have the potential to improve communication between patients and their 
physicians, assess headache severity and act as outcome measures to monitor treatment 
efficacy. Disability-based tools are also being increasingly recommended as part of generalised 
headache management guidelines to produce an individualised treatment plan for each patient 
in concert with other clinical assessments. It is not possible as yet to unequivocally recommend 
the optimal impact tool for use in primary care, but it should be usable by GPs, pharmacists, 
nurses and patients, and for research purposes. 
 
Chapter 4.2 describes an audit that assessed the outcome of a nurse intervention strategy in 
patients presenting with headache to a primary care surgery. Patients aged 18–65 years 
attending the surgery who reported headache in the previous 3 months were assessed by a 
nurse and completed a MIDAS Questionnaire and a questionnaire investigating headache 
features and physician consultations. All patients were given oral and written advice on 
headache management by the nurse. Patients were reviewed after 3 and 6 months with the 
same questionnaires. A total of 195 patients took part in the study. At baseline, 136 (69.7%) 
were MIDAS Grade I/II and 59 (30.3%) were Grade III/IV. Compared with baseline, patients 
reported significant mean reductions at 6 months in: total MIDAS scores (5.9 versus 9.6; p = 
0.014); headache frequency (MIDAS A score: 7.0 versus 12.6; p = 0.009); headache severity 
(MIDAS B score: 5.0 versus 6.0; p = 0.003); and physician consultations for headache (3-month 
period: 0.05 versus 0.30; p = 0.05). In conclusion, advice on headache management given by a 
nurse can potentially lead to significantly improved patient outcomes. MIDAS appeared to be a 
sensitive outcome measure for reduction in disability in headache sufferers. These results 
warrant further investigation in randomised, controlled clinical studies. 
 
Chapter 4.3 describes a sub-analysis of Study 3.4 investigating the psychometric properties of 
Internet HIT (HIT-DYNA®) compared with the SPI©. Also compared were the abilities of the SPI 
and HIT in terms of discriminating headache severity and diagnosis. Result showed that the HIT 
score correlated 0.28 with the severity of the headaches whereas the SPI correlated 0.76 on its 
Total Mood Disturbance score. The correlations of the HIT items with pain severity never rose 
above 0.26 whereas the correlations of the SPI items were all typically about 0.7. The SPI 
significantly discriminated with headache severity levels (none, mild, moderate, severe, 
extreme), with t values of 2–20. The HIT scores were far less powerful at discriminating severity, 
with t test values from 2–5. HIT scores at screening significantly discriminated with diagnosis, 
with the resolution between TTH and CDH reaching 1/100 million. The SPI summary scores and 
subscales did not discriminate with diagnosis. These differences between HIT and SPI were 
confirmed by factor analysis. In conclusion, the results showed the HIT to be poorly related to 
the severity of the pain but very closely related to the diagnostic label. In contrast to this, the SPI 
was very closely related to severity but not related to diagnosis.   
 
Chapter 4.4 describes a prospective, open investigation designed to validate a new inclusive 
diagnostic questionnaire for headache, the 8-item Headache Diagnostic Screening 
Questionnaire (DSQ), containing questions screening for possible sinister symptoms, and 
evaluating headache-related disability, frequency and duration, the use of symptomatic 
medications and the presence of migraine aura symptoms. Patients completed the DSQ on their 
own and with a pharmacist’s help. The same pharmacist, a GP and a headache specialist 
conducted a differential headache diagnosis according to their usual practices. Diagnoses were 
deduced from the DSQ using an algorithm by a healthcare professional, who was blind to the 
other diagnoses. The primary endpoint was the sensitivity of the DSQ, measured as the 
proportion of correct diagnoses assessed from the patient, pharmacist and GP responses, 
compared with the gold standard of specialist diagnosis, for each headache subtype. Eighty 
seven patients (80.5% women, mean age 52.9 years) completed the study, all completing the 
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questionnaire without help within a few minutes. Most patients were diagnosed by the specialist 
with migraine (with or without aura) or CDH (with or without medication overuse headache 
[MOH]). The overall sensitivity of the patient-completed DSQ was good (59.3%) and similar to 
the pharmacist-completed DSQ (66.6%) and GP diagnosis (59.4%). The accuracy of the DSQ-
derived diagnoses was greatest for total migraine, migraine with aura, MOH and migraine 
without aura. The accuracy of the pharmacists’ headache diagnosis was improved markedly 
when they used the DSQ, particularly with regard to diagnosing migraine with and without aura 
and MOH. In conclusion, the Headache DSQ is a brief, rapid to use and accurate diagnostic 
screening questionnaire for headache, and is especially sensitive for migraine and MOH. It can 
be recommended for screening new headache patients at and below the primary care level. 
 
Chapters 4.5 and 4.6 describe the design and testing of a new 4-item assessment tool, the 
Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire for use by clinicians, to 
quickly evaluate how a recently prescribed acute medication is working, and to identify patients 
who require a change of their current acute treatment. A 27-item Migraine-ACT questionnaire 
was developed by an international advisory board of headache specialists. Questions were 
formulated in four domains: headache impact, global assessment of relief, consistency of 
response and emotional response, all with yes (score = 1) or no (score = 0) answers. Migraine 
patients (n = 185) attending secondary care headache clinics entered a multinational, 
prospective, observational study to investigate the test-retest reliability and construct validity of 
the 27-item Migraine-ACT. Patients completed the Migraine-ACT on two occasions, separated 
by a 1-week interval, and test-retest reliability was assessed by Pearson product moment and 
Spearman rank measures. Construct validity was assessed by correlating patients’ answers to 
the 27-item Migraine-ACT with those to other questionnaires (individual domains and total 
scores) conceptually related to it; the Short-Form 36 quality of life questionnaire (SF-36), the 
Migraine Disability Assessment (MIDAS) questionnaire and the Migraine Therapy Assessment 
Questionnaire (MTAQ). Discriminatory t-tests were used to identify the four Migraine-ACT 
questions (one in each domain) which discriminated best between the domains of the SF-36, 
MIDAS, and MTAQ.  These four items constituted the final 4-item Migraine-ACT. The test-retest 
reliability of the 27 Migraine-ACT questions ranged from good to excellent, and correlation 
coefficients were highly significant for all items. The consistency of reporting the yes and no 
answers was also excellent. Correlations of Migraine-ACT items with SF-36 and MIDAS items 
and SF-36, MIDAS and MTAQ total scores indicated that the following were the most 
discriminating items, in the respective four domains, and constitute the final Migraine-ACT 
questionnaire: 
• Consistency of response - Does your migraine medication work consistently, in the 
majority of your attacks? 
• Global assessment of relief - Does the headache pain disappear within 2 hours? 
• Impact - Are you able to function normally within 2 hours? 
• Emotional response - Are you comfortable enough with your medication to be able 
to plan your daily activities 
The 4-item Migraine-ACT was shown to be highly reliable (Spearman / Pearson measure r = 
0.82). The individual questions, and the total 4-item Migraine-ACT score, showed good 
correlation with items of the SF-36, MIDAS and MTAQ questionnaires, particularly with the total 
MTAQ and SF-36 scores. Additional testing confirmed the good reliability, validity and potential 
clinical utility of the 4-item questionnaire. In conclusion, the 4-item Migraine-ACT questionnaire 
is brief and simple to complete and score, and has demonstrated reliability, accuracy and 
simplicity. A score of ≤ 2 indicates that a change in medication may be warranted. Migraine-ACT 
can therefore be recommended for everyday clinical use by clinicians. 
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Chapter 5 describes the main discussion points arising from this research. The searches and 
studies contained in this thesis have confirmed the clinical importance of assessing disability 
when managing headache patients. Disability-based assessments play key roles in the 
screening, diagnosis and treatment of these patients. While there is no definitive method to 
measure disability, several tools are available and have utility in diagnosis (HIT), assessing 
headache severity and monitoring treatments (MIDAS) and in assessing emotional disability 
(SPI). Disability assessments also play key roles in the development of other questionnaires. 
The DSQ sensitively screens for diagnosis using questions on disability and other headache 
features, features consistent with those of other diagnostic questionnaires. Migraine-ACT 
assesses the need to change acute medications using questions on headache-related disability, 
emotional impact, and overall response and consistency of response. 
 
The main limitations of the naturalistic studies were that they were open-label, small in terms of 
numbers of patients and sometimes duration, resulting in lack of power and possible design 
asymmetries. Larger, controlled studies are now required to take this research forward. 
However, the type of naturalistic, prospective, open, longitudinal study described here is 
eminently suited for research in primary care. 
 
In conclusion, the main clinical applications of this work are: 
• The validation of naturalistic studies for use in primary care. 
• The use of disability-based measures for assessing headache patients in screening, 
diagnosis, to assess severity, and as part of guidelines for treatment. 
• The development of a disability-based tool (DSQ) for diagnosing headaches. 
• The development of a disability-based tool (Migraine-ACT) for assessing the need to 
change a migraine patient’s acute medication. 
 
 
 
